细胞株Cell Lines 55-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心http://www.biovector.net
- 价 格：¥19200
- 货 号：NTCC-CV55
- 产 地：北京
- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作QQ:1843439339 (微信同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
细胞株Cell Lines-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心
ID KFr13
AC CVCL_V534
SY KFr
DR CGH-DB; 327-2
DR CGH-DB; 349-3
RX PubMed=3467111;
RX PubMed=10741911;
RX PubMed=11185891;
RX PubMed=17671176;
RX PubMed=18319717;
RX PubMed=18483383;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C7978; Ovarian serous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_V533 ! KF28
SX Female
CA Cancer cell line
//
ID KFr13Tx
AC CVCL_V535
SY KFr13 TX; KFr13TX
RX PubMed=10741911;
RX PubMed=18319717;
RX PubMed=18483383;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
DI NCIt; C7978; Ovarian serous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_V534 ! KFr13
SX Female
CA Cancer cell line
//
ID KFra
AC CVCL_M713
RX PubMed=7844449;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C7978; Ovarian serous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_F843 ! KF-1
SX Female
CA Cancer cell line
//
ID KFrb
AC CVCL_M714
RX PubMed=7844449;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C7978; Ovarian serous cystadenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_F843 ! KF-1
SX Female
CA Cancer cell line
//
ID KFT-R
AC CVCL_0I58
DR CCLV; CCLV-RIE 1014
RX PubMed=19941903;
OX NCBI_TaxID=9986; ! Oryctolagus cuniculus
CA Spontaneously immortalized cell line
//
ID KG-1
AC CVCL_0374
SY KG1
DR BTO; BTO:0000670
DR CLO; CLO_0007093
DR CLO; CLO_0007094
DR CLO; CLO_0051560
DR EFO; EFO_0002218
DR MCCL; MCC:0000269
DR CLDB; cl3022
DR CLDB; cl3023
DR CLDB; cl3024
DR CLDB; cl3025
DR ATCC; CCL-246
DR ATCC; CRL-8031
DR BCRC; 60158
DR BCRJ; 0132
DR BioSample; SAMN01821643
DR BioSample; SAMN03473103
DR CCLE; KG1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CCRID; 3131C0001000700105
DR CCRID; 3142C0001000000094
DR ChEMBL-Cells; CHEMBL3307794
DR ChEMBL-Targets; CHEMBL612264
DR Cosmic; 683545
DR Cosmic; 717682
DR Cosmic; 787443
DR Cosmic; 851998
DR Cosmic; 907278
DR Cosmic; 919118
DR Cosmic; 924047
DR Cosmic; 975261
DR Cosmic; 981581
DR Cosmic; 985581
DR Cosmic; 996311
DR Cosmic; 998743
DR Cosmic; 999726
DR Cosmic; 1012078
DR Cosmic; 1019831
DR Cosmic; 1037660
DR Cosmic; 1070689
DR Cosmic; 1078730
DR Cosmic; 1107180
DR Cosmic; 1127253
DR Cosmic; 1150903
DR Cosmic; 1176582
DR Cosmic; 1181606
DR Cosmic; 1197928
DR Cosmic; 1281321
DR Cosmic; 1308223
DR Cosmic; 1523823
DR Cosmic; 1524832
DR Cosmic; 1582389
DR Cosmic; 1623637
DR Cosmic; 2060796
DR Cosmic; 2089672
DR Cosmic; 2131541
DR Cosmic; 2306212
DR Cosmic-CLP; 907278
DR DSMZ; ACC-14
DR ECACC; 86111306
DR GDSC; 907278
DR GEO; GSM236787
DR GEO; GSM236823
DR GEO; GSM887208
DR GEO; GSM888281
DR GEO; GSM1374597
DR GEO; GSM1669984
DR IGRhCellID; KG1
DR IZSLER; BS TCL 190
DR JCRB; JCRB0065
DR JCRB; JCRB9051
DR KCB; KCB 200552YJ
DR KCLB; 10246
DR Lonza; 746
DR NCBI_Iran; C119
DR RCB; RCB1166
RX PubMed=306682;
RX PubMed=3094604;
RX PubMed=3856862;
RX PubMed=6582512;
RX PubMed=6996765;
RX PubMed=9290701;
RX PubMed=11021758;
RX PubMed=15843827;
RX PubMed=16408098;
RX PubMed=17254797;
RX PubMed=22460905;
RX PubMed=23955599;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KG-1
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-169.html
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~38 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=17254797; PubMed=25877200; RCB
ST Amelogenin: X,Y
ST CSF1PO: 7
ST D13S317: 11,12
ST D16S539: 10,11
ST D18S51: 10,18 (PubMed=17254797)
ST D18S51: 10.2,18 (PubMed=25877200)
ST D21S11: 28,29
ST D3S1358: 15,16
ST D5S818: 13
ST D7S820: 8,10
ST D8S1179: 13,14
ST FGA: 22
ST Penta D: 8,9
ST Penta E: 7,13
ST TH01: 7,8
ST TPOX: 7,9
ST vWA: 14,19
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KG-1-C
AC CVCL_2971
SY KG-1C; KG1C
DR CLO; CLO_0050639
DR BCRJ; 0378
DR BioSample; SAMN03471662
DR CCLE; KG1C_CENTRAL_NERVOUS_SYSTEM
DR Cosmic; 685872
DR Cosmic; 1746964
DR Cosmic; 2302336
DR GDSC; 1240164
DR GEO; GSM326250
DR GEO; GSM827298
DR GEO; GSM887207
DR GEO; GSM888280
DR JCRB; JCRB0236
DR RCB; RCB0270
RX PubMed=222111;
RX PubMed=9290701;
RX PubMed=14618099;
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): JCRB; RCB
ST Amelogenin: X,Y
ST CSF1PO: 12,13
ST D13S317: 9
ST D16S539: 9
ST D5S818: 11,12
ST D7S820: 11
ST TH01: 6
ST TPOX: 9
ST vWA: 18
DI NCIt; C3288; Oligodendroglioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KG-1a
AC CVCL_1824
SY KG-1A; KG1A; KG1a
DR BTO; BTO:0005076
DR CLO; CLO_0007095
DR CLO; CLO_0051561
DR CLDB; cl3026
DR CLDB; cl3027
DR ATCC; CCL-246.1
DR BCRC; 60224
DR BioSample; SAMN01821644
DR BioSample; SAMN03470993
DR CCRID; 3111C0002000000028
DR CLS; 300234/p579_KG1A
DR Cosmic; 787444
DR Cosmic; 821042
DR Cosmic; 985582
DR Cosmic; 994174
DR Cosmic; 1127254
DR Cosmic; 1319553
DR DSMZ; ACC-421
DR ECACC; 91030101
DR GEO; GSM1374598
DR IZSLER; BS TCL 196
DR Lonza; 835
DR NCBI_Iran; C520
DR RCB; RCB1928
DR TKG; TKG 0402
RX PubMed=3094604;
RX PubMed=6967340;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KG-1
CC Doubling time: ~50 hours (DSMZ).
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; CLS; COG; DSMZ; PubMed=11416159; PubMed=25877200; RCB; TKG
ST Amelogenin: X,Y
ST CSF1PO: 7
ST D13S317: 11,12
ST D16S539: 10,11
ST D18S51: 10.2,18
ST D19S433: 11,16.2 (COG)
ST D19S433: 16.2 (PubMed=25877200)
ST D21S11: 28,29
ST D2S1338: 20,23
ST D3S1358: 15,16
ST D5S818: 13
ST D7S820: 8,10
ST D8S1179: 14 (COG)
ST D8S1179: 13,14 (CLS; PubMed=11416159; PubMed=25877200)
ST FGA: 22
ST Penta D: 8,9
ST Penta E: 7,13
ST TH01: 7,8
ST TPOX: 7,9 (ATCC; CLS; COG; DSMZ; ECACC; RCB; TKG)
ST TPOX: 7 (PubMed=25877200)
ST vWA: 14,19
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0374 ! KG-1
SX Male
CA Cancer cell line
//
ID KG-R
AC CVCL_0I71
DR CCLV; CCLV-RIE 0252
OX NCBI_TaxID=9685; ! Felis catus
CA Spontaneously immortalized cell line
//
ID KG55T
AC CVCL_W464
SY KG-55-T
RX PubMed=6194659;
RX PubMed=6310497;
DI NCIt; C3099; Hepatocellular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KGN
AC CVCL_0375
DR BTO; BTO:0005671
DR CLO; CLO_0051454
DR MCCL; MCC:0000270
DR BioSample; SAMN03472163
DR ChEMBL-Cells; CHEMBL3308155
DR ChEMBL-Targets; CHEMBL2366154
DR Cosmic; 924186
DR Cosmic; 1149409
DR Cosmic; 1213591
DR Cosmic; 1305320
DR Cosmic; 1312287
DR Cosmic; 1429993
DR Cosmic; 2368538
DR Cosmic-CLP; 924186
DR GDSC; 924186
DR GEO; GSM1669985
DR RCB; RCB1154
RX PubMed=11145608;
RX PubMed=15541573;
RX PubMed=18980698;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP; RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 9
ST D16S539: 10,12
ST D5S818: 13
ST D7S820: 11
ST TH01: 9
ST TPOX: 8,9
ST vWA: 17
DI NCIt; C6261; Ovarian granulosa cell tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KGU
AC CVCL_E723
DR dbMHC; 48921
DR ECACC; 94050339
DR IHW; IHW9309
DR IMGT/HLA; 10910
WW http://bioinformatics.hsanmartino.it/ecbr/cl309.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KgV
AC CVCL_5T73
SY Kgv
RX PubMed=1717631;
RX PubMed=2303715;
CC Transformant: NCBI_TaxID; 11841; Gross passage A murine leukemia virus (Gross-MuLV).
CC Breed/subspecies: BALB.K.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KH OS R1
AC CVCL_T431
RX PubMed=17096323;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2546 ! KHOS/NP
SX Female
CA Cancer cell line
//
ID KH OS R2
AC CVCL_T432
SY KHOSR2
RX PubMed=17096323;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_T431 ! KH OS R1
SX Female
CA Cancer cell line
//
ID KH OS R3
AC CVCL_T433
RX PubMed=17096323;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_T432 ! KH OS R2
SX Female
CA Cancer cell line
//
ID KH-39
AC CVCL_W214
SY KH39
DR Cosmic; 845929
RX PubMed=7154478;
RX PubMed=10723130;
CC Doubling time: 16.0 hours (PubMed=7154478).
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KH-R
AC CVCL_G348
DR CCLV; CCLV-RIE 0090
OX NCBI_TaxID=9913; ! Bos taurus
CA Finite cell line
//
ID KH2
AC CVCL_C317
DR BTO; BTO:0004414
CC Breed/subspecies: C57BL/6 x 129/Sv.
OX NCBI_TaxID=10090; ! Mus musculus
CA Embryonic stem cell
//
ID KH88
AC CVCL_G364
DR TKG; TKG 0704
RX PubMed=8289484;
ST Source(s): TKG
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8,12
ST D16S539: 9
ST D5S818: 11,14
ST D7S820: 8,10
ST TH01: 6
ST TPOX: 8
ST vWA: 14,18
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KHAGNI
AC CVCL_E724
DR dbMHC; 48922
DR ECACC; 94022534
DR IHW; IHW9248
DR IMGT/HLA; 10912
WW http://bioinformatics.hsanmartino.it/ecbr/cl248.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KhES-1
AC CVCL_B231
SY KHES-1; KhES1; KUIMSe001-A
DR GEO; GSM1040238
DR GEO; GSM1040308
DR GEO; GSM1489246
DR GEO; GSM1489457
DR hPSCreg; KUIMSe001-A
DR ISCR; 550
DR RCB; HES0001
DR SKIP; SKIP000147
RX PubMed=17572666;
RX PubMed=21460823;
RX PubMed=22802639;
RX PubMed=24259714;
WW http://www.nbrp.jp/report/reportProjectEn.jsp?project=esCell
CC From: Institute for Frontier Medical Sciences; Kyoto University; Kyoto; Japan.
CC Omics: DNA methylation analysis.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KhES-1 CAG-EGFP
AC CVCL_T924
DR SKIP; SKIP000150
CC Transfected with: UniProtKB; P42212; GFP (with L-64, T-65 and L-231 = EGFP).
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B231 ! KhES-1
SX Female
CA Embryonic stem cell
//
ID KhES-1 subline 1
AC CVCL_T917
RX PubMed=16931777;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B231 ! KhES-1
SX Female
CA Embryonic stem cell
//
ID KhES-1 subline 2
AC CVCL_T918
RX PubMed=16931777;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B231 ! KhES-1
SX Female
CA Embryonic stem cell
//
ID KhES-1 subline 3
AC CVCL_T919
RX PubMed=16931777;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B231 ! KhES-1
SX Female
CA Embryonic stem cell
//
ID KhES-2
AC CVCL_B232
SY KHES-2; KhES2; KUIMSe002-A
DR GEO; GSM1519868
DR hPSCreg; KUIMSe002-A
DR ISCR; 551
DR RCB; HES0002
DR SKIP; SKIP000151
RX PubMed=17572666;
WW http://www.nbrp.jp/report/reportProjectEn.jsp?project=esCell
CC From: Institute for Frontier Medical Sciences; Kyoto University; Kyoto; Japan.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KhES-2 subline 1
AC CVCL_T920
RX PubMed=16931777;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B232 ! KhES-2
SX Female
CA Embryonic stem cell
//
ID KhES-2 subline 2
AC CVCL_T921
RX PubMed=16931777;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B232 ! KhES-2
SX Female
CA Embryonic stem cell
//
ID KhES-3
AC CVCL_B233
SY KHES-3; KhES3; KUIMSe003-A
DR GEO; GSM1040239
DR GEO; GSM1040309
DR GEO; GSM1489247
DR GEO; GSM1489259
DR GEO; GSM1489458
DR GEO; GSM1942576
DR GEO; GSM1942580
DR GEO; GSM1942581
DR GEO; GSM1942582
DR GEO; GSM1942583
DR GEO; GSM1942584
DR GEO; GSM1942585
DR GEO; GSM1942586
DR GEO; GSM1942587
DR hPSCreg; KUIMSe003-A
DR ISCR; 552
DR RCB; HES0003
DR SKIP; SKIP000152
RX PubMed=17572666;
RX PubMed=21460823;
RX PubMed=22802639;
RX PubMed=24259714;
RX PubMed=25665923;
WW http://www.nbrp.jp/report/reportProjectEn.jsp?project=esCell
CC From: Institute for Frontier Medical Sciences; Kyoto University; Kyoto; Japan.
CC Omics: DNA methylation analysis.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KhES-3 subline 1
AC CVCL_T922
RX PubMed=16931777;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B233 ! KhES-3
SX Male
CA Embryonic stem cell
//
ID KhES-3 subline 2
AC CVCL_T923
RX PubMed=16931777;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_B233 ! KhES-3
SX Male
CA Embryonic stem cell
//
ID KhES-4
AC CVCL_T797
SY KHES-4; KhES4
DR GEO; GSM1040240
DR GEO; GSM1040310
DR RCB; HES0004
DR SKIP; SKIP000154
RX PubMed=24259714;
WW http://www.nbrp.jp/report/reportProjectEn.jsp?project=esCell
CC From: Institute for Frontier Medical Sciences; Kyoto University; Kyoto; Japan.
CC Omics: DNA methylation analysis.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KhES-5
AC CVCL_T798
SY KHES-5; KhES5
DR GEO; GSM1040241
DR GEO; GSM1040311
DR RCB; HES0005
DR SKIP; SKIP000156
RX PubMed=24259714;
WW http://www.nbrp.jp/report/reportProjectEn.jsp?project=esCell
CC From: Institute for Frontier Medical Sciences; Kyoto University; Kyoto; Japan.
CC Omics: DNA methylation analysis.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KHm-1
AC CVCL_W210
SY KHm1
RX PubMed=29705;
RX PubMed=197244;
RX PubMed=286091;
RX PubMed=10629075;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KHM-10B
AC CVCL_2973
SY KHM10B
DR Cosmic; 2297032
DR GEO; GSM119555
DR JCRB; JCRB0165
DR JCRB; NIHS0195
RX PubMed=8609722;
RX PubMed=16960149;
CC Characteristics: EBV-negative.
CC Discontinued: JCRB; NIHS0195; true.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8,11
ST D16S539: 9,12
ST D5S818: 11,12
ST D7S820: 10,12
ST TH01: 6
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C7954; Adult Burkitt leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KHM-11
AC CVCL_A633
DR Cosmic; 720771
DR Cosmic; 2081388
DR Cosmic; 2367278
RX PubMed=7934174;
RX PubMed=10936422;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KHM-11ad
AC CVCL_A634
SY 11ad
RX PubMed=10352328;
RX PubMed=10936422;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_A633 ! KHM-11
SX Male
CA Cancer cell line
//
ID KHM-1A
AC CVCL_9546
RX PubMed=2458153;
RX PubMed=10936422;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_2972 ! KHM-1B
SX Male
CA Cancer cell line
//
ID KHM-1B
AC CVCL_2972
SY KHM1B
DR EFO; EFO_0006609
DR BioSample; SAMN03472941
DR CCLE; KHM1B_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 2081389
DR GEO; GSM887209
DR GEO; GSM888282
DR JCRB; JCRB0133
DR JCRB; NIHS0190
RX PubMed=2458153;
RX PubMed=10936422;
RX PubMed=22460905;
RX PubMed=25485619;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0190; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 9
ST D18S51: 16,18
ST D21S11: 30,31
ST D3S1358: 15
ST D5S818: 11
ST D7S820: 10
ST D8S1179: 11,12
ST FGA: 24
ST Penta D: 9,12
ST Penta E: 8,16
ST TH01: 6
ST TPOX: 11
ST vWA: 14,17
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_9546 ! KHM-1A
SX Male
CA Cancer cell line
//
ID KHM-2B
AC CVCL_8526
DR JCRB; JCRB1394
RX PubMed=2123067;
RX PubMed=7849311;
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 11,12
ST D16S539: 11
ST D5S818: 9,10
ST D7S820: 8,11
ST TH01: 7
ST TPOX: 9,11
ST vWA: 18,20
DI NCIt; C9143; Adult B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KHm-3
AC CVCL_W211
SY KHm3
RX PubMed=286091;
RX PubMed=10629075;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KHM-3S
AC CVCL_2974
DR BioSample; SAMN03470805
DR BioSample; SAMN03470833
DR GEO; GSM827196
DR JCRB; JCRB0138
DR JCRB; NIHS0192
RX PubMed=1319985;
CC Discontinued: JCRB; NIHS0192; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,9
ST D16S539: 9,13 (JCRB)
ST D16S539: 9,13,14 (PubMed=25877200)
ST D18S51: 12,16
ST D21S11: 30
ST D3S1358: 15,18
ST D5S818: 10
ST D7S820: 10,11
ST D8S1179: 12
ST FGA: 20
ST Penta D: 10,11
ST Penta E: 5,22
ST TH01: 6
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KHM-4
AC CVCL_9545
DR CGH-DB; 9160-4
RX PubMed=1611184;
RX PubMed=10936422;
RX PubMed=15215163;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KHm-5
AC CVCL_W212
SY KHm5
RX PubMed=286091;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KHM-5M
AC CVCL_2975
SY KHM/5M
DR BioSample; SAMN03470813
DR BioSample; SAMN03470887
DR CGH-DB; 57-1
DR Cosmic; 2054085
DR JCRB; JCRB0148
DR JCRB; NIHS0194
RX PubMed=1728417;
RX PubMed=16924234;
RX PubMed=23833040;
CC Discontinued: JCRB; NIHS0194; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 11.3,12.3 (JCRB)
ST CSF1PO: 12,13 (PubMed=25877200)
ST D13S317: 8,11
ST D16S539: 9,10
ST D18S51: 16,19
ST D19S433: 14
ST D21S11: 28,31
ST D2S1338: 19,23
ST D3S1358: 15
ST D5S818: 12
ST D7S820: 10,11
ST D8S1179: 13
ST FGA: 22,23
ST Penta D: 9,11
ST Penta E: 11,18
ST TH01: 7
ST TPOX: 8
ST vWA: 18
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KHm-6
AC CVCL_W213
SY KHm6
RX PubMed=286091;
RX PubMed=10629075;
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KHOS-240S
AC CVCL_2544
SY KHOS240S
DR BTO; BTO:0003923
DR CLO; CLO_0007098
DR EFO; EFO_0002219
DR CLDB; cl3028
DR ATCC; CRL-1545
DR CLS; 300433/p2464_KHOS-240S
DR Cosmic; 1074392
DR ECACC; 86112810
DR GEO; GSM186426
DR GEO; GSM186427
DR GEO; GSM827381
DR GEO; GSM1676358
DR GEO; GSM1701688
DR IGRhCellID; KHOS240S
RX PubMed=62397;
RX PubMed=26351324;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): ATCC; CLS; ECACC
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 10,13
ST D18S51: 14,17
ST D21S11: 31.2,32.2
ST D3S1358: 15
ST D5S818: 13
ST D7S820: 11,12
ST D8S1179: 11,14
ST FGA: 24
ST Penta D: 9,10
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 11
ST vWA: 18
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2546 ! KHOS/NP
SX Female
CA Cancer cell line
//
ID KHOS-312H
AC CVCL_2545
SY KHOS-321H; KHOS312H; KHOS321H
DR BTO; BTO:0003924
DR CLO; CLO_0007099
DR CLO; CLO_0007100
DR CLDB; cl3029
DR ATCC; CRL-1546
DR ChEMBL-Cells; CHEMBL3308382
DR ChEMBL-Targets; CHEMBL614591
DR CLS; 300447/p500_KHOS-312H
DR Cosmic; 1074400
DR ECACC; 86112811
DR GEO; GSM827383
DR GEO; GSM1676359
DR GEO; GSM1701689
RX PubMed=62397;
RX PubMed=26351324;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Caution: Due to an error in some ATCC catalogs, this cell line has been referred to as both KHOS-312H and KHOS-321H by ATCC and in the literature. The correct name is KHOS-312H.
ST Source(s): ATCC; CLS; ECACC
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 10,13
ST D18S51: 14,17
ST D21S11: 31.2,32.2
ST D3S1358: 15
ST D5S818: 13
ST D7S820: 11,12
ST D8S1179: 11,14
ST FGA: 24
ST Penta D: 9,10
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 8,11
ST vWA: 18
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2546 ! KHOS/NP
SX Female
CA Cancer cell line
//
ID KHOS/NP
AC CVCL_2546
SY KHOS-NP; KHOS NP; KHOSNP; R-970-5; KHOS
DR BTO; BTO:0003922
DR CLO; CLO_0007096
DR CLO; CLO_0007097
DR CLO; CLO_0008725
DR CLDB; cl3030
DR CLDB; cl3031
DR ATCC; CRL-1544
DR ATCC; CRL-7723
DR ChEMBL-Cells; CHEMBL3308001
DR ChEMBL-Targets; CHEMBL612598
DR CLS; 300235/p584_KHOS-NP
DR Cosmic; 1044083
DR Cosmic; 1074393
DR ECACC; 84102903
DR GEO; GSM186428
DR GEO; GSM186429
DR GEO; GSM827385
DR GEO; GSM1676341
DR GEO; GSM1701672
DR IZSLER; BS TCL 80
RX PubMed=26351324;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Omics: Protein expression by reverse-phase protein arrays.
CC Discontinued: ATCC; CRL-7723; true.
ST Source(s): ATCC; CLS; ECACC
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 10,13
ST D18S51: 17
ST D21S11: 31.2,32.2
ST D3S1358: 15
ST D5S818: 13
ST D7S820: 11,12
ST D8S1179: 11,14
ST FGA: 24
ST Penta D: 9,10
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 8,11
ST vWA: 18
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0439 ! MNNG/HOS Cl #5
SX Female
CA Cancer cell line
//
ID KHYG-1
AC CVCL_2976
SY KHYG1
DR Cosmic; 1534877
DR Cosmic; 1542070
DR Cosmic; 2025323
DR Cosmic; 2390214
DR DSMZ; ACC-725
DR GEO; GSM472000
DR JCRB; JCRB0156
DR JCRB; NIHS0226
DR Lonza; 733
RX PubMed=10803505;
RX PubMed=10803526;
RX PubMed=19194464;
RX PubMed=21052088;
RX PubMed=25586472;
CC Characteristics: IL2 dependent.
CC Doubling time: ~30-40 hours (DSMZ).
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0226; true.
ST Source(s): DSMZ; JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 9,13
ST D16S539: 9
ST D5S818: 9,11
ST D7S820: 10,11
ST TH01: 6
ST TPOX: 9,11
ST vWA: 17
DI NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KI
AC CVCL_E725
DR dbMHC; 48923
DR ECACC; 94071423
DR IHW; IHW9333
DR IMGT/HLA; 10914
WW http://bioinformatics.hsanmartino.it/ecbr/cl333.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID Ki-JK
AC CVCL_2093
SY KI-JK; KIJK
DR CCLE; KIJK_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 850202
DR Cosmic; 1086365
DR DSMZ; ACC-695
DR GEO; GSM887210
DR GEO; GSM888283
DR JCRB; JCRB1065
DR JCRB; NIHS0222
RX PubMed=8169113;
RX PubMed=15356658;
RX PubMed=22460905;
RX PubMed=25355872;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~50-70 hours (DSMZ).
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
CC Discontinued: JCRB; NIHS0222; true.
ST Source(s): DSMZ; JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12,13
ST D13S317: 9,12
ST D16S539: 10
ST D5S818: 11,12
ST D7S820: 10,12
ST TH01: 8,9
ST TPOX: 10,11
ST vWA: 17,18
DI NCIt; C3720; Anaplastic large cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ki-PeCa-L1
AC CVCL_C022
RX PubMed=22503055;
CC Derived from metastatic site: Lymph node.
DI NCIt; C7729; Squamous cell carcinoma of the penis
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C023 ! Ki-PeCa-P1
SX Male
CA Cancer cell line
//
ID Ki-PeCa-P1
AC CVCL_C023
RX PubMed=22503055;
DI NCIt; C7729; Squamous cell carcinoma of the penis
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C022 ! Ki-PeCa-L1
SX Male
CA Cancer cell line
//
ID Kia
AC CVCL_X928
SY KIA
DR NIH-ARP; 2771-179
RX PubMed=7535998;
CC Group: Non-human primate cell line.
CC Transformant: NCBI_TaxID; 33747; Simian T-lymphotropic virus 1 (STLV-1).
OX NCBI_TaxID=9556; ! Papio cynocephalus
CA Transformed cell line
//
ID Kid92
AC CVCL_A088
SY KID-92; Kid-92
DR Cosmic; 999752
RX PubMed=8847894;
DI NCIt; C9143; Adult B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kie-BL
AC CVCL_W937
SY KIE-BL; KIE
RX PubMed=2824665;
RX PubMed=2943927;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kif-5
AC CVCL_Y515
SY KiF-5; Kif5; KIF5
DR EFO; EFO_0002712
RX PubMed=11238448;
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID KIJ265T
AC CVCL_AV54
SY KIJ-265T
RX PubMed=22826467;
RX PubMed=23633458;
WW http://technologies.ventures.mayoclinic.org/technologies/2010-305_new-cell-lines
CC Miscellaneous: STR profile from personal communication of Marlow L.A.
ST Source(s): Direct_author_submission
ST Amelogenin: X
ST CSF1PO: 10,13
ST D13S317: 11,12
ST D16S539: 12,14
ST D18S51: 15
ST D3S1358: 16
ST D5S818: 11
ST D7S820: 9,10
ST D8S1179: 11,13
ST FGA: 24
ST TH01: 7
ST TPOX: 8,11
ST vWA: 16,19
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KiKu
AC CVCL_D885
SY KIKU
RX CelloPub=CLPUB00063;
RX PubMed=2450650;
RX PubMed=3164747;
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_T738 ! KiKu-M
SX Female
CA Cancer cell line
//
ID KiKu-M
AC CVCL_T738
SY KIKU-M
RX CelloPub=CLPUB00063;
RX PubMed=2450650;
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_D885 ! KiKu
SX Female
CA Cancer cell line
//
ID KIL
AC CVCL_HC59
SY KIL C.2
DR ATCC; PTA-6651
RX Patent=US9121008;
RX PubMed=15650053;
WW https://www.kerafast.com/product/2099/natural-killer-cell-line-kil
CC Characteristics: Established from co-cultures of post-5-fluorouracil bone marrow mononuclear cells and OP-9S/LMJSN (CVCL_HC58).
CC Characteristics: IL7 dependent.
CC Discontinued: ATCC; PTA-6651; probable.
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
CA Factor-dependent cell line
//
ID KIM-1
AC CVCL_7969
RX DOI=10.2957/kanzo.25.532;
DI NCIt; C3099; Hepatocellular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KIM127
AC CVCL_0F09
SY KIM 127
DR ATCC; CRL-2838
RX PubMed=1371129;
RX PubMed=7690325;
CC Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KIM185
AC CVCL_0F10
DR ATCC; CRL-2839
RX PubMed=7690325;
CC Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KIME
AC CVCL_E726
SY KIM-ND
DR dbMHC; 48924
DR ECACC; 94022535
DR IHW; IHW9212
DR IMGT/HLA; 10915
WW http://bioinformatics.hsanmartino.it/ecbr/cl212.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KIMI-1
AC CVCL_W479
RX PubMed=2085478;
DI NCIt; C4028; Cervical squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W480 ! KIMI-2
SX Female
CA Cancer cell line
//
ID KIMI-2
AC CVCL_W480
RX PubMed=2085478;
DI NCIt; C4028; Cervical squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W479 ! KIMI-1
SX Female
CA Cancer cell line
//
ID Kimura
AC CVCL_IU38
RX PubMed=9454894;
RX PubMed=12967475;
CC Characteristics: EBV-negative.
CC Omics: Transcriptome analysis.
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID Kin Sun
AC CVCL_Y125
DR ATCC; CRL-1241
CC Discontinued: ATCC; CRL-1241; true.
DI NCIt; C3040; Fibrodysplasia ossificans progressiva
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID KIND-1
AC CVCL_B234
SY KIND1; NIRRHe001-A
DR hPSCreg; NIRRHe001-A
DR ISCR; 1645
RX PubMed=18699724;
RX PubMed=21614653;
CC From: National Institute for Research in Reproductive Health; Mumbai; India.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KIND-2
AC CVCL_B235
SY KIND2; NIRRHe002-A
DR hPSCreg; NIRRHe002-A
DR ISCR; 1646
RX PubMed=18699724;
RX PubMed=21614653;
CC From: National Institute for Research in Reproductive Health; Mumbai; India.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KINGS-1
AC CVCL_1328
SY Kings-1
DR BioSample; SAMN03470889
DR CGH-DB; 143-1
DR ChEMBL-Cells; CHEMBL3308264
DR ChEMBL-Targets; CHEMBL2366229
DR Cosmic; 907279
DR Cosmic; 2367531
DR Cosmic-CLP; 907279
DR GDSC; 907279
DR GEO; GSM1669986
DR IFO; IFO50435
RX CelloPub=CLPUB00151;
RX PubMed=16232199;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 9,11
ST D18S51: 18,26
ST D19S433: 13,14
ST D21S11: 30,31
ST D2S1338: 17,19
ST D3S1358: 15
ST D5S818: 11,13
ST D7S820: 10,12
ST D8S1179: 11,16
ST FGA: 23,24
ST Penta D: 10,13
ST Penta E: 16,25
ST TH01: 7,9
ST TPOX: 8,11
ST vWA: 14,17
DI NCIt; C9477; Anaplastic astrocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KiPS3F-7
AC CVCL_C994
SY [K]iPS3F-7; ESi028-A-1
DR BioSamples; SAMEA7774168
DR hPSCreg; ESi028-A-1
WW http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-ejecucion/fd-programas-investigacion/fd-investigacion-terapia-celular-medicina-regenerativa/fd-banco-nacional-lineas-celulares/fd-lineas-celulares-disponibles/KiPS3F_7.pdf
CC From: Center of Regenerative Medicine in Barcelona; Barcelona; Spain.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Induced pluripotent stem cell
//
ID KiPS3F1
AC CVCL_C995
SY KIPS3F1
DR ISCR; 229
RX PubMed=18931654;
CC From: The Salk Institute for Biological Studies; San Diego; USA.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C996 ! KiPS3F2
OI CVCL_C999 ! KiPS4F1
OI CVCL_D000 ! KiPS4F2
OI CVCL_D001 ! KiPS4F3
OI CVCL_D002 ! KiPS4F4
SX Male
CA Induced pluripotent stem cell
//
ID KiPS3F2
AC CVCL_C996
SY KIPS3F2
DR ISCR; 252
RX PubMed=18931654;
CC From: The Salk Institute for Biological Studies; San Diego; USA.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C995 ! KiPS3F1
OI CVCL_C999 ! KiPS4F1
OI CVCL_D000 ! KiPS4F2
OI CVCL_D001 ! KiPS4F3
OI CVCL_D002 ! KiPS4F4
SX Male
CA Induced pluripotent stem cell
//
ID KiPS4F-1
AC CVCL_C997
SY [K]iPS4F-1; ESi028-A
DR BioSamples; SAMEA7790668
DR hPSCreg; ESi028-A
WW http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-ejecucion/fd-programas-investigacion/fd-investigacion-terapia-celular-medicina-regenerativa/fd-banco-nacional-lineas-celulares/fd-lineas-celulares-disponibles/KiPS4f_1.pdf
CC From: Center of Regenerative Medicine in Barcelona; Barcelona; Spain.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C998 ! KiPS4F-8
SX Male
CA Induced pluripotent stem cell
//
ID KiPS4F-8
AC CVCL_C998
SY [K]iPS4F-8; ESi008-A
DR BioSamples; SAMEA3303318
DR hPSCreg; ESi008-A
WW http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-ejecucion/fd-programas-investigacion/fd-investigacion-terapia-celular-medicina-regenerativa/fd-banco-nacional-lineas-celulares/fd-lineas-celulares-disponibles/KiPS4F_8.pdf
CC From: Center of Regenerative Medicine in Barcelona; Barcelona; Spain.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C997 ! KiPS4F-1
SX Male
CA Induced pluripotent stem cell
//
ID KiPS4F1
AC CVCL_C999
SY KIPS4F1
DR ISCR; 251
RX PubMed=18931654;
CC From: The Salk Institute for Biological Studies; San Diego; USA.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C995 ! KiPS3F1
OI CVCL_C996 ! KiPS3F2
OI CVCL_D000 ! KiPS4F2
OI CVCL_D001 ! KiPS4F3
OI CVCL_D002 ! KiPS4F4
SX Male
CA Induced pluripotent stem cell
//
ID KiPS4F2
AC CVCL_D000
SY KIPS4F2
DR ISCR; 250
RX PubMed=18931654;
CC From: The Salk Institute for Biological Studies; San Diego; USA.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C995 ! KiPS3F1
OI CVCL_C996 ! KiPS3F2
OI CVCL_C999 ! KiPS4F1
OI CVCL_D001 ! KiPS4F3
OI CVCL_D002 ! KiPS4F4
SX Male
CA Induced pluripotent stem cell
//
ID KiPS4F3
AC CVCL_D001
SY KIPS4F3
DR ISCR; 232
RX PubMed=18931654;
CC From: The Salk Institute for Biological Studies; San Diego; USA.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C995 ! KiPS3F1
OI CVCL_C996 ! KiPS3F2
OI CVCL_C999 ! KiPS4F1
OI CVCL_D000 ! KiPS4F2
OI CVCL_D002 ! KiPS4F4
SX Male
CA Induced pluripotent stem cell
//
ID KiPS4F4
AC CVCL_D002
SY KIPS4F4
DR ISCR; 231
RX PubMed=18931654;
CC From: The Salk Institute for Biological Studies; San Diego; USA.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_C995 ! KiPS3F1
OI CVCL_C996 ! KiPS3F2
OI CVCL_C999 ! KiPS4F1
OI CVCL_D000 ! KiPS4F2
OI CVCL_D001 ! KiPS4F3
SX Male
CA Induced pluripotent stem cell
//
ID KIS-1
AC CVCL_M506
RX PubMed=2852183;
RX PubMed=3034807;
RX PubMed=19358282;
DI NCIt; C8851; Diffuse large B-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kit225
AC CVCL_5443
SY KIT225; Kit-225; KIT 225; Kit 225
DR CCRID; 3111C0002000000021
DR GEO; GSM1374599
DR Lonza; 331
RX PubMed=3115332;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=Kit225
CC Omics: Transcriptome analysis.
DI NCIt; C70649; T-cell chronic lymphocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kit225/K6
AC CVCL_5445
SY Kit-225-K6; Kit 225-K6; Kit 225 K6; Kit225-K6; Kit225 K6
DI NCIt; C70649; T-cell chronic lymphocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5443 ! Kit225
SX Male
CA Cancer cell line
//
ID KIZ-81A
AC CVCL_0A01
SY Tufted Deer
DR CLO; CLO_0009446
DR CLDB; cl4573
DR ECACC; 96011147
RX CelloPub=CLPUB00215;
CC Problematic cell line: Misidentified. Originally thought to be of tufted deer origin (Elaphodus cephalophus) but seems to be (see ECACC 96011147) from another yet undefined deer species.
OX NCBI_TaxID=9850; ! Cervidae
SX Male
CA Finite cell line
//
ID KJ 16
AC CVCL_D668
DR BCRJ; 0133
CC Discontinued: BCRJ; 0133; probable.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Hybridoma
//
ID KJ 23
AC CVCL_D669
DR BCRJ; 0134
CC Discontinued: BCRJ; 0134; probable.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Hybridoma
//
ID KJ 25
AC CVCL_D670
DR BCRJ; 0135
CC Discontinued: BCRJ; 0135; probable.
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Hybridoma
//
ID KJ-A
AC CVCL_1Q78
DR RCB; RCB2725
RX PubMed=17317792;
CC Breed/subspecies: Fischer 344/DuCrj.
DI NCIt; C60442; Rat malignant fibrous histiocytoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Male
CA Cancer cell line
//
ID Kj-LCL
AC CVCL_6D80
RX PubMed=8127151;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KJ-SV40
AC CVCL_9W54
RX PubMed=6314331;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KJ29
AC CVCL_8252
SY KJ-29
DR BTO; BTO:0002971
RX DOI=10.1016/S0309-1651(86)80049-2;
RX PubMed=8572614;
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KJOS-II
AC CVCL_M781
RX PubMed=19424640;
CC Derived from metastatic site: Axillary lymph node.
DI NCIt; C3879; Thyroid gland medullary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KK
AC CVCL_F844
DR CGH-DB; 328-2
DR Cosmic; 931361
DR Cosmic; 1223313
DR Cosmic; 1328072
DR Cosmic; 1434897
DR Cosmic; 2074242
DR GEO; GSM659379
RX PubMed=7844449;
RX PubMed=8148309;
RX PubMed=15677628;
RX PubMed=17671176;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
DI NCIt; C40078; Ovarian clear cell adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KK-1 [Human leukemia]
AC CVCL_X908
DR CGH-DB; 9028-4
RX PubMed=1861543;
RX PubMed=10570904;
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_X909 ! KK-5
SX Male
CA Cancer cell line
//
ID KK-1 [Mouse granulosa]
AC CVCL_6663
SY KK1
RX PubMed=7565808;
RX PubMed=15541573;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Transformed cell line
//
ID KK-3
AC CVCL_6664
RX PubMed=7565808;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Transformed cell line
//
ID KK-5
AC CVCL_X909
RX PubMed=1861543;
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_X908 ! KK-1 [Human leukemia]
SX Male
CA Cancer cell line
//
ID KK-m
AC CVCL_HF89
SY KKm
RX CelloPub=CLPUB00362;
RX PubMed=16127291;
CC Derived from metastatic site: Lymph node.
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_HF90 ! KK-p
CA Cancer cell line
//
ID KK-p
AC CVCL_HF90
SY KKp
RX CelloPub=CLPUB00362;
RX PubMed=16127291;
DI NCIt; C4648; Tongue squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_HF89 ! KK-m
CA Cancer cell line
//
ID KK0127
AC CVCL_8X90
DR ECACC; 89061801
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C3362; Schizophrenia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KK0206
AC CVCL_Z615
RX PubMed=17374419;
CC Doubling time: 72 hours (PubMed=17374419).
CC Derived from metastatic site: Lymph node.
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KK0560
AC CVCL_8X91
DR ECACC; 92090407
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KK0713
AC CVCL_8X92
DR ECACC; 95112206
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8X93 ! KK0920
SX Female
CA Transformed cell line
//
ID KK0920
AC CVCL_8X93
DR ECACC; 97090907
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8X92 ! KK0713
SX Female
CA Transformed cell line
//
ID KK1050
AC CVCL_8X94
DR ECACC; 98061804
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KK124
AC CVCL_N704
SY KK 124
RX PubMed=1325212;
RX PubMed=3018508;
RX PubMed=6243721;
RX PubMed=6243722;
RX PubMed=6265077;
RX PubMed=6286763;
RX PubMed=8344493;
RX PubMed=9973220;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Caution: It is possible that KK124 and KK125 (CVCL_B495) are the same cell line.
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KK125
AC CVCL_B495
SY KK 125
DR Cosmic; 931126
RX PubMed=2052620;
RX PubMed=9473234;
CC Caution: It is possible that KK124 (CVCL_N704) and KK125 are the same cell line.
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KK47
AC CVCL_8253
SY KK-47
DR BTO; BTO:0003552
DR ChEMBL-Cells; CHEMBL3308615
DR ChEMBL-Targets; CHEMBL614674
DR Cosmic; 925824
DR Cosmic; 2037949
DR GEO; GSM492492
DR GEO; GSM1374600
DR GEO; GSM1574547
DR TKG; TKG 0663
RX PubMed=470258;
RX PubMed=604596;
RX PubMed=1353119;
RX PubMed=3708594;
RX PubMed=6244232;
RX PubMed=24018021;
RX PubMed=25997541;
CC Part of: BLA-40 bladder carcinoma cell line panel.
CC Part of: UBC-40 urothelial bladder cancer cell line index.
CC Omics: CNV analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): TKG
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,13.3
ST D16S539: 9,10
ST D5S818: 11,12,13
ST D7S820: 8,12
ST TH01: 7
ST TPOX: 12
ST vWA: 17,18
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KK47/ADM
AC CVCL_8254
RX PubMed=1353119;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8253 ! KK47
SX Male
CA Cancer cell line
//
ID KK47/DDP10
AC CVCL_8255
DR CGH-DB; 9111-4
RX PubMed=9072542;
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8253 ! KK47
SX Male
CA Cancer cell line
//
ID KK47/DDP20
AC CVCL_8256
DR CGH-DB; 9112-4
RX PubMed=9072542;
RX PubMed=14973057;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8253 ! KK47
SX Male
CA Cancer cell line
//
ID KKA
AC CVCL_5T72
RX PubMed=2303715;
CC Transformant: NCBI_TaxID; 11841; Gross passage A murine leukemia virus (Gross-MuLV).
CC Breed/subspecies: BALB.K.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KKB
AC CVCL_J855
DR CLO; CLO_0050221
DR RCB; RCB1601
RX PubMed=1717631;
RX PubMed=2303715;
CC Transformant: NCBI_TaxID; 11841; Gross passage A murine leukemia virus (Gross-MuLV).
CC Breed/subspecies: BALB.K.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KKC
AC CVCL_J856
DR CLO; CLO_0050219
DR RCB; RCB1597
RX PubMed=2303715;
CC Transformant: NCBI_TaxID; 11841; Gross passage A murine leukemia virus (Gross-MuLV).
CC Breed/subspecies: BALB.K.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KKF
AC CVCL_J857
DR CLO; CLO_0050220
DR RCB; RCB1600
RX PubMed=1717631;
CC Transformant: NCBI_TaxID; 11841; Gross passage A murine leukemia virus (Gross-MuLV).
CC Breed/subspecies: BALB.K.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID KKLS
AC CVCL_1B37
DR ChEMBL-Cells; CHEMBL3307839
DR ChEMBL-Targets; CHEMBL613996
RX CelloPub=CLPUB00239;
RX PubMed=8608561;
CC Doubling time: 25-30 hours (CelloPub=CLPUB00239).
CC Derived from metastatic site: Lymph node.
DI NCIt; C4004; Gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KKM-A
AC CVCL_X152
RX PubMed=1696435;
DI NCIt; C6064; Maxillary sinus squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_X153 ! KKM-B
OI CVCL_X154 ! KKM-C
OI CVCL_X155 ! KKM-D
SX Male
CA Cancer cell line
//
ID KKM-B
AC CVCL_X153
RX PubMed=1696435;
DI NCIt; C6064; Maxillary sinus squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_X152 ! KKM-A
OI CVCL_X154 ! KKM-C
OI CVCL_X155 ! KKM-D
SX Male
CA Cancer cell line
//
ID KKM-C
AC CVCL_X154
RX PubMed=1696435;
DI NCIt; C6064; Maxillary sinus squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_X152 ! KKM-A
OI CVCL_X153 ! KKM-B
OI CVCL_X155 ! KKM-D
SX Male
CA Cancer cell line
//
ID KKM-D
AC CVCL_X155
RX PubMed=1696435;
DI NCIt; C6064; Maxillary sinus squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_X152 ! KKM-A
OI CVCL_X153 ! KKM-B
OI CVCL_X154 ! KKM-C
SX Male
CA Cancer cell line
//
ID KKPS5
AC CVCL_6E28
RX PubMed=26111446;
CC Characteristics: Arid3a deficient cells seem to be multipotent, developmentally plastic cells.
CC Knockout cell: Method=KO mouse; MGI; MGI:1328360; Arid3a.
OX NCBI_TaxID=10090; ! Mus musculus
CA Spontaneously immortalized cell line
//
ID KKS-2
AC CVCL_Y277
RX PubMed=9177455;
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KKU-100
AC CVCL_3996
SY KKU100; K100
DR BTO; BTO:0003934
DR JCRB; JCRB1568
RX CelloPub=CLPUB00275;
RX PubMed=15884115;
RX PubMed=15948244;
RX PubMed=20493868;
RX PubMed=21871105;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 9
ST D16S539: 10,11
ST D5S818: 11,13
ST D7S820: 8,11
ST TH01: 8,9
ST TPOX: 8,9
ST vWA: 17,19
DI NCIt; C36077; Hilar cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KKU-M055
AC CVCL_M258
SY KKUM055; M055
DR JCRB; JCRB1551
RX PubMed=15884115;
RX PubMed=21871105;
RX PubMed=22926522;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 11
ST D16S539: 10,13
ST D5S818: 11
ST D7S820: 7,8
ST TH01: 9
ST TPOX: 8
ST vWA: 17,19
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KKU-M139
AC CVCL_M259
SY KKUM139; M139; KKU-139
DR BTO; BTO:0005467
RX PubMed=20493868;
RX PubMed=21871105;
RX PubMed=22926522;
RX PubMed=25998688;
CC Doubling time: 17.36 +- 1.26 hours (PubMed=25998688).
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KKU-M139/GEM
AC CVCL_HF57
RX PubMed=25998688;
CC Doubling time: 20.32 +- 2.79 hours (PubMed=25998688).
CC Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M259 ! KKU-M139
CA Cancer cell line
//
ID KKU-M156
AC CVCL_M260
SY KKUM156; M156
DR JCRB; JCRB1561
RX PubMed=15884115;
RX PubMed=20493868;
RX PubMed=21871105;
RX PubMed=22926522;
CC Problematic cell line: Contaminated. Shown to be a KKU-M213 derivative (see JCRB web site).
CC Discontinued: JCRB; JCRB1561; probable.
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M261 ! KKU-M213
SX Male
CA Cancer cell line
//
ID KKU-M213
AC CVCL_M261
SY KKUM213; M213
DR JCRB; JCRB1557
RX PubMed=20493868;
RX PubMed=21871105;
RX PubMed=22926522;
CC Discontinued: JCRB; JCRB1557; probable.
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KKU-M213L0H
AC CVCL_M262
RX PubMed=22926522;
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M261 ! KKU-M213
SX Male
CA Cancer cell line
//
ID KKU-M213L5H
AC CVCL_M263
RX PubMed=22926522;
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M261 ! KKU-M213
SX Male
CA Cancer cell line
//
ID KKU-M214
AC CVCL_M264
SY KKUM214; M214
DR JCRB; JCRB1556
RX PubMed=15884115;
RX PubMed=21871105;
RX PubMed=22926522;
RX PubMed=25998688;
CC Problematic cell line: Contaminated. Shown to be a KKU-M213 derivative (see JCRB web site).
CC Doubling time: 22.68 +- 2.20 hours (PubMed=25998688).
CC Discontinued: JCRB; JCRB1556; probable.
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M261 ! KKU-M213
SX Male
CA Cancer cell line
//
ID KKU-M214/GEM
AC CVCL_HF58
RX PubMed=25998688;
CC Problematic cell line: Contaminated. Parent cell line (KKU-M214) shown to be a KKU-M213 derivative.
CC Doubling time: 25.21 +- 1.88 hours (PubMed=25998688).
CC Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M264 ! KKU-M214
SX Male
CA Cancer cell line
//
ID KKU-OCA17
AC CVCL_M265
RX PubMed=15884115;
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KL277
AC CVCL_8962
DR CLO; CLO_0007101
DR ATCC; CRL-2030
RX PubMed=1648172;
OX NCBI_TaxID=10032; ! Cricetulus migratorius
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KL295
AC CVCL_G230
DR CLO; CLO_0007102
DR ATCC; CRL-1996
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KL304
AC CVCL_G231
DR CLO; CLO_0007103
DR ATCC; CRL-2027
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KL5B
AC CVCL_T059
RX PubMed=10069471;
CC Doubling time: 26 hours, at 19th passage (PubMed=10069471).
CC Transformant: ChEBI; CHEBI:134609; Nitrosobis(2-oxopropyl)amine.
OX NCBI_TaxID=10036; ! Mesocricetus auratus
HI CVCL_T060 ! KL5N
SX Male
CA Transformed cell line
//
ID KL5N
AC CVCL_T060
RX PubMed=10069471;
RX PubMed=10824687;
CC Doubling time: 48 hours (PubMed=10069471).
OX NCBI_TaxID=10036; ! Mesocricetus auratus
SX Male
CA Spontaneously immortalized cell line
//
ID KLBIQ-Chsu-I
AC CVCL_Z275
RX PubMed=25381037;
CC Group: Insect cell line.
CC Doubling time: ~62 hours (PubMed=25381037).
CC Misspelling: 'ZJBIQ-Chsu-I' in abstract of PubMed=25381037.
OX NCBI_TaxID=168631; ! Chilo suppressalis
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KLC
AC CVCL_AS99
SY GM16726
DR CLO; CLO_0018423
DR Coriell; GM16726
RX PubMed=10509003;
DI NCIt; C8644; B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KLC-HSV2
AC CVCL_AT00
SY GM16727
DR CLO; CLO_0018422
DR Coriell; GM16727
RX PubMed=10509003;
CC Characteristics: In vitro infected by HSV-2.
DI NCIt; C8644; B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_AS99 ! KLC
SX Male
CA Cancer cell line
//
ID KLE
AC CVCL_1329
DR BTO; BTO:0005079
DR CLO; CLO_0007104
DR EFO; EFO_0002220
DR ATCC; CRL-1622
DR BCRJ; 0365
DR BioSample; SAMN03473101
DR CCLE; KLE_ENDOMETRIUM
DR CCRID; 3111C0001CCC000379
DR CCRID; 3142C0001000000120
DR ChEMBL-Cells; CHEMBL3308518
DR ChEMBL-Targets; CHEMBL2366239
DR Cosmic; 713476
DR Cosmic; 713493
DR Cosmic; 809133
DR Cosmic; 846179
DR Cosmic; 871554
DR Cosmic; 889114
DR Cosmic; 924187
DR Cosmic; 980636
DR Cosmic; 1007161
DR Cosmic; 1066225
DR Cosmic; 1070809
DR Cosmic; 1177622
DR Cosmic; 1223485
DR Cosmic; 1241349
DR Cosmic; 1576461
DR Cosmic; 1622900
DR Cosmic; 1696759
DR Cosmic; 2030477
DR Cosmic-CLP; 924187
DR GDSC; 924187
DR GEO; GSM374973
DR GEO; GSM375432
DR GEO; GSM844574
DR GEO; GSM844575
DR GEO; GSM887211
DR GEO; GSM888284
DR GEO; GSM1669987
DR IGRhCellID; KLE
DR IZSLER; BS TCL 230
RX PubMed=1541432;
RX PubMed=6706226;
RX PubMed=8123477;
RX PubMed=22460905;
RX PubMed=22710073;
RX PubMed=25485619;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 13,14
ST D13S317: 12
ST D16S539: 11,12
ST D18S51: 13,17
ST D21S11: 28,30
ST D3S1358: 17
ST D5S818: 9,12
ST D7S820: 11,12
ST D8S1179: 8,14
ST FGA: 23,25
ST Penta D: 13
ST Penta E: 7
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 16
DI NCIt; C7359; Endometrial adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KLM-1
AC CVCL_5146
SY KLM1
DR CLO; CLO_0050104
DR EFO; EFO_0006610
DR BioSample; SAMN03472943
DR CCLE; KLM1_PANCREAS
DR GEO; GSM888285
DR RCB; RCB2138
DR TKG; TKG 0490
RX PubMed=8872523;
RX PubMed=22460905;
RX PubMed=25485619;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
ST Source(s): PubMed=25877200; RCB; TKG
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 10
ST D16S539: 12
ST D18S51: 13
ST D21S11: 31
ST D3S1358: 15
ST D5S818: 11,12
ST D7S820: 11
ST D8S1179: 10,15
ST FGA: 24
ST Penta D: 9
ST Penta E: 9,20
ST TH01: 9
ST TPOX: 9,11
ST vWA: 15,19
DI NCIt; C9120; Pancreatic ductal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4717 ! PK-1
SX Male
CA Cancer cell line
//
ID KLM-2
AC CVCL_8257
SY KLM 2
RX PubMed=230517;
RX PubMed=6978745;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C7171; Acute monoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KLN205
AC CVCL_3533
SY KLN 205; KLN-205
DR BTO; BTO:0001589
DR CLO; CLO_0007105
DR CLO; CLO_0050214
DR CLDB; cl3032
DR ATCC; CRL-1453
DR BCRC; 60207
DR CLS; 400419/p650_KLN-205
DR ECACC; 90110519
DR RCB; RCB2623
DR TKG; TKG 0214
RX PubMed=418873;
RX PubMed=7419233;
CC Breed/subspecies: DBA/2.
DI NCIt; C21769; Malignant tumors of the mouse pulmonary system
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID KLN205-MUC1
AC CVCL_8725
DR CLO; CLO_0050213
DR RCB; RCB2614
DR TKG; TKG 0473
CC Transfected with: HGNC; 7508; MUC1.
CC Breed/subspecies: DBA/2.
DI NCIt; C21769; Malignant tumors of the mouse pulmonary system
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3533 ! KLN205
CA Cancer cell line
//
ID KLO
AC CVCL_E727
DR dbMHC; 48925
DR ECACC; 94050324
DR IHW; IHW9213
DR IMGT/HLA; 10919
WW http://bioinformatics.hsanmartino.it/ecbr/cl213.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KM
AC CVCL_Y114
SY Kin and Maru
RX PubMed=11676982;
CC Doubling time: 16 hours (PubMed=11676982).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Anecdotal: Cell name corresponds to the first letters of the names of the first and last authors.
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KM-1
AC CVCL_W405
SY KM1
DR CGH-DB; 14-1
DR CGH-DB; 9126-4
RX PubMed=9738977;
RX PubMed=15215163;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KM-101
AC CVCL_DE25
SY KM 101; KM101
RX PubMed=2347717;
RX PubMed=3182348;
RX PubMed=3858834;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [pSV3-gpt].
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_0376 ! KM-102
OI CVCL_DE26 ! KM-103
OI CVCL_DE27 ! KM-104
OI CVCL_DE28 ! KM-105
SX Male
CA Transformed cell line
//
ID KM-102
AC CVCL_0376
SY KM 102; KM102
DR MCCL; MCC:0000271
RX PubMed=3182348;
RX PubMed=3858834;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KM102
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [pSV3-gpt].
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DE25 ! KM-101
OI CVCL_DE26 ! KM-103
OI CVCL_DE27 ! KM-104
OI CVCL_DE28 ! KM-105
SX Male
CA Transformed cell line
//
ID KM-103
AC CVCL_DE26
SY KM 103; KM103
RX PubMed=3182348;
RX PubMed=3858834;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [pSV3-gpt].
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DE25 ! KM-101
OI CVCL_0376 ! KM-102
OI CVCL_DE27 ! KM-104
OI CVCL_DE28 ! KM-105
SX Male
CA Transformed cell line
//
ID KM-104
AC CVCL_DE27
SY KM 104; KM104
RX PubMed=2347717;
RX PubMed=3182348;
RX PubMed=3858834;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [pSV3-gpt].
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DE25 ! KM-101
OI CVCL_0376 ! KM-102
OI CVCL_DE26 ! KM-103
OI CVCL_DE28 ! KM-105
SX Male
CA Transformed cell line
//
ID KM-105
AC CVCL_DE28
SY KM 105; KM105
RX PubMed=3182348;
RX PubMed=3858834;
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [pSV3-gpt].
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DE25 ! KM-101
OI CVCL_0376 ! KM-102
OI CVCL_DE26 ! KM-103
OI CVCL_DE27 ! KM-104
SX Male
CA Transformed cell line
//
ID KM-11
AC CVCL_W410
DR CGH-DB; 18-1
DR CGH-DB; 9131-4
RX PubMed=15215163;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KM-3
AC CVCL_0011
SY KM3; Km3
DR BTO; BTO:0000681
DR BioSample; SAMN03151905
RX PubMed=68013;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a Reh derivative (PubMed=12592342, PubMed=20143388).
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1650 ! Reh
SX Female
CA Cancer cell line
//
ID KM-4
AC CVCL_W406
SY KM4
DR CGH-DB; 15-1
DR CGH-DB; 9127-4
DR GEO; GSM143341
DR GEO; GSM290292
RX PubMed=11429052;
RX PubMed=15215163;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KM-5
AC CVCL_W407
SY KM5
DR CGH-DB; 16-1
DR CGH-DB; 9128-4
RX PubMed=10557056;
RX PubMed=11429052;
RX PubMed=12886255;
RX PubMed=15215163;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KM-6
AC CVCL_W408
SY KM6
DR CGH-DB; 17-1
DR CGH-DB; 9129-4
RX PubMed=15215163;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KM-7
AC CVCL_W409
SY KM7
DR CGH-DB; 19-1
DR CGH-DB; 9130-4
RX PubMed=11429052;
RX PubMed=15215163;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KM-H2
AC CVCL_1330
AS CVCL_2978
SY KM H-2; KMH2
DR BTO; BTO:0004972
DR CLO; CLO_0007112
DR CLDB; cl3033
DR BioSample; SAMN03473401
DR CCLE; KMH2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308204
DR ChEMBL-Targets; CHEMBL2366250
DR Cosmic; 909976
DR Cosmic; 988704
DR Cosmic; 1013910
DR Cosmic; 1086357
DR Cosmic; 1191707
DR Cosmic; 1289700
DR Cosmic; 1290219
DR Cosmic; 1432041
DR Cosmic; 2276325
DR Cosmic; 2361388
DR Cosmic; 2464308
DR Cosmic-CLP; 909976
DR DSMZ; ACC-8
DR GDSC; 909976
DR GEO; GSM335391
DR GEO; GSM552446
DR GEO; GSM499723
DR GEO; GSM499731
DR GEO; GSM637987
DR GEO; GSM887214
DR GEO; GSM888288
DR GEO; GSM1669990
DR Lonza; 21
DR PRIDE; PXD000589
RX PubMed=2602653;
RX PubMed=2690233;
RX PubMed=3013343;
RX PubMed=8547074;
RX PubMed=22460905;
RX PubMed=25355872;
RX PubMed=25894527;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~48 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Cell surface proteome.
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X
ST CSF1PO: 10,14
ST D13S317: 10,11
ST D16S539: 9
ST D5S818: 11,13
ST D7S820: 10,11,12
ST TH01: 7,9
ST TPOX: 8,11,12 (Cosmic-CLP)
ST TPOX: 8,10,11 (DSMZ)
ST vWA: 17,18
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KM0027
AC CVCL_8X95
DR ECACC; 01033027
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KM105
AC CVCL_G371
DR TKG; TKG 0215
OX NCBI_TaxID=10090; ! Mus musculus
CA Hybridoma
//
ID KM114
AC CVCL_9188
DR CLO; CLO_0007106
DR ATCC; TIB-242
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KM12
AC CVCL_1331
SY KM-12; KM.12
DR BTO; BTO:0003172
DR EFO; EFO_0006282
DR BioSample; SAMN03471909
DR CCLE; KM12_LARGE_INTESTINE
DR ChEMBL-Cells; CHEMBL3307689
DR ChEMBL-Targets; CHEMBL614709
DR Cosmic; 875903
DR Cosmic; 887227
DR Cosmic; 905989
DR Cosmic; 974247
DR Cosmic; 1092609
DR Cosmic; 1175843
DR Cosmic; 1305356
DR Cosmic; 1312340
DR Cosmic; 1436018
DR Cosmic; 1479631
DR Cosmic; 1676739
DR Cosmic; 1805256
DR Cosmic; 1995469
DR Cosmic; 1998451
DR Cosmic; 2301990
DR Cosmic-CLP; 905989
DR GDSC; 905989
DR GEO; GSM50191
DR GEO; GSM50255
DR GEO; GSM206516
DR GEO; GSM750797
DR GEO; GSM799334
DR GEO; GSM799397
DR GEO; GSM844576
DR GEO; GSM844577
DR GEO; GSM846361
DR GEO; GSM887212
DR GEO; GSM888286
DR GEO; GSM1153404
DR GEO; GSM1181253
DR GEO; GSM1181266
DR GEO; GSM1346877
DR GEO; GSM1448073
DR GEO; GSM1669988
DR SKY/M-FISH/CGH; 2795
RX PubMed=2041050;
RX PubMed=9515795;
RX PubMed=17088437;
RX PubMed=19372543;
RX PubMed=22336246;
RX PubMed=22460905;
RX PubMed=23856246;
RX PubMed=23933261;
RX PubMed=24755471;
RX PubMed=25926053;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=26537799;
RX PubMed=27397505;
RX PubMed=27807467;
RX PubMed=28196595;
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW https://strap.nci.nih.gov/celline_detail.php?sample_id=21
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: JFCR39 cancer cell line panel.
CC Part of: MD Anderson Cell Lines Project.
CC Part of: NCI60 cancer cell line panel.
CC Doubling time: 23 hours (PubMed=25984343); 23.7 hours (DTP).
CC Microsatellite instability: Instable (MSI-high) (PubMed=25926053; Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep glycome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'KIM12' in GEO GSM846361.
ST Source(s): Cosmic-CLP; PubMed=11416159; PubMed=19372543; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 12,15
ST D16S539: 11
ST D18S51: 13
ST D19S433: 11,14
ST D21S11: 27
ST D3S1358: 14
ST D5S818: 10,17 (Cosmic-CLP)
ST D5S818: 10,18 (PubMed=19372543)
ST D5S818: 10 (PubMed=25877200)
ST D7S820: 8,9 (Cosmic-CLP)
ST D7S820: 8,8.3 (PubMed=19372543; PubMed=25877200)
ST D8S1179: 11,13
ST FGA: 20,22
ST Penta D: 12
ST Penta E: 14,18
ST TH01: 9.3
ST TPOX: 11,12
ST vWA: 17 (PubMed=11416159)
ST vWA: 17,19 (Cosmic-CLP; PubMed=19372543; PubMed=25877200)
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Cancer cell line
//
ID KM12-C
AC CVCL_9547
SY KM12 C; KM-12C; KM12C; Km12C
DR BTO; BTO:0003312
DR ATCC; CRL-12533
DR GEO; GSM1448186
DR KCLB; 80015
RX PubMed=2846163;
RX PubMed=3349467;
RX PubMed=10091941;
RX PubMed=25926053;
CC Registration: Chiron Master Culture Collection; CMCC 11611 (CMCC #11611).
CC Microsatellite instability: Instable (MSI) (PubMed=25926053).
CC Omics: Transcriptome analysis.
CC Discontinued: ATCC; CRL-12533; probable.
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1331 ! KM12
SX Sex undetermined
CA Cancer cell line
//
ID KM12-HX
AC CVCL_4M93
SY KM12HX
RX PubMed=1679016;
RX PubMed=7529188;
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9547 ! KM12-C
SX Sex undetermined
CA Cancer cell line
//
ID KM12-L4
AC CVCL_5946
SY KM12L4; Km12L4; KM12 L4; Km 12 L4
DR GEO; GSM1448187
DR KCLB; 80014
RX PubMed=2846163;
RX PubMed=3349467;
RX PubMed=8909255;
RX PubMed=10091941;
RX PubMed=25926053;
CC Microsatellite instability: Instable (MSI) (PubMed=25926053).
CC Omics: Transcriptome analysis.
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1331 ! KM12
SX Sex undetermined
CA Cancer cell line
//
ID KM12-L4A
AC CVCL_W220
SY Km 12 L4A; KM12L4-A; KM12L4A; KM12L4a
DR ATCC; CRL-12496
RX PubMed=3349467;
CC Registration: Chiron Master Culture Collection; CMCC 11606 (CMCC #11606).
CC Discontinued: ATCC; CRL-12496; true.
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5946 ! KM12-L4
SX Sex undetermined
CA Cancer cell line
//
ID KM12-Luc
AC CVCL_J258
SY KM-12-Luc
DR JCRB; JCRB1389
DR JCRB; NIHS0647
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
CC Discontinued: JCRB; NIHS0647; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 12,15,16
ST D16S539: 11
ST D5S818: 10,18,19
ST D7S820: 8,8.3
ST TH01: 9.3
ST TPOX: 11,12
ST vWA: 17,19
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1331 ! KM12
SX Sex undetermined
CA Cancer cell line
//
ID KM12-LX
AC CVCL_4M94
SY KM12LX
RX PubMed=1679016;
RX PubMed=7529188;
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9547 ! KM12-C
SX Sex undetermined
CA Cancer cell line
//
ID KM12-OxR
AC CVCL_5920
SY KM12L4 OxR
RX PubMed=16857785;
CC Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; L-OHP).
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5946 ! KM12-L4
SX Sex undetermined
CA Cancer cell line
//
ID KM12-SM
AC CVCL_9548
SY KM12SM; KM12 SM
DR Cosmic; 1524332
DR GEO; GSM1448188
DR KCLB; 80016
DR TOKU-E; 3802
RX PubMed=2846163;
RX PubMed=10091941;
RX PubMed=10987313;
RX PubMed=25926053;
CC Microsatellite instability: Instable (MSI) (PubMed=25926053).
CC Omics: Transcriptome analysis.
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_9547 ! KM12-C
SX Sex undetermined
CA Cancer cell line
//
ID KM12L4/OXR
AC CVCL_AU12
WW https://www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/core-facilities-and-services/characterized-cell-line-core-facility/services/cclc-list-to-distribute-updated.xlsx
CC Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; L-OHP).
DI NCIt; C4910; Colon carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_5946 ! KM12-L4
SX Sex undetermined
CA Cancer cell line
//
ID KM20
AC CVCL_L095
SY KM-20
DR GEO; GSM1448074
DR KCLB; 80017
RX PubMed=2846163;
RX PubMed=12060639;
RX PubMed=25926053;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (ICLAC; an early sample of KM20 had been tested by the core facility where the cell line was established and the STR profile corresponds to that of HT-29).
CC Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC Omics: Transcriptome analysis.
CC Discontinued: KCLB; 80017; probable.
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KM20-C
AC CVCL_0B38
SY KM20C; KM20c; KM-20C
DR BTO; BTO:0005615
RX PubMed=3349467;
CC Problematic cell line: Contaminated. Parent cell line (KM20) has been shown to be a HT-29 derivative.
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_L095 ! KM20
SX Female
CA Cancer cell line
//
ID KM201
AC CVCL_9189
SY KM 201
DR CLO; CLO_0007107
DR ATCC; TIB-240
DR ECACC; 93081113
RX PubMed=2406365;
CC Discontinued: ECACC; 93081113; probable.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KM20L2
AC CVCL_D889
SY KM-20L2; KM 20L2; KM 2012
DR BTO; BTO:0005911
DR ChEMBL-Cells; CHEMBL3307782
DR ChEMBL-Targets; CHEMBL614791
RX PubMed=3349467;
RX PubMed=15703300;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
WW https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=15703300; resulting in a decision not to include the cell line in the NCI60 panel).
CC Misspelling: Occasionally 'KM202L'.
DI NCIt; C43584; Rectosigmoid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0320 ! HT-29
SX Female
CA Cancer cell line
//
ID KM3 [Contaminated human melanoma]
AC CVCL_1R51
SY Mel-Km3; Km3
DR BioSample; SAMN03151998
RX PubMed=7520026;
RX PubMed=8980186;
RX PubMed=9120293;
RX PubMed=12740908;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Misidentified. Originally thought to be of human origin (astrocytoma) but found to be from rat (PubMed=12740908, PubMed=20143388). Originally thought to originate from a woman patient lymph nodes metastases of a melanoma.
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Sex undetermined
CA Undefined cell line type
//
ID KM3 [Human myeloma]
AC CVCL_GZ65
SY KM-3
RX PubMed=15198896;
RX PubMed=16706120;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KM3/BTZ
AC CVCL_GZ66
RX CelloPub=CLPUB00356;
RX DOI=10.6040/j.issn.1671-7554.2013.02.007;
CC Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_GZ65 ! KM3 [Human myeloma]
CA Cancer cell line
//
ID KM3/DDP
AC CVCL_GZ71
RX PubMed=26045737;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_GZ65 ! KM3 [Human myeloma]
CA Cancer cell line
//
ID KM703
AC CVCL_9190
SY KM 703
DR CLO; CLO_0007108
DR ATCC; CRL-1896
DR BCRJ; 0137
DR ECACC; 94090613
RX PubMed=2406365;
CC Discontinued: BCRJ; 0137; probable.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KM81
AC CVCL_9191
DR CLO; CLO_0007109
DR ATCC; TIB-241
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KM9304
AC CVCL_BS96
DR KCB; KCB 93048M
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KM9405
AC CVCL_BS92
DR CCRID; 3153C0001000000045
DR KCB; KCB 94013
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMA
AC CVCL_6413
DR CLO; CLO_0007110
DR ATCC; CRL-9856
DR BioSample; SAMN03471079
RX Patent=US5447861;
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 11,12
ST D16S539: 12,13
ST D5S818: 12,13
ST D7S820: 11,12
ST TH01: 6,9
ST TPOX: 8,9
ST vWA: 17
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Finite cell line
//
ID KMB-17
AC CVCL_6836
SY KMB17
DR CCRID; 3111C0002000000004
DR CCRID; 3142C0001000000005
DR CCRID; 3153C0001000000011
DR KCB; KCB 200410YJ
RX PubMed=6459859;
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID KMBC
AC CVCL_M267
DR Cosmic; 924010
RX CelloPub=CLPUB00275;
RX PubMed=1312890;
RX PubMed=9824643;
RX PubMed=21533411;
CC Doubling time: 67 hours (PubMed=9824643).
DI NCIt; C4436; Cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMBC-2
AC CVCL_2977
SY KMBC2
DR BioSample; SAMN03472464
DR CCLE; KMBC2_URINARY_TRACT
DR GEO; GSM887213
DR GEO; GSM888287
DR JCRB; JCRB1148
DR JCRB; NIHS0440
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0440; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 8,10
ST D16S539: 9,11
ST D5S818: 10,11
ST D7S820: 12
ST TH01: 8,9
ST TPOX: 8
ST vWA: 18
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KMBC-Hep
AC CVCL_0T72
RX PubMed=9824643;
CC Doubling time: 45 hours (PubMed=9824643).
DI NCIt; C4436; Cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_M267 ! KMBC
SX Male
CA Cancer cell line
//
ID KMC-1
AC CVCL_B269
RX CelloPub=CLPUB00275;
RX PubMed=1332997;
DI NCIt; C35417; Intrahepatic cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMC-2
AC CVCL_A635
RX PubMed=7742926;
DI NCIt; C118630; Liver adenosquamous carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMC8.8
AC CVCL_9192
DR CLO; CLO_0007111
DR ATCC; CRL-2212
RX PubMed=8630385;
CC Monoclonal antibody target: UniProtKB; P40240; Mouse Cd9.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KMCH-1
AC CVCL_7970
RX CelloPub=CLPUB00275;
RX PubMed=3032760;
CC Doubling time: ~39 hours (PubMed=3032760).
DI NCIt; C3828; Combined hepatocellular carcinoma and cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMCH-2
AC CVCL_7971
RX CelloPub=CLPUB00275;
RX PubMed=8738727;
CC Doubling time: ~44 hours (at 20th passage), ~32 hours (at 55th passage) (PubMed=8738727).
DI NCIt; C3828; Combined hepatocellular carcinoma and cholangiocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMEB1
AC CVCL_A275
SY SDUe002-A
DR hPSCreg; SDUe002-A
DR ISCR; 1374
RX PubMed=18393673;
RX PubMed=20198448;
CC From: University of Southern Denmark; Denmark.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KMEB2
AC CVCL_A276
SY SDUe007-A
DR hPSCreg; SDUe007-A
DR ISCR; 1375
RX PubMed=18393673;
RX PubMed=20198448;
CC From: University of Southern Denmark; Denmark.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KMEB3
AC CVCL_A277
SY SDUe003-A
DR hPSCreg; SDUe003-A
DR ISCR; 1376
RX PubMed=18393673;
RX PubMed=20198448;
CC From: University of Southern Denmark; Denmark.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KMEB4
AC CVCL_A278
SY SDUe004-A
DR hPSCreg; SDUe004-A
DR ISCR; 1377
RX PubMed=18393673;
RX PubMed=20198448;
CC From: University of Southern Denmark; Denmark.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Embryonic stem cell
//
ID KMEB5
AC CVCL_A279
SY SDUe005-A
DR hPSCreg; SDUe005-A
DR ISCR; 1378
RX PubMed=18393673;
RX PubMed=20198448;
CC From: University of Southern Denmark; Denmark.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Embryonic stem cell
//
ID KMeC
AC CVCL_L360
RX PubMed=15585963;
CC Breed/subspecies: Mixed breed.
DI NCIt; C120298; Canine melanoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Male
CA Cancer cell line
//
ID KMF-1
AC CVCL_AR98
DR BioSample; SAMN03472370
DR JCRB; NIHS0349
CC Discontinued: JCRB; NIHS0349; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 9,11
ST D13S317: 8
ST D16S539: 10,11
ST D5S818: 12,13
ST D7S820: 11,12
ST TH01: 6,7
ST TPOX: 8,11
ST vWA: 14,16
OX NCBI_TaxID=9606; ! Homo sapiens
CA Undefined cell line type
//
ID KMG-A
AC CVCL_D882
RX PubMed=2450224;
RX PubMed=21544480;
CC Doubling time: 28.5 hours (PubMed=2450224); 26 hours (PubMed=21544480).
DI NCIt; C3844; Gallbladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_M735 ! KMG-C
SX Male
CA Cancer cell line
//
ID KMG-C
AC CVCL_M735
SY KMGC
RX PubMed=21544480;
CC Doubling time: 19 hours (PubMed=21544480).
DI NCIt; C3844; Gallbladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_D882 ! KMG-A
SX Male
CA Cancer cell line
//
ID KMH-2
AC CVCL_S641
DR BioSample; SAMN03472496
DR Cosmic; 2054094
DR Cosmic-CLP; 1298167
DR GDSC; 1298167
DR GEO; GSM827259
DR GEO; GSM1669989
DR JCRB; JCRB1066
DR JCRB; NIHS0268
RX PubMed=11686581;
RX PubMed=23833040;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Discontinued: JCRB; NIHS0268; true.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 9
ST D16S539: 9,12
ST D5S818: 12,13
ST D7S820: 11
ST TH01: 9
ST TPOX: 8,11
ST vWA: 14,15
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMI6
AC CVCL_9193
AS CVCL_F274
SY KM16
DR CLO; CLO_0007113
DR ATCC; CRL-2179
DR BCRJ; 0136
RX PubMed=7532155;
CC Monoclonal antibody target: UniProtKB; P09055; Mouse Itgb1/Cd19.
CC Discontinued: BCRJ; 0136; probable.
OX NCBI_TaxID=10090; ! Mus musculus
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_2199 ! Sp2/0-Ag14
CA Hybridoma
//
ID KMITL-HA-E1
AC CVCL_Z388
SY KMITL-HA-E 1
RX CelloPub=CLPUB00168;
CC Group: Insect cell line.
OX NCBI_TaxID=29058; ! Helicoverpa armigera
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KMITL-PX-E1
AC CVCL_Z386
RX CelloPub=CLPUB00169;
CC Group: Insect cell line.
CC Doubling time: 61.22 hours, at 18th passage (CelloPub=CLPUB00169).
OX NCBI_TaxID=51655; ! Plutella xylostella
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KMK-R
AC CVCL_0I59
SY KMK
DR CCLV; CCLV-RIE 0901
RX PubMed=19941903;
OX NCBI_TaxID=9986; ! Oryctolagus cuniculus
CA Spontaneously immortalized cell line
//
ID KML-1
AC CVCL_2979
DR JCRB; JCRB1347
DR JCRB; NIHS0547
RX PubMed=7572991;
CC Discontinued: JCRB; NIHS0547; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 8
ST D16S539: 11
ST D5S818: 9,12
ST D7S820: 11,12
ST TH01: 7,9
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C3457; B-cell non-Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KML1
AC CVCL_4J73
RX Patent=US5132222;
RX PubMed=3091508;
CC Breed/subspecies: MRL/lpr.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Spontaneously immortalized cell line
//
ID KML1-7
AC CVCL_4J74
RX Patent=US5132222;
RX PubMed=2197220;
CC Breed/subspecies: MRL/lpr.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4J73 ! KML1
SX Female
CA Spontaneously immortalized cell line
//
ID KMLS-1
AC CVCL_2980
DR JCRB; JCRB0200
DI NCIt; C3194; Liposarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KMM-1
AC CVCL_2981
SY KMM1
DR CLO; CLO_0050164
DR EFO; EFO_0006611
DR BioSample; SAMN03472343
DR BioSample; SAMN03472922
DR CCLE; KMM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 27-1
DR CGH-DB; 9159-4
DR Cosmic; 720778
DR Cosmic; 759908
DR Cosmic; 760396
DR Cosmic; 2081390
DR Cosmic; 2367282
DR GEO; GSM143349
DR GEO; GSM290293
DR GEO; GSM887215
DR GEO; GSM888289
DR JCRB; JCRB1180
DR JCRB; NIHS0481
DR RCB; RCB0193
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=2519219;
RX PubMed=2768132;
RX PubMed=8943038;
RX PubMed=9290701;
RX PubMed=10936422;
RX PubMed=15215163;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=21173094;
RX PubMed=22460905;
RX PubMed=25485619;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0481; true.
ST Source(s): JCRB; PubMed=25877200; RCB
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 9,12 (JCRB; PubMed=25877200)
ST D13S317: 9 (RCB)
ST D16S539: 11
ST D18S51: 12,14
ST D21S11: 32.2
ST D3S1358: 15,17
ST D5S818: 10,11
ST D7S820: 9,10
ST D8S1179: 12,16
ST FGA: 23,26
ST Penta D: 11
ST Penta E: 11,15
ST TH01: 6
ST TPOX: 9,11
ST vWA: 16,17
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMM-56
AC CVCL_M491
SY KMM 56
RX PubMed=6429256;
RX PubMed=10936422;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMU-CS12
AC CVCL_W482
SY CS12
RX PubMed=19424076;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_W483 ! KMU-CSN
SX Male
CA Adult stem cell
//
ID KMU-CSN
AC CVCL_W483
SY CSN; GI2CS-
RX PubMed=19424076;
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_W484 ! KMU-GI2
SX Male
CA Adult stem cell
//
ID KMU-GI2
AC CVCL_W484
RX PubMed=17645461;
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Adult stem cell
//
ID KMU-R
AC CVCL_0I72
DR CCLV; CCLV-RIE 0098
OX NCBI_TaxID=9913; ! Bos taurus
CA Finite cell line
//
ID KMU100
AC CVCL_W481
SY KMU-100
RX PubMed=8025023;
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KMO-90
AC CVCL_A636
DR Cosmic; 710458
RX PubMed=7727782;
RX PubMed=8412323;
DI NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMOE-1
AC CVCL_W022
RX PubMed=6949905;
DI NCIt; C7152; Erythroleukemia
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1332 ! KMOE-2
OI CVCL_W023 ! KMOE-3N
SX Female
CA Cancer cell line
//
ID KMOE-2
AC CVCL_1332
DR CLO; CLO_0007114
DR CLDB; cl3034
DR BioSample; SAMN03473322
DR ChEMBL-Cells; CHEMBL3308236
DR ChEMBL-Targets; CHEMBL2366347
DR Cosmic; 787445
DR Cosmic; 907280
DR Cosmic; 975262
DR Cosmic; 1012079
DR Cosmic; 1465969
DR Cosmic; 2131542
DR Cosmic; 2306213
DR Cosmic-CLP; 907280
DR DSMZ; ACC-37
DR GDSC; 907280
DR GEO; GSM1669991
RX PubMed=6949905;
RX PubMed=16408098;
RX PubMed=27397505;
CC Doubling time: ~40-50 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X
ST CSF1PO: 9,12
ST D13S317: 8,11
ST D16S539: 9,11
ST D5S818: 8,10
ST D7S820: 10
ST TH01: 6,9
ST TPOX: 9
ST vWA: 14,17
DI NCIt; C7152; Erythroleukemia
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W022 ! KMOE-1
OI CVCL_W023 ! KMOE-3N
SX Female
CA Cancer cell line
//
ID KMOE-3N
AC CVCL_W023
RX PubMed=6949905;
DI NCIt; C7152; Erythroleukemia
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W022 ! KMOE-1
OI CVCL_1332 ! KMOE-2
SX Female
CA Cancer cell line
//
ID KMP
AC CVCL_4531
DR CLO; CLO_0007115
DR CLDB; cl5215
DR IZSLER; BS CL 147
RX PubMed=9208425;
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
CA Undefined cell line type
//
ID KMP-1
AC CVCL_8489
SY KMP1
DR Cosmic; 916479
RX PubMed=10091760;
CC Doubling time: 70.4 hours (PubMed=10091760).
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMP-2
AC CVCL_8490
SY KMP2
DR CGH-DB; 167-1
DR Cosmic; 916480
DR JCRB; JCRB1427
RX PubMed=10091760;
RX PubMed=18380791;
CC Doubling time: 16.6 hours (PubMed=10091760).
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 8,11
ST D16S539: 9
ST D5S818: 11,12
ST D7S820: 10,12
ST TH01: 7,10
ST TPOX: 8,11
ST vWA: 18,19
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMP-3
AC CVCL_8491
SY KMP3
DR CGH-DB; 168-1
DR Cosmic; 916481
DR JCRB; JCRB1440
RX PubMed=10091760;
RX PubMed=18380791;
CC Doubling time: 23 hours (PubMed=10091760).
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8
ST D16S539: 8,9
ST D5S818: 12
ST D7S820: 11
ST TH01: 6,8
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMP-4
AC CVCL_8492
SY KMP4
DR CGH-DB; 169-1
DR Cosmic; 916482
RX PubMed=10091760;
RX PubMed=18380791;
CC Doubling time: 57 hours (PubMed=10091760).
DI NCIt; C5721; Pancreatic adenosquamous carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMP-5
AC CVCL_8493
SY KMP5
DR CGH-DB; 170-1
DR Cosmic; 916483
RX PubMed=10091760;
RX PubMed=18380791;
CC Doubling time: 28.9 hours (PubMed=10091760).
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMP-6
AC CVCL_8494
SY KMP6
DR Cosmic; 916484
RX PubMed=10091760;
CC Doubling time: 32.5 hours (PubMed=10091760).
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMP-7
AC CVCL_8495
SY KMP7
DR CGH-DB; 171-1
DR JCRB; JCRB1429
RX PubMed=18380791;
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 10
ST D16S539: 9,12
ST D5S818: 10,12
ST D7S820: 8,10
ST TH01: 9
ST TPOX: 11
ST vWA: 17,19
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMP-8
AC CVCL_8496
SY KMP8
DR CGH-DB; 172-1
DR JCRB; JCRB1461
RX PubMed=18380791;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 10
ST D16S539: 9
ST D5S818: 10
ST D7S820: 11,12
ST TH01: 9
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C8294; Pancreatic adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KMPC-3
AC CVCL_2982
DR BioSample; SAMN03472465
DR JCRB; JCRB1150
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 9,11
ST D13S317: 11
ST D16S539: 9,11
ST D5S818: 11,13
ST D7S820: 12
ST TH01: 7,9
ST TPOX: 11
ST vWA: 16,17
DI NCIt; C6142; Renal pelvis carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KMRC-1
AC CVCL_2983
SY KMRC1
DR BioSample; SAMN03470891
DR CCLE; KMRC1_KIDNEY
DR Cosmic; 1995470
DR Cosmic-CLP; 1298168
DR GDSC; 1298168
DR GEO; GSM827174
DR GEO; GSM887216
DR GEO; GSM888290
DR GEO; GSM1669992
DR JCRB; JCRB1010
DR JCRB; NIHS0271
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0271; true.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 8
ST D16S539: 9,12
ST D18S51: 12
ST D19S433: 13,14
ST D21S11: 30,32.1
ST D2S1338: 18,19
ST D3S1358: 15
ST D5S818: 11
ST D7S820: 11,12
ST D8S1179: 10,13
ST FGA: 21,22,23
ST Penta D: 9,13
ST Penta E: 11
ST TH01: 7,8
ST TPOX: 8
ST vWA: 17,19
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMRC-2
AC CVCL_2984
SY KMRC2
DR BioSample; SAMN03470950
DR CCLE; KMRC2_KIDNEY
DR GEO; GSM827291
DR GEO; GSM887218
DR GEO; GSM888292
DR JCRB; JCRB1011
DR JCRB; NIHS0272
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0272; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D16S539: 9,11
ST D18S51: 13,16
ST D19S433: 13.2,14
ST D21S11: 29
ST D2S1338: 18,23
ST D3S1358: 15
ST D5S818: 11,14
ST D7S820: 10,11
ST D8S1179: 14,15
ST FGA: 23,24
ST Penta D: 12
ST Penta E: 19,20
ST TH01: 7,9
ST TPOX: 8
ST vWA: 14,18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMRC-20
AC CVCL_2986
SY KMRC20
DR BioSample; SAMN03470962
DR CCLE; KMRC20_KIDNEY
DR Cosmic; 1995471
DR Cosmic-CLP; 1298169
DR GDSC; 1298169
DR GEO; GSM827175
DR GEO; GSM887217
DR GEO; GSM888291
DR GEO; GSM1669993
DR JCRB; JCRB1071
DR LINCS; 50023
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8
ST D16S539: 9,11
ST D18S51: 14,16
ST D19S433: 13,13.2
ST D21S11: 28,30
ST D2S1338: 24
ST D3S1358: 15
ST D5S818: 9,11
ST D7S820: 10,11
ST D8S1179: 12,13
ST FGA: 21,22
ST Penta D: 10,13
ST Penta E: 10,16
ST TH01: 7,9
ST TPOX: 11
ST vWA: 14,17
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KMRC-21
AC CVCL_AR99
DR BioSample; SAMN03472372
DR JCRB; NIHS0351
CC Discontinued: JCRB; NIHS0351; true.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 10
ST D16S539: 9,13
ST D5S818: 11,13
ST D7S820: 10,11
ST TH01: 7,9.3
ST TPOX: 11
ST vWA: 15,20
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMRC-3
AC CVCL_2985
SY KMRC3
DR BioSample; SAMN03472532
DR CCLE; KMRC3_KIDNEY
DR GEO; GSM887219
DR GEO; GSM888293
DR JCRB; JCRB1012
DR JCRB; NIHS0273
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0273; true.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 10
ST D5S818: 10,12
ST D7S820: 8,9
ST TH01: 6,9
ST TPOX: 11
ST vWA: 15,16
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMRC-5
AC CVCL_2987
DR JCRB; JCRB1007
CC Discontinued: JCRB; JCRB1007; probable.
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMRM-A1
AC CVCL_AS00
DR BioSample; SAMN03472371
DR JCRB; NIHS0350
CC Discontinued: JCRB; NIHS0350; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 10,13
ST D16S539: 9,13
ST D5S818: 10,11
ST D7S820: 8
ST TH01: 6,9
ST TPOX: 8
ST vWA: 16,17
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KMRM-M1
AC CVCL_2988
DR BioSample; SAMN03470949
DR JCRB; JCRB1014
CC Derived from metastatic site: Muscle.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 12,13
ST D16S539: 12
ST D18S51: 18,19
ST D19S433: 12,14
ST D21S11: 30,31
ST D2S1338: 23
ST D3S1358: 15,16
ST D5S818: 10,11
ST D7S820: 11,12
ST D8S1179: 10,13
ST FGA: 23
ST Penta D: 9,10
ST Penta E: 12,25
ST TH01: 6,9
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMRM-S2
AC CVCL_4W62
RX PubMed=23379954;
CC Derived from metastatic site: Skin.
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMS-11
AC CVCL_2989
SY KMS11; kms11; kms 11
DR BTO; BTO:0003932
DR EFO; EFO_0005694
DR BioSample; SAMN03473171
DR CCLE; KMS11_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 21-1
DR CGH-DB; 9133-4
DR Cosmic; 720765
DR Cosmic; 759900
DR Cosmic; 759906
DR Cosmic; 760389
DR Cosmic; 760402
DR Cosmic; 760645
DR Cosmic; 850216
DR Cosmic; 1740213
DR Cosmic; 2081391
DR Cosmic; 2302410
DR Cosmic; 2367280
DR Cosmic; 2391798
DR Cosmic-CLP; 1659817
DR ENCODE; ENCBS682HMC
DR ENCODE; ENCBS987CHP
DR GDSC; 1659817
DR GEO; GSM143337
DR GEO; GSM290294
DR GEO; GSM887220
DR GEO; GSM888294
DR GEO; GSM1666387
DR GEO; GSM1692593
DR GEO; GSM1692594
DR GEO; GSM1692595
DR JCRB; JCRB1179
DR JCRB; NIHS0482
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=2519219;
RX PubMed=2768132;
RX PubMed=8943038;
RX PubMed=10936422;
RX PubMed=15215163;
RX PubMed=16956823;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=21173094;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 70 hours (PubMed=25984343).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0482; true.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 13
ST D13S317: 12
ST D16S539: 9,13
ST D18S51: 13,14
ST D21S11: 28,30
ST D3S1358: 15
ST D5S818: 10,12
ST D7S820: 11,12
ST D8S1179: 13
ST FGA: 22,24
ST Penta D: 11,12
ST Penta E: 15,16
ST TH01: 6,9
ST TPOX: 12
ST vWA: 17,18
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMS-11 WHSC1(+/-)
AC CVCL_HE02
SY WHSC1 (+/-) KMS-11; KMS-11 MMSET T-KO; KMS-11/TKO; KMS11/TKO; TKO
DR BTO; BTO:0005876
RX PubMed=17942756;
WW https://www.horizondiscovery.com/whsc1-kms-11-cell-line-hd-108-002
CC Characteristics: In KMS-11 one of the two WHSC1 alleles is translocated. This cell line is KO for the translocated allele.
CC Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 12766; WHSC1.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2989 ! KMS-11
SX Female
CA Cancer cell line
//
ID KMS-11 WHSC1(trans/-)
AC CVCL_HE03
SY WHSC1 (trans/-) KMS-11; KMS-11 MMSET Non-T-KO; KMS-11/NTKO; KMS11/NTKO; NTKO
DR BTO; BTO:0005875
RX PubMed=17942756;
WW https://www.horizondiscovery.com/human-whsc1-trans-kms-11-cell-line-hd-108-001
CC Characteristics: In KMS-11 one of the two WHSC1 alleles is translocated. This cell line is KO for the non-translocated allele.
CC Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 12766; WHSC1.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2989 ! KMS-11
SX Female
CA Cancer cell line
//
ID KMS-11/BTZ
AC CVCL_4V71
SY KMS11/BTZ
DR JCRB; JCRB1642
RX PubMed=20555361;
CC Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 13
ST D13S317: 12
ST D16S539: 9,13
ST D5S818: 10,12
ST D7S820: 11,12
ST TH01: 6,9
ST TPOX: 12
ST vWA: 17,18
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2989 ! KMS-11
SX Female
CA Cancer cell line
//
ID KMS-11/Cfz
AC CVCL_IQ84
DR GEO; GSM1692587
DR GEO; GSM1692588
DR GEO; GSM1692589
RX PubMed=26109433;
CC Selected for resistance to: ChEBI; CHEBI:65347; Carfilzomib (Kyprolis; PX-171-007).
CC Omics: Transcriptome analysis.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2989 ! KMS-11
SX Female
CA Cancer cell line
//
ID KMS-11R
AC CVCL_D705
DR Cosmic; 1740214
RX PubMed=22869148;
CC Selected for resistance to: AZ12908010.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2989 ! KMS-11
SX Female
CA Cancer cell line
//
ID KMS-12-BM
AC CVCL_1334
SY KMS 12 BM; KMS-12BM; KMS12-BM; KMS12BM; KMS-12; KMS12
DR EFO; EFO_0006612
DR BioSample; SAMN01821691
DR BioSample; SAMN03472933
DR CCLE; KMS12BM_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 28-1
DR CGH-DB; 9141-4
DR Cosmic; 2081425
DR Cosmic; 2367302
DR Cosmic-CLP; 907281
DR DSMZ; ACC-551
DR GDSC; 907281
DR GEO; GSM143346
DR GEO; GSM290295
DR GEO; GSM887221
DR GEO; GSM888295
DR GEO; GSM1374601
DR GEO; GSM1669994
DR IZSLER; BS TCL 240
DR JCRB; JCRB0429
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=2479409;
RX PubMed=2519219;
RX PubMed=2768132;
RX PubMed=9290701;
RX PubMed=10936422;
RX PubMed=11039672;
RX PubMed=15215163;
RX PubMed=16956823;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=21173094;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 60 hours (PubMed=25984343); ~60 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 9
ST D13S317: 8
ST D16S539: 11
ST D18S51: 14,15
ST D21S11: 30.2,32.2
ST D3S1358: 16
ST D5S818: 14
ST D7S820: 11
ST D8S1179: 10,16
ST FGA: 20
ST Penta D: 14
ST Penta E: 12,18
ST TH01: 6,9
ST TPOX: 8,11
ST vWA: 14,16
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1333 ! KMS-12-PE
SX Female
CA Cancer cell line
//
ID KMS-12-PE
AC CVCL_1333
SY KMS 12 PE; KMS-12PE; KMS12-PE; KMS12PE
DR EFO; EFO_0006613
DR BioSample; SAMN01821645
DR BioSample; SAMN01821692
DR BioSample; SAMN03472936
DR CGH-DB; 29-1
DR CGH-DB; 9140-4
DR ChEMBL-Cells; CHEMBL3308553
DR ChEMBL-Targets; CHEMBL2366257
DR Cosmic; 753568
DR Cosmic; 2081426
DR Cosmic; 2367301
DR DSMZ; ACC-606
DR GEO; GSM827273
DR IZSLER; BS TCL 239
DR JCRB; JCRB0430
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=2479409;
RX PubMed=2519219;
RX PubMed=2768132;
RX PubMed=9290701;
RX PubMed=9738977;
RX PubMed=10936422;
RX PubMed=11039672;
RX PubMed=15215163;
RX PubMed=16956823;
RX PubMed=21173094;
RX PubMed=25485619;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~60-80 hours (DSMZ).
CC Omics: Deep RNAseq analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 9
ST D13S317: 8
ST D16S539: 11
ST D18S51: 15
ST D21S11: 30.2,32.2
ST D3S1358: 16
ST D5S818: 14
ST D7S820: 11,12
ST D8S1179: 16
ST FGA: 20
ST Penta D: 14
ST Penta E: 12,18
ST TH01: 6,9
ST TPOX: 8,11
ST vWA: 14,16
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1334 ! KMS-12-BM
SX Female
CA Cancer cell line
//
ID KMS-18
AC CVCL_A637
SY KMS18
DR CCLE; KMS18_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 22-1
DR CGH-DB; 9134-4
DR Cosmic; 759902
DR Cosmic; 2081392
DR Cosmic; 2081439
DR Cosmic; 2367277
DR Cosmic; 2391797
DR GEO; GSM143334
DR GEO; GSM290296
DR GEO; GSM887222
DR GEO; GSM888296
DR JCRB; NIHS0483
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=9472091;
RX PubMed=10936422;
RX PubMed=15215163;
RX PubMed=16956823;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0483; true.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMS-20
AC CVCL_2990
SY KMS20
DR BioSample; SAMN03472431
DR CCLE; KMS20_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 23-1
DR CGH-DB; 9135-4
DR Cosmic; 2081393
DR GEO; GSM143350
DR GEO; GSM290297
DR GEO; GSM887223
DR GEO; GSM888297
DR JCRB; JCRB1196
DR JCRB; NIHS0484
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=15215163;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=22460905;
RX PubMed=25984343;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 60 hours (PubMed=25984343).
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0484; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 8
ST D16S539: 9
ST D5S818: 9,13
ST D7S820: 12
ST TH01: 7
ST TPOX: 8,9
ST vWA: 17
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMS-21-BM
AC CVCL_2991
SY KMS-21BM; KMS21BM
DR EFO; EFO_0006614
DR BioSample; SAMN03152019
DR BioSample; SAMN03472923
DR CCLE; KMS21BM_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 30-1
DR CGH-DB; 9143-4
DR GEO; GSM887224
DR GEO; GSM888298
DR JCRB; JCRB1185
DR JCRB; NIHS0485
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=11697507;
RX PubMed=12592342;
RX PubMed=15215163;
RX PubMed=20143388;
RX PubMed=22460905;
RX PubMed=25485619;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Probably misidentified. Originally thought to be a myeloma cell line and to be a sister line to KMS-21-PE (CVCL_A445) but this does not seem to be the case (PubMed=12592342, PubMed=20143388).
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0485; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 8,14
ST D16S539: 9
ST D18S51: 13
ST D21S11: 31,32.2
ST D3S1358: 15,17
ST D5S818: 10,11
ST D7S820: 8,13
ST D8S1179: 12
ST FGA: 19,22,23
ST Penta D: 9,10
ST Penta E: 11,12
ST TH01: 7,9
ST TPOX: 8
ST vWA: 18
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Undefined cell line type
//
ID KMS-21-PE
AC CVCL_A445
SY KMS-21PE; KMS21PE
DR CGH-DB; 31-1
DR CGH-DB; 9142-4
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=11697507;
RX PubMed=15215163;
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMS-24
AC CVCL_8312
SY KMS24
DR CGH-DB; 9136-4
DR JCRB; JCRB1184
RX PubMed=15215163;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 8,14
ST D16S539: 9
ST D5S818: 10,11
ST D7S820: 8,13
ST TH01: 7,9
ST TPOX: 8
ST vWA: 18
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMS-26
AC CVCL_2992
SY KMS26
DR EFO; EFO_0006615
DR BioSample; SAMN03472894
DR CCLE; KMS26_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 24-1
DR CGH-DB; 9137-4
DR Cosmic; 2081394
DR Cosmic; 2391799
DR GEO; GSM143338
DR GEO; GSM290298
DR GEO; GSM887225
DR GEO; GSM888299
DR JCRB; JCRB1187
DR JCRB; NIHS0487
RX DOI=10.1002/1438-826X(200005)1:1<48::AID-GNFD48>3.0.CO;2-B;
RX PubMed=15215163;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 35 hours (PubMed=25984343).
CC Omics: Deep RNAseq analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0487; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 12
ST D16S539: 10
ST D18S51: 13,20
ST D21S11: 30,31.2
ST D3S1358: 16
ST D5S818: 13
ST D7S820: 8,12
ST D8S1179: 14,15
ST FGA: 24
ST Penta D: 11
ST Penta E: 12
ST TH01: 7,8
ST TPOX: 11,12
ST vWA: 17,20
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMS-27
AC CVCL_2993
SY KMS27
DR EFO; EFO_0006616
DR BioSample; SAMN03472924
DR CCLE; KMS27_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 25-1
DR CGH-DB; 9138-4
DR Cosmic; 2391811
DR GEO; GSM143347
DR GEO; GSM290299
DR GEO; GSM887226
DR GEO; GSM888300
DR JCRB; JCRB1188
DR JCRB; NIHS0488
RX PubMed=15215163;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Deep RNAseq analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0488; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 10,11
ST D16S539: 11,12
ST D18S51: 14,16
ST D21S11: 30,32.2
ST D3S1358: 16,17
ST D5S818: 10,12
ST D7S820: 11
ST D8S1179: 11,12
ST FGA: 22,23
ST Penta D: 9,12
ST Penta E: 13,18.4
ST TH01: 6,9
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMS-28BM
AC CVCL_2994
SY KMS-28-BM; KMS28BM; KMS-28; KMS28
DR EFO; EFO_0006617
DR BioSample; SAMN03472925
DR CCLE; KMS28BM_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 32-1
DR CGH-DB; 9145-4
DR Cosmic; 2081427
DR Cosmic; 2367288
DR GEO; GSM143331
DR GEO; GSM290300
DR GEO; GSM887227
DR GEO; GSM888301
DR JCRB; JCRB1192
DR JCRB; NIHS0490
RX PubMed=15215163;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=22460905;
RX PubMed=25485619;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0490; true.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 9,11
ST D18S51: 14,15
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 14
ST D7S820: 8,11
ST D8S1179: 10,11
ST FGA: 20,23
ST Penta D: 9,11
ST Penta E: 12,15
ST TH01: 7,9.3
ST TPOX: 8,9
ST vWA: 17
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_2995 ! KMS-28PE
SX Female
CA Cancer cell line
//
ID KMS-28PE
AC CVCL_2995
SY KMS-28-PE; KMS28PE
DR EFO; EFO_0006618
DR CGH-DB; 33-1
DR CGH-DB; 9144-4
DR Cosmic; 2081428
DR Cosmic; 2081440
DR Cosmic; 2367289
DR GEO; GSM621589
DR JCRB; JCRB1191
DR JCRB; NIHS0489
RX PubMed=15215163;
RX PubMed=25485619;
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Discontinued: JCRB; NIHS0489; true.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 9,11
ST D5S818: 14
ST D7S820: 8,11
ST TH01: 7,9.3
ST TPOX: 8,9
ST vWA: 17
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_2994 ! KMS-28BM
SX Female
CA Cancer cell line
//
ID KMS-33
AC CVCL_8527
SY KMS33
DR JCRB; JCRB1391
DR JCRB; NIHS0491
CC Discontinued: JCRB; NIHS0491; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 14
ST D16S539: 10
ST D5S818: 10
ST D7S820: 10,12
ST TH01: 9
ST TPOX: 8,11
ST vWA: 14,18
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMS-34
AC CVCL_2996
SY KMS34
DR EFO; EFO_0006619
DR BioSample; SAMN03472430
DR BioSample; SAMN03472927
DR CCLE; KMS34_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 26-1
DR CGH-DB; 9139-4
DR Cosmic; 2081395
DR Cosmic; 2367284
DR Cosmic; 2391796
DR GEO; GSM143332
DR GEO; GSM290301
DR GEO; GSM887228
DR GEO; GSM888302
DR GEO; GSM1692596
DR GEO; GSM1692597
DR GEO; GSM1692598
DR JCRB; JCRB1195
RX PubMed=15215163;
RX PubMed=17171682;
RX PubMed=18700954;
RX PubMed=19306352;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 100 hours (PubMed=25984343).
CC Omics: Deep RNAseq analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 10,13,14 (JCRB)
ST D16S539: 10,13 (PubMed=25877200)
ST D18S51: 13,15
ST D21S11: 32.2
ST D3S1358: 15,17
ST D5S818: 12
ST D7S820: 10,11
ST D8S1179: 12,13
ST FGA: 24
ST Penta D: 9,13
ST Penta E: 14,16
ST TH01: 7,9
ST TPOX: 8,9
ST vWA: 14 (JCRB)
ST vWA: 14,17 (PubMed=25877200)
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMS-34/Cfz
AC CVCL_IQ85
DR GEO; GSM1692590
DR GEO; GSM1692591
DR GEO; GSM1692592
RX PubMed=26109433;
CC Selected for resistance to: ChEBI; CHEBI:65347; Carfilzomib (Kyprolis; PX-171-007).
CC Omics: Transcriptome analysis.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2996 ! KMS-34
SX Female
CA Cancer cell line
//
ID KMS-4
AC CVCL_D657
SY S55194
DR Cosmic; 735616
RX PubMed=3021699;
RX PubMed=6654524;
CC Derived from metastatic site: Right supraclavicular lymph node.
DI NCIt; C4910; Colon carcinoma
DI NCIt; C3339; Familial adenomatous polyposis
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KMS-5
AC CVCL_A446
SY KMS5
DR CGH-DB; 20-1
DR CGH-DB; 9132-4
DR Cosmic; 850215
RX PubMed=2519219;
RX PubMed=2768132;
RX PubMed=9290701;
RX PubMed=10936422;
RX PubMed=15215163;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KMS-6
AC CVCL_2997
DR BTO; BTO:0002041
DR BioSample; SAMN03471628
DR JCRB; JCRB0432
RX PubMed=9290701;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 9,12
ST D13S317: 10,11
ST D16S539: 9,11
ST D5S818: 10,12
ST D7S820: 9
ST TH01: 9
ST TPOX: 11,12
ST vWA: 14,18
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID KMST-6
AC CVCL_2998
SY KMST6
DR BTO; BTO:0002039
DR CLO; CLO_0050468
DR BioSample; SAMN03471629
DR BioSample; SAMN03472044
DR JCRB; JCRB0433
DR RCB; RCB1955
DR TKG; TKG 0482
RX PubMed=2423124;
RX PubMed=3972471;
RX PubMed=8105370;
RX PubMed=8148305;
RX PubMed=8557247;
RX PubMed=9290701;
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-172.html
CC Transformant: NCIt; C129640; Cobalt-60 gamma radiation.
ST Source(s): JCRB; RCB; TKG
ST Amelogenin: X
ST CSF1PO: 9,12 (JCRB)
ST CSF1PO: 12 (RCB; TKG)
ST D13S317: 10,11
ST D16S539: 11
ST D5S818: 10,12
ST D7S820: 9
ST TH01: 9
ST TPOX: 11,12
ST vWA: 14,18
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2997 ! KMS-6
SX Female
CA Transformed cell line
//
ID KMST-6/RAS
AC CVCL_M810
RX PubMed=7520808;
RX PubMed=7524638;
RX PubMed=8118610;
RX PubMed=8601579;
RX PubMed=9290701;
CC Transfected with: HGNC; 5173; HRAS (with L-61).
CC Transformant: NCIt; C129640; Cobalt-60 gamma radiation.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2998 ! KMST-6
SX Female
CA Transformed cell line
//
ID KMST-6/T
AC CVCL_2999
DR BTO; BTO:0002040
DR JCRB; JCRB0434
RX PubMed=8601579;
RX PubMed=9290701;
CC Transformant: NCIt; C129640; Cobalt-60 gamma radiation.
CC Discontinued: JCRB; JCRB0434; true.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2998 ! KMST-6
SX Female
CA Transformed cell line
//
ID KMST-6/TNF
AC CVCL_A447
RX PubMed=9661049;
CC Transfected with: HGNC; 11892; TNF.
CC Transformant: NCIt; C129640; Cobalt-60 gamma radiation.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2998 ! KMST-6
SX Female
CA Transformed cell line
//
ID KMT-17 clone A3
AC CVCL_0U14
SY KMT-17 clone A-3; KMT-17 cl A-3
RX PubMed=3632916;
RX PubMed=3815375;
CC Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok).
DI NCIt; C60403; Rat fibrosarcoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Cancer cell line
//
ID KMT-2
AC CVCL_5301
DR BioSample; SAMN03151819
DR RCB; RCB0712
RX PubMed=2198959;
RX PubMed=16643607;
RX PubMed=20143388;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KMT-2
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a KG-1 derivative (PubMed=16643607, PubMed=20143388).
CC Discontinued: RCB; RCB0712; true.
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0374 ! KG-1
SX Male
CA Cancer cell line
//
ID KMY-1
AC CVCL_5302
DR CLO; CLO_0050830
DR RCB; RCB1754
RX PubMed=9144584;
CC Breed/subspecies: Fischer 344.
DI NCIt; C124250; Rat malignant meningioma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_5305 ! KMY-J
SX Female
CA Cancer cell line
//
ID KMY-2
AC CVCL_5303
DR CLO; CLO_0050832
DR RCB; RCB1755
RX PubMed=9144584;
CC Breed/subspecies: Fischer 344.
DI NCIt; C124250; Rat malignant meningioma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_5305 ! KMY-J
SX Female
CA Cancer cell line
//
ID KMY-3
AC CVCL_5304
DR CLO; CLO_0050831
DR RCB; RCB1756
RX PubMed=9144584;
CC Breed/subspecies: Fischer 344.
DI NCIt; C124250; Rat malignant meningioma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_5305 ! KMY-J
SX Female
CA Cancer cell line
//
ID KMY-J
AC CVCL_5305
DR CLO; CLO_0050833
DR RCB; RCB1753
RX PubMed=9144584;
CC Breed/subspecies: Fischer 344.
DI NCIt; C124250; Rat malignant meningioma
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Female
CA Cancer cell line
//
ID KMY0901
AC CVCL_G258
DR CCRID; 3153C0001000000154
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0902
AC CVCL_G259
DR CCRID; 3153C0001000000155
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0903
AC CVCL_G260
DR CCRID; 3153C0001000000156
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0904
AC CVCL_G261
DR CCRID; 3153C0001000000157
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0905
AC CVCL_G262
DR CCRID; 3153C0001000000158
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0906
AC CVCL_G263
DR CCRID; 3153C0001000000161
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0907
AC CVCL_G264
DR CCRID; 3153C0001000000163
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0908
AC CVCL_G265
DR CCRID; 3153C0001000000164
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0909
AC CVCL_G266
DR CCRID; 3153C0001000000162
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0910
AC CVCL_G267
DR CCRID; 3153C0001000000159
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0911
AC CVCL_G268
DR CCRID; 3153C0001000000160
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0919
AC CVCL_G269
DR CCRID; 3153C0001000000166
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0920
AC CVCL_G270
DR CCRID; 3153C0001000000165
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0922
AC CVCL_G271
DR CCRID; 3153C0001000000168
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0923
AC CVCL_G272
DR CCRID; 3153C0001000000170
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0926
AC CVCL_G273
DR CCRID; 3153C0001000000171
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0927
AC CVCL_G274
DR CCRID; 3153C0001000000167
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY0928
AC CVCL_G275
DR CCRID; 3153C0001000000169
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY1002
AC CVCL_G276
DR CCRID; 3153C0001000000197
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY1008
AC CVCL_G277
DR CCRID; 3153C0001000000198
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY1022
AC CVCL_G278
DR CCRID; 3153C0001000000199
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMY1036
AC CVCL_G279
DR CCRID; 3153C0001000000200
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMYB
AC CVCL_G280
DR CCRID; 3153C0001000000152
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMYF
AC CVCL_G281
DR CCRID; 3153C0001000000151
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KMYM
AC CVCL_G282
DR CCRID; 3153C0001000000153
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KN
AC CVCL_IU95
DR Cosmic; 2546844
RX PubMed=17325662;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KN-41
AC CVCL_W215
SY KN41
RX PubMed=7154478;
CC Doubling time: 20.9 hours (PubMed=7154478).
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KN-OH1
AC CVCL_S865
SY KN-OH-1
RX PubMed=9393981;
RX PubMed=12904596;
DI NCIt; C4817; Ewing sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KN0025
AC CVCL_8X96
DR ECACC; 98112404
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C82341; Spinocerebellar ataxia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KN0117
AC CVCL_8X97
DR ECACC; 99081012
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KN0118
AC CVCL_8X98
DR ECACC; 99081013
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KN0120
AC CVCL_8X99
DR ECACC; 99081015
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KNA
AC CVCL_8885
DR CLO; CLO_0007116
DR CLDB; cl3035
DR ECACC; 96020765
RX PubMed=10640177;
RX PubMed=15541571;
RX PubMed=22538498;
CC Doubling time: 3.5 days (PubMed=10640177).
CC Discontinued: ECACC; 96020765; probable.
DI NCIt; C3326; Adrenal gland pheochromocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KNBCCS6
AC CVCL_IU64
RX PubMed=18679421;
RX Patent=US20140243523;
CC Characteristics: Heterozygous for the PTCH1 p.His652Ter mutation.
DI NCIt; C2892; Nevoid basal cell carcinoma syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID KNBCCS6 E6/E7
AC CVCL_IU65
RX Patent=US20140243523;
CC Characteristics: Heterozygous for the PTCH1 p.His652Ter mutation.
CC Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16) [E6/E7 (pLE6/E7SN)].
DI NCIt; C2892; Nevoid basal cell carcinoma syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_IU64 ! KNBCCS6
SX Female
CA Transformed cell line
//
ID KNE
AC CVCL_E728
DR dbMHC; 48926
DR ECACC; 94022536
DR IHW; IHW9214
DR IMGT/HLA; 10923
WW http://bioinformatics.hsanmartino.it/ecbr/cl214.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KNRK
AC CVCL_3731
SY NRK 1569
DR CLO; CLO_0007117
DR CLDB; cl3036
DR ATCC; CRL-1569
DR ECACC; 87061001
RX PubMed=4333712;
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-170.html
CC Transformant: NCBI_TaxID; 11808; Kirsten murine sarcoma virus (Ki-MSV).
CC Breed/subspecies: Osborne-Mendel.
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_3758 ! NRK
CA Transformed cell line
//
ID KNS-42
AC CVCL_0378
SY KNS42
DR BTO; BTO:0005859
DR MCCL; MCC:0000273
DR BioSample; SAMN03472787
DR CCLE; KNS42_CENTRAL_NERVOUS_SYSTEM
DR BCRJ; 0295
DR CGH-DB; 144-1
DR ChEMBL-Cells; CHEMBL3308538
DR ChEMBL-Targets; CHEMBL2366261
DR Cosmic; 687573
DR Cosmic; 907282
DR Cosmic; 2367532
DR Cosmic-CLP; 907282
DR GDSC; 907282
DR GEO; GSM887229
DR GEO; GSM888303
DR GEO; GSM1669995
DR GEO; GSM2197880
DR GEO; GSM2197881
DR GEO; GSM2197882
DR GEO; GSM2197883
DR GEO; GSM2197884
DR GEO; GSM2197885
DR IFO; IFO50356
RX CelloPub=CLPUB00152;
RX PubMed=2448680;
RX PubMed=16232199;
RX PubMed=19365568;
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 48 hours (PubMed=19365568).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: CNV analysis.
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 8
ST D16S539: 9,12
ST D5S818: 12
ST D7S820: 8,11
ST TH01: 6
ST TPOX: 8,11
ST vWA: 18,19
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KNS-60
AC CVCL_2798
SY KNS 60; KNS60
DR BioSample; SAMN03470967
DR BioSample; SAMN03472788
DR CCLE; KNS60_CENTRAL_NERVOUS_SYSTEM
DR CGH-DB; 145-1
DR Cosmic; 687574
DR Cosmic; 2367533
DR Cosmic; 2516021
DR GEO; GSM887230
DR GEO; GSM888304
DR IFO; IFO50357
RX CelloPub=CLPUB00152;
RX PubMed=16232199;
RX PubMed=22460905;
RX PubMed=25984343;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 38 hours (PubMed=25984343).
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 10,11
ST D18S51: 15
ST D19S433: 13
ST D21S11: 29
ST D2S1338: 25
ST D3S1358: 16,18
ST D5S818: 11
ST D7S820: 9,12 (JCRB)
ST D7S820: 9 (PubMed=25877200)
ST D8S1179: 14
ST FGA: 18
ST Penta D: 9,10
ST Penta E: 8
ST TH01: 7,8 (JCRB)
ST TH01: 7 (PubMed=25877200)
ST TPOX: 9
ST vWA: 15,19
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KNS-62
AC CVCL_1335
SY KNS62
DR EFO; EFO_0006620
DR BioSample; SAMN03472612
DR CCLE; KNS62_LUNG
DR ChEMBL-Cells; CHEMBL3308237
DR ChEMBL-Targets; CHEMBL2366244
DR Cosmic; 753569
DR Cosmic; 1995472
DR Cosmic; 2060532
DR Cosmic-CLP; 753569
DR GDSC; 753569
DR GEO; GSM887231
DR GEO; GSM888305
DR GEO; GSM1669996
DR IFO; IFO50358
RX PubMed=7358770;
RX PubMed=15746151;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Brain.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 9,12
ST D13S317: 11
ST D16S539: 9,11
ST D21S11: 32
ST D3S1358: 15
ST D5S818: 9
ST D7S820: 11
ST D8S1179: 13,14
ST FGA: 23
ST Penta D: 11,13
ST Penta E: 10,11
ST TH01: 7,9
ST TPOX: 8
ST vWA: 17
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KNS-81
AC CVCL_2799
SY KNS81
DR BioSample; SAMN03470965
DR CCLE; KNS81_CENTRAL_NERVOUS_SYSTEM
DR CGH-DB; 146-1
DR Cosmic; 687575
DR Cosmic; 2516022
DR GEO; GSM887232
DR GEO; GSM888306
DR IFO; IFO50359
DR TOKU-E; 4091
RX CelloPub=CLPUB00152;
RX PubMed=16232199;
RX PubMed=22460905;
RX PubMed=25984343;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 110 hours (PubMed=25984343).
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 9,12
ST D13S317: 9
ST D16S539: 10,12
ST D18S51: 13,19
ST D19S433: 13.2,14
ST D21S11: 29,30
ST D2S1338: 22,23
ST D3S1358: 14,16
ST D5S818: 9,12
ST D7S820: 11
ST D8S1179: 11,17
ST FGA: 20,22
ST Penta D: 9
ST Penta E: 11,15
ST TH01: 7,9
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KNS-81-FD
AC CVCL_1336
SY KNS-81FD
DR ChEMBL-Cells; CHEMBL3308306
DR ChEMBL-Targets; CHEMBL2366203
DR Cosmic; 924188
DR Cosmic; 2367534
DR Cosmic-CLP; 924188
DR GDSC; 924188
DR GEO; GSM1669997
DR IFO; IFO50444
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 9,12
ST D13S317: 9
ST D16S539: 10,12
ST D5S818: 9,12
ST D7S820: 11
ST TH01: 7,9
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2799 ! KNS-81
SX Male
CA Cancer cell line
//
ID KNS-89
AC CVCL_2800
SY KN-S89; KNS89
DR BioSample; SAMN03151976
DR CGH-DB; 147-1
DR Cosmic; 687576
DR IFO; IFO50360
RX PubMed=16232199;
RX PubMed=20143388;
RX PubMed=22570425;
WW http://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a U-251MG derivative (PubMed=20143388, PubMed=22570425).
CC Discontinued: IFO; IFO50360; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 10,11
ST D16S539: 12
ST D5S818: 11,12
ST D7S820: 10,12
ST TH01: 9.3
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C60781; Astrocytoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0021 ! U-251MG
SX Male
CA Cancer cell line
//
ID KNS-R
AC CVCL_0I60
SY KNS
DR CCLV; CCLV-RIE 0050
RX PubMed=19941903;
OX NCBI_TaxID=9913; ! Bos taurus
CA Spontaneously immortalized cell line
//
ID KO-001-19
AC CVCL_W538
DR SKIP; SKIP000289
RX PubMed=24389010;
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W539 ! KO-001-25
SX Female
CA Induced pluripotent stem cell
//
ID KO-001-25
AC CVCL_W539
DR SKIP; SKIP000277
RX PubMed=24389010;
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W538 ! KO-001-19
SX Female
CA Induced pluripotent stem cell
//
ID KO-1
AC CVCL_J425
RX PubMed=15541796;
OX NCBI_TaxID=9685; ! Felis catus
CA Cancer cell line
//
ID KO-6
AC CVCL_R824
SY Kokanee Ovary-6
RX DOI=10.3147/jsfp.28.27;
RX PubMed=6542066;
CC Group: Fish cell line.
OX NCBI_TaxID=8023; ! Oncorhynchus nerka
SX Female
CA Spontaneously immortalized cell line
//
ID KO51
AC CVCL_3000
AS CVCL_8454
SY K051; K-051
DR BioSample; SAMN03151809
DR Cosmic; 749072
DR Cosmic; 787440
DR Cosmic; 975257
DR Cosmic; 1281320
DR JCRB; JCRB0122
DR JCRB; NIHS0163
DR JCRB; NIHS0244
RX PubMed=7693050;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a K-562 derivative (PubMed=12592342, PubMed=20143388).
CC Discontinued: JCRB; NIHS0163; true.
CC Discontinued: JCRB; NIHS0244; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 8
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 9.3
ST TPOX: 8,9
ST vWA: 16
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0004 ! K-562
SX Female
CA Cancer cell line
//
ID KO52
AC CVCL_1321
AS CVCL_8455
SY K052
DR BioSample; SAMN03470799
DR CCLE; KO52_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308169
DR ChEMBL-Targets; CHEMBL2366354
DR Cosmic; 749073
DR Cosmic; 907284
DR Cosmic; 2131543
DR Cosmic; 2306214
DR Cosmic-CLP; 1330932
DR GDSC; 907284
DR GEO; GSM827240
DR GEO; GSM887233
DR GEO; GSM888307
DR GEO; GSM1669969
DR GEO; GSM1669998
DR JCRB; JCRB0123
DR JCRB; NIHS0164
RX PubMed=7693050;
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Instable (MSI-low) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0164; true.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 8,12
ST D16S539: 9,11
ST D5S818: 11
ST D7S820: 9,10
ST TH01: 6,7
ST TPOX: 8
ST vWA: 16
DI NCIt; C9154; Adult acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOA-1
AC CVCL_L997
RX Patent=EP0679888A2;
RX PubMed=12594358;
RX PubMed=15316547;
RX PubMed=16501317;
CC Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4631.
DI NCIt; C8026; Salivary gland adenoid cystic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOA-1L3
AC CVCL_L998
RX PubMed=15316547;
DI NCIt; C8026; Salivary gland adenoid cystic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_L997 ! KOA-1
CA Cancer cell line
//
ID Kobayashi
AC CVCL_J354
DR BTO; BTO:0002532
RX PubMed=3034807;
RX PubMed=8847894;
RX PubMed=9454894;
RX PubMed=12967475;
RX PubMed=15028022;
CC Characteristics: EBV-negative.
CC Omics: Transcriptome analysis.
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOBK-101
AC CVCL_W265
SY KOBK101
DR CGH-DB; 9200-4
RX DOI=10.2177/jsci.6.279;
RX PubMed=1999287;
RX PubMed=3082812;
RX PubMed=10360377;
RX PubMed=10995006;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOBK-130
AC CVCL_W266
SY KOBK130
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOBK-134
AC CVCL_W270
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOBK-96
AC CVCL_W269
RX DOI=10.2177/jsci.6.279;
RX PubMed=10360377;
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOC-1S
AC CVCL_L701
RX CelloPub=CLPUB00065;
RX PubMed=8428685;
DI NCIt; C7550; Ovarian serous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOC-2S
AC CVCL_L702
RX CelloPub=CLPUB00066;
RX PubMed=8428685;
DI NCIt; C7550; Ovarian serous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOC-4C
AC CVCL_L703
SY KOC-4c
RX CelloPub=CLPUB00067;
DI NCIt; C40078; Ovarian clear cell adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOC-5C
AC CVCL_5306
SY KOC-5c
DR BTO; BTO:0004969
RX CelloPub=CLPUB00067;
RX PubMed=15534119;
DI NCIt; C40078; Ovarian clear cell adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOC-7C
AC CVCL_5307
SY KOC-7c; KOC7C
DR BTO; BTO:0004970
DR Cosmic; 2074243
DR GEO; GSM659380
DR PRIDE; PXD000901
RX CelloPub=CLPUB00067;
RX PubMed=15534119;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C40078; Ovarian clear cell adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOCL-33
AC CVCL_3991
SY KOCL33; KOCL 33; Kocl-33
DR BTO; BTO:0004937
DR Cosmic; 996295
DR Cosmic; 1037745
DR Cosmic; 2391170
RX PubMed=1465024;
RX PubMed=9529133;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=15843827;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOCL-44
AC CVCL_3992
SY KOCL44
DR BTO; BTO:0004938
DR Cosmic; 996296
DR Cosmic; 1037746
DR Cosmic; 2391171
RX PubMed=1465024;
RX PubMed=9529133;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOCL-45
AC CVCL_3993
SY KOCL45
DR BTO; BTO:0004939
DR Cosmic; 996297
DR Cosmic; 1037747
RX PubMed=1465024;
RX PubMed=9529133;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOCL-48
AC CVCL_6867
SY KOCL48
DR Cosmic; 996320
DR Cosmic; 1037673
RX PubMed=1465024;
RX PubMed=9529133;
RX PubMed=9738977;
DI NCIt; C9163; Childhood acute monocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOCL-50
AC CVCL_6866
SY KOCL50
DR Cosmic; 1037748
RX PubMed=1465024;
RX PubMed=9529133;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOCL-51
AC CVCL_6865
SY KOCL51
DR Cosmic; 1037749
DR Cosmic; 2391173
RX PubMed=1465024;
RX PubMed=9529133;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOCL-58
AC CVCL_3994
SY KOCL58
DR BTO; BTO:0004940
DR Cosmic; 996298
DR Cosmic; 1037750
RX PubMed=1465024;
RX PubMed=9529133;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOCL-69
AC CVCL_3995
SY KOCL69
DR BTO; BTO:0004941
DR Cosmic; 996299
DR Cosmic; 1037751
RX PubMed=9529133;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KoG
AC CVCL_W101
SY Koi Gill
RX DOI=10.5897/AJMR2013.5723;
CC Group: Fish cell line.
CC Breed/subspecies: Koi.
OX NCBI_TaxID=1045269; ! Cyprinus carpio haematopterus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Koi-Fin
AC CVCL_V645
RX Patent=CN102399743A;
CC Group: Fish cell line.
CC Registration: International Depositary Authority, China Center for Type Culture Collection (CCTCC); C201199.
CC Breed/subspecies: Koi.
OX NCBI_TaxID=1045269; ! Cyprinus carpio haematopterus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KOIA-LCL
AC CVCL_8726
SY KOIA-9LCL
DR CLO; CLO_0051019
DR BioSample; SAMN03472080
DR Cosmic; 889111
DR RCB; RCB1874
DR TKG; TKG 0506
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
ST Source(s): RCB; TKG
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 9,11
ST D16S539: 11,13
ST D5S818: 8,11
ST D7S820: 11
ST TH01: 6,9
ST TPOX: 8,9
ST vWA: 17,18
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KON
AC CVCL_3001
DR BioSample; SAMN03471653
DR CGH-DB; 369-2
DR Cosmic; 1995473
DR Cosmic-CLP; 1298215
DR GDSC; 1298215
DR GEO; GSM827191
DR GEO; GSM1669999
DR JCRB; JCRB0194
RX DOI=10.5794/jjoms.41.19;
RX PubMed=17599052;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Misspelling: 'KOS' in CGH-DB 369-2.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11,12
ST D16S539: 9,11
ST D5S818: 11,13
ST D7S820: 8,11
ST TH01: 7,9
ST TPOX: 9,11
ST vWA: 17 (Cosmic-CLP)
ST vWA: 16,17 (JCRB)
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOP
AC CVCL_6753
SY Knockout Of P38
DR CLO; CLO_0050529
DR RCB; RCB2148
RX PubMed=16198317;
CC Knockout cell: Method=KO mouse; MGI; MGI:1346865; Mapk14.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Spontaneously immortalized cell line
//
ID KOP-R
AC CVCL_D289
SY KOP/R
DR CCLV; CCLV-RIE 0244
OX NCBI_TaxID=9913; ! Bos taurus
CA Finite cell line
//
ID KOPB-26
AC CVCL_7972
SY KOPB26
DR Cosmic; 1150900
RX PubMed=1465024;
RX PubMed=3491484;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOPB-38
AC CVCL_W277
SY KOPB38
RX PubMed=10360377;
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPM-28
AC CVCL_7973
SY KOPM28
DR Cosmic; 787497
RX PubMed=3494166;
RX PubMed=12506034;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPM-30
AC CVCL_7974
SY KOPM30
RX PubMed=10942233;
RX PubMed=12506034;
DI NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34;q11.2) BCR-ABL1
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_7976 ! KOPN-30bi
CA Cancer cell line
//
ID KOPM-53
AC CVCL_7975
SY KOPM53
RX PubMed=10942233;
RX PubMed=12506034;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPM-88
AC CVCL_M647
SY KOPM88
RX PubMed=17408461;
CC Misspelling: Occasionally 'KOMP88'.
DI NCIt; C3171; Acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOPN-1
AC CVCL_3937
SY Kopn-1
DR BTO; BTO:0004944
DR Cosmic; 996302
DR Cosmic; 1037721
DR Cosmic; 2391172
RX PubMed=1465024;
RX PubMed=9738977;
RX PubMed=10360377;
RX PubMed=15843827;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOPN-30bi
AC CVCL_7976
SY KOPN30bi
RX PubMed=10360377;
RX PubMed=10942233;
RX PubMed=10995006;
RX PubMed=12506034;
RX PubMed=20519628;
DI NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34;q11.2) BCR-ABL1
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_7974 ! KOPM-30
CA Cancer cell line
//
ID KOPN-32
AC CVCL_A325
SY Kopn-32; Kopn32
RX PubMed=10360377;
RX PubMed=10490826;
RX PubMed=10995006;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-34
AC CVCL_A326
SY KOPN34
RX PubMed=20519628;
DI NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-35
AC CVCL_A327
SY Kopn-35; Kopn35
RX PubMed=10360377;
RX PubMed=10490826;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-36
AC CVCL_A328
SY Kopn-36; KOPN36; Kopn36
RX PubMed=10360377;
RX PubMed=10490826;
RX PubMed=20519628;
DI NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-39
AC CVCL_W273
RX PubMed=10360377;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-41
AC CVCL_3943
DR BTO; BTO:0004943
DR Cosmic; 996301
DR Cosmic; 1037723
RX DOI=10.11412/jjph1987.13.86;
RX PubMed=10360377;
RX PubMed=10995006;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOPN-46
AC CVCL_W274
RX PubMed=10360377;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-47
AC CVCL_W275
RX PubMed=10360377;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-49
AC CVCL_W276
RX PubMed=10360377;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-54
AC CVCL_A329
SY Kopn-54; Kopn54
RX PubMed=10490826;
DI NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-55bi
AC CVCL_7977
SY KOPN55bi
RX PubMed=10360377;
RX PubMed=10942233;
RX PubMed=10995006;
RX PubMed=12506034;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-57bi
AC CVCL_7978
SY KOPN57bi
RX PubMed=10360377;
RX PubMed=10942233;
RX PubMed=10995006;
RX PubMed=12506034;
RX PubMed=20519628;
DI NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34;q11.2) BCR-ABL1
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-60
AC CVCL_A330
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-61
AC CVCL_A331
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-62
AC CVCL_A332
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-63
AC CVCL_A333
SY Kopn-63; Kopn63
RX PubMed=10360377;
RX PubMed=10490826;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-66bi
AC CVCL_7979
SY KOPN66bi
RX PubMed=10360377;
RX PubMed=10942233;
RX PubMed=10995006;
RX PubMed=12506034;
RX PubMed=20519628;
DI NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34;q11.2) BCR-ABL1
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-67
AC CVCL_7980
SY KOPN67; KO-PN-67
RX PubMed=10942233;
RX PubMed=10995006;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-72bi
AC CVCL_7981
SY KOPN72bi
RX PubMed=10360377;
RX PubMed=10942233;
RX PubMed=10995006;
RX PubMed=12506034;
RX PubMed=20519628;
DI NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34;q11.2) BCR-ABL1
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-79
AC CVCL_A334
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-8
AC CVCL_1866
SY Kopn-8; KOPN8
DR BioSample; SAMN03473535
DR CCLE; KOPN8_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 998710
DR Cosmic; 999747
DR Cosmic; 1037722
DR Cosmic; 1130256
DR Cosmic; 1191708
DR Cosmic; 2491068
DR Cosmic; 2542838
DR Cosmic-CLP; 1330933
DR DSMZ; ACC-552
DR GDSC; 1330933
DR GEO; GSM887234
DR GEO; GSM888308
DR GEO; GSM1670000
RX PubMed=9067587;
RX PubMed=22460905;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~48 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,11
ST D16S539: 9,11
ST D5S818: 9,11
ST D7S820: 8,10
ST TH01: 6,10
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOPN-83bi
AC CVCL_W271
SY KOPN83bi
RX PubMed=10360377;
DI NCIt; C68659; Childhood B acute lymphoblastic leukemia with t(9;22)(q34;q11.2) BCR-ABL1
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-84
AC CVCL_A335
RX PubMed=20519628;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPN-K
AC CVCL_A638
DR Cosmic; 998695
DR Cosmic; 1037724
RX PubMed=10360377;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPT-11
AC CVCL_A111
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPT-4
AC CVCL_A112
DR Cosmic; 721702
DR Cosmic; 1375592
RX PubMed=10071127;
RX PubMed=10360377;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPT-5
AC CVCL_A113
RX DOI=10.2177/jsci.16.338;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOPT-6
AC CVCL_A114
SY KOPT6
DR Cosmic; 1281373
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOPT-K1
AC CVCL_4965
SY KOPT-KI; KOPTK-1; KOPTK1; KopTK1; Koptk1
DR BTO; BTO:0004964
DR EFO; EFO_0006283
DR Cosmic; 721714
DR Cosmic; 913407
DR Cosmic; 944545
DR Cosmic; 998730
DR Cosmic; 1037683
DR Cosmic; 1115584
DR Cosmic; 1151783
DR Cosmic; 1224374
DR Cosmic; 1524801
DR Cosmic; 1641389
DR ENCODE; ENCBS345YKN
DR ENCODE; ENCBS869LIS
RX PubMed=7475267;
RX PubMed=10071127;
RX PubMed=10360377;
RX PubMed=10995006;
RX PubMed=20519628;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KOS-001
AC CVCL_GY89
SY BWKOS
RX PubMed=21848623;
CC Breed/subspecies: Border Collie.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
CA Cancer cell line
//
ID KOS-002
AC CVCL_GY90
SY CSKOS
RX PubMed=21848623;
CC Breed/subspecies: Irish Setter.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID KOS-003
AC CVCL_GY91
SY MCKOS
RX PubMed=21848623;
RX PubMed=24416158;
RX PubMed=25190452;
CC Breed/subspecies: Labrador Retriever mix.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
CA Cancer cell line
//
ID KOS-004
AC CVCL_GY92
SY SKKOS
RX PubMed=21848623;
CC Breed/subspecies: Mixed breed.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
CA Cancer cell line
//
ID KOSC-2
AC CVCL_1337
SY KOSC2; KOSC-2 cl3-43
DR BTO; BTO:0005968
DR BioSample; SAMN03470801
DR CGH-DB; 371-2
DR ChEMBL-Cells; CHEMBL3308750
DR ChEMBL-Targets; CHEMBL1075481
DR Cosmic; 753570
DR Cosmic-CLP; 753570
DR GDSC; 753570
DR GEO; GSM827195
DR GEO; GSM1670001
DR JCRB; JCRB0126.1
RX PubMed=8314315;
RX PubMed=17599052;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11
ST D16S539: 9,12
ST D5S818: 9
ST D7S820: 10,11
ST TH01: 6,7
ST TPOX: 8
ST vWA: 15,17
DI NCIt; C34447; Head and neck squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KOSC-3
AC CVCL_2789
SY KOSC3
DR BTO; BTO:0005969
DR BioSample; SAMN03151615
DR BioSample; SAMN03470802
DR Cosmic; 753571
DR Cosmic; 1120706
DR JCRB; JCRB0127
DR JCRB; NIHS0166
RX PubMed=8314315;
RX PubMed=20143388;
WW http://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a Ca9-22 derivative (PubMed=20143388).
CC Discontinued: JCRB; NIHS0166; true.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 11
ST D16S539: 9,10
ST D5S818: 12
ST D7S820: 11,13
ST TH01: 6
ST TPOX: 8,11
ST vWA: 16
DI NCIt; C129857; Gingival squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1102 ! Ca9-22
SX Male
CA Cancer cell line
//
ID KOSCC-11
AC CVCL_S681
DR Cosmic; 2266789
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KOSCC-25A
AC CVCL_S682
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_S683 ! KOSCC-25B
OI CVCL_S684 ! KOSCC-25C
OI CVCL_S685 ! KOSCC-25D
OI CVCL_S686 ! KOSCC-25E
SX Male
CA Cancer cell line
//
ID KOSCC-25B
AC CVCL_S683
DR Cosmic; 2266790
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_S682 ! KOSCC-25A
OI CVCL_S684 ! KOSCC-25C
OI CVCL_S685 ! KOSCC-25D
OI CVCL_S686 ! KOSCC-25E
SX Male
CA Cancer cell line
//
ID KOSCC-25C
AC CVCL_S684
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_S682 ! KOSCC-25A
OI CVCL_S683 ! KOSCC-25B
OI CVCL_S685 ! KOSCC-25D
OI CVCL_S686 ! KOSCC-25E
SX Male
CA Cancer cell line
//
ID KOSCC-25D
AC CVCL_S685
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_S682 ! KOSCC-25A
OI CVCL_S683 ! KOSCC-25B
OI CVCL_S684 ! KOSCC-25C
OI CVCL_S686 ! KOSCC-25E
SX Male
CA Cancer cell line
//
ID KOSCC-25E
AC CVCL_S686
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_S682 ! KOSCC-25A
OI CVCL_S683 ! KOSCC-25B
OI CVCL_S684 ! KOSCC-25C
OI CVCL_S685 ! KOSCC-25D
SX Male
CA Cancer cell line
//
ID KOSCC-33A
AC CVCL_S687
DR Cosmic; 2266791
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_S688 ! KOSCC-33B
CA Cancer cell line
//
ID KOSCC-33B
AC CVCL_S688
RX PubMed=12011992;
DI NCIt; C4833; Oral cavity squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_S687 ! KOSCC-33A
CA Cancer cell line
//
ID KOSE
AC CVCL_E729
DR dbMHC; 48927
DR ECACC; 88052056
DR IHW; IHW9056
DR IMGT/HLA; 10927
WW http://bioinformatics.hsanmartino.it/ecbr/cl56.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KOT-1
AC CVCL_N511
RX PubMed=9566709;
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_N512 ! KOT-2
SX Female
CA Cancer cell line
//
ID KOT-2
AC CVCL_N512
RX PubMed=9566709;
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_N511 ! KOT-1
SX Female
CA Cancer cell line
//
ID KOZ
AC CVCL_E730
DR dbMHC; 48928
DR ECACC; 94050341
DR IHW; IHW9310
DR IMGT/HLA; 10928
WW http://bioinformatics.hsanmartino.it/ecbr/cl310.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KP-1N
AC CVCL_3002
SY Kp-1N; KP-1 N; KP1N; KP1
DR BTO; BTO:0003549
DR BioSample; SAMN03151887
DR CCLE; KP1N_PANCREAS
DR CGH-DB; 173-1
DR CGH-DB; 9368-4
DR Cosmic; 918052
DR Cosmic; 1122345
DR Cosmic; 1518234
DR Cosmic; 1995474
DR Cosmic-CLP; 1298216
DR GDSC; 1298216
DR GEO; GSM827208
DR GEO; GSM1670002
DR JCRB; JCRB0177.0
DR JCRB; NIHS0274.0
RX PubMed=2172194;
RX PubMed=18380791;
RX PubMed=27397505;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a PANC-1 derivative.
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Discontinued: JCRB; NIHS0274.0; true.
CC Derived from metastatic site: Liver.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11
ST D16S539: 11
ST D5S818: 11,13
ST D7S820: 8,10
ST TH01: 7,8
ST TPOX: 8,11
ST vWA: 15
DI NCIt; C9120; Pancreatic ductal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0480 ! PANC-1
SX Male
CA Cancer cell line
//
ID KP-1NL
AC CVCL_3003
SY KP-1N-L; KP-1-NL; KP1-NL; KP1NL
DR CCLE; KP1NL_PANCREAS
DR CGH-DB; 174-1
DR CGH-DB; 9369-4
DR Cosmic; 918048
DR GEO; GSM1588617
DR JCRB; JCRB0177.1
DR JCRB; NIHS0274.1
RX PubMed=2172194;
RX PubMed=18380791;
RX PubMed=25984343;
CC Problematic cell line: Contaminated. Parent cell line (KP-1N) has been shown to be a PANC-1 derivative.
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 25 hours (PubMed=25984343).
CC Omics: shRNA library screening.
CC Discontinued: JCRB; NIHS0274.1; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11
ST D16S539: 11
ST D5S818: 11,13
ST D7S820: 8,10
ST TH01: 7,8
ST TPOX: 8,11
ST vWA: 15
DI NCIt; C9120; Pancreatic ductal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3002 ! KP-1N
SX Male
CA Cancer cell line
//
ID KP-1NL-Luc#2
AC CVCL_4Y21
SY KP-1-NL-Luc#2
DR JCRB; NIHS0714
CC Problematic cell line: Contaminated. Grand-parent cell line (KP-1N) has been shown to be a PANC-1 derivative.
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
DI NCIt; C9120; Pancreatic ductal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3003 ! KP-1NL
SX Male
CA Cancer cell line
//
ID KP-2
AC CVCL_3004
SY KP2
DR BTO; BTO:0003550
DR EFO; EFO_0006621
DR BioSample; SAMN03472830
DR BioSample; SAMN03472944
DR CCLE; KP2_PANCREAS
DR CGH-DB; 175-1
DR CGH-DB; 9370-4
DR Cosmic; 918057
DR Cosmic-CLP; 1298218
DR GDSC; 1298218
DR GEO; GSM887235
DR GEO; GSM888309
DR JCRB; JCRB0181
RX PubMed=2172194;
RX PubMed=18380791;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 36 hours (PubMed=25984343).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,13
ST D16S539: 9,10 (JCRB)
ST D16S539: 10 (Cosmic-CLP; PubMed=25877200)
ST D18S51: 14
ST D21S11: 31,32.2
ST D3S1358: 15,16
ST D5S818: 9,13
ST D7S820: 10,12
ST D8S1179: 14,17
ST FGA: 20
ST Penta D: 9,12
ST Penta E: 12,13,15
ST TH01: 9
ST TPOX: 8,11
ST vWA: 14
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KP-2/CMV-Luc
AC CVCL_4W98
DR JCRB; JCRB1491
DR JCRB; NIHS0715
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,13
ST D16S539: 9,10
ST D5S818: 9,13
ST D7S820: 10,12
ST TH01: 9
ST TPOX: 8,11
ST vWA: 14
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3004 ! KP-2
SX Female
CA Cancer cell line
//
ID KP-2N
AC CVCL_0U12
DR Cosmic; 1122346
DR Cosmic; 1518238
RX PubMed=2172194;
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3004 ! KP-2
SX Female
CA Cancer cell line
//
ID KP-3
AC CVCL_3005
SY KP3
DR BTO; BTO:0003551
DR EFO; EFO_0006622
DR BioSample; SAMN03471644
DR BioSample; SAMN03472945
DR CCLE; KP3_PANCREAS
DR CGH-DB; 176-1
DR CGH-DB; 9371-4
DR Cosmic; 918053
DR Cosmic-CLP; 1298219
DR GDSC; 1298219
DR GEO; GSM827292
DR GEO; GSM887236
DR GEO; GSM888310
DR GEO; GSM1670003
DR JCRB; JCRB0178.0
DR JCRB; NIHS0275.0
RX PubMed=2172194;
RX PubMed=18380791;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=KP-3
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0275.0; true.
CC Derived from metastatic site: Liver.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 9,11
ST D16S539: 9,13
ST D18S51: 17
ST D21S11: 30,32
ST D3S1358: 16
ST D5S818: 13
ST D7S820: 10,12
ST D8S1179: 13,14
ST FGA: 23
ST Penta D: 12,13
ST Penta E: 15,17
ST TH01: 6,9.3
ST TPOX: 9,11
ST vWA: 17,18 (Cosmic-CLP; JCRB)
ST vWA: 18 (PubMed=25877200)
DI NCIt; C5721; Pancreatic adenosquamous carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-3-Luc#5
AC CVCL_4Y22
DR JCRB; NIHS0716
CC Transfected with: UniProtKB; P08659; Firefly luciferase.
DI NCIt; C5721; Pancreatic adenosquamous carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3005 ! KP-3
SX Male
CA Cancer cell line
//
ID KP-3L
AC CVCL_3006
SY KP-3-L; KP3L; KP-3Ls
DR BioSample; SAMN03472946
DR CGH-DB; 177-1
DR CGH-DB; 9372-4
DR Cosmic; 918049
DR JCRB; JCRB0178.1
DR JCRB; NIHS0275.1
RX PubMed=2172194;
RX PubMed=18380791;
CC Discontinued: JCRB; NIHS0275.1; true.
CC Derived from metastatic site: Liver.
ST Source(s): JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 9,11
ST D16S539: 9,13
ST D18S51: 17
ST D21S11: 30,32,33
ST D3S1358: 16,17
ST D5S818: 13
ST D7S820: 10,12 (JCRB)
ST D7S820: 12 (PubMed=25877200)
ST D8S1179: 13,14
ST FGA: 23
ST Penta D: 12,13
ST Penta E: 15,17
ST TH01: 6,9.3
ST TPOX: 9,11 (JCRB)
ST TPOX: 11 (PubMed=25877200)
ST vWA: 17,18 (JCRB)
ST vWA: 18 (PubMed=25877200)
DI NCIt; C5721; Pancreatic adenosquamous carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3005 ! KP-3
SX Male
CA Cancer cell line
//
ID KP-3N
AC CVCL_0U13
DR Cosmic; 1122347
RX PubMed=2172194;
CC Derived from metastatic site: Liver.
DI NCIt; C5721; Pancreatic adenosquamous carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3005 ! KP-3
SX Male
CA Cancer cell line
//
ID KP-4
AC CVCL_1338
SY KP 4; KP4
DR CLO; CLO_0050109
DR EFO; EFO_0006623
DR BioSample; SAMN03472375
DR BioSample; SAMN03472831
DR CCLE; KP4_PANCREAS
DR CGH-DB; 9373-4
DR ChEMBL-Cells; CHEMBL3308751
DR ChEMBL-Targets; CHEMBL1075482
DR Cosmic; 753572
DR Cosmic-CLP; 753572
DR GDSC; 753572
DR GEO; GSM827214
DR GEO; GSM887237
DR GEO; GSM888311
DR GEO; GSM1374602
DR GEO; GSM1670004
DR JCRB; JCRB0182
DR RCB; RCB1005
RX PubMed=21559554;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=KP-4
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 27 hours (PubMed=25984343).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200; RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 10
ST D16S539: 10
ST D18S51: 15
ST D21S11: 29,30
ST D3S1358: 15
ST D5S818: 10,12
ST D7S820: 10,11
ST D8S1179: 11,13
ST FGA: 21,25
ST Penta D: 9,14
ST Penta E: 12
ST TH01: 9,10
ST TPOX: 9,11 (Cosmic-CLP; JCRB)
ST TPOX: 9 (PubMed=25877200)
ST vWA: 14
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-4-1
AC CVCL_8727
SY KP 4-1; KP4-1
DR CLO; CLO_0050110
DR GEO; GSM1588609
DR RCB; RCB1006
RX PubMed=21559554;
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 10
ST D16S539: 10
ST D5S818: 10,12
ST D7S820: 10,11
ST TH01: 9,10
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1338 ! KP-4
SX Male
CA Cancer cell line
//
ID KP-4-2
AC CVCL_8728
SY KP 4-2; KP4-2
DR CLO; CLO_0050111
DR RCB; RCB1007
RX PubMed=21559554;
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 10
ST D16S539: 10
ST D5S818: 10,12
ST D7S820: 10,11
ST TH01: 9,10
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1338 ! KP-4
SX Male
CA Cancer cell line
//
ID KP-4-3
AC CVCL_8729
SY KP 4-3; KP4-3
DR CLO; CLO_0050108
DR RCB; RCB1008
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 10
ST D16S539: 10
ST D5S818: 10,12
ST D7S820: 10,11
ST TH01: 9,10
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1338 ! KP-4
SX Male
CA Cancer cell line
//
ID KP-4-4
AC CVCL_Y142
DR CGH-DB; 178-1
DR Cosmic; 918059
RX PubMed=18380791;
DI NCIt; C3850; Pancreatic carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1338 ! KP-4
SX Male
CA Cancer cell line
//
ID KP-6
AC CVCL_9543
RX PubMed=8656685;
RX PubMed=10936422;
CC Characteristics: IL6 dependent.
CC Derived from metastatic site: Pleural effusion.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-EW-MS
AC CVCL_7982
DR BTO; BTO:0004788
DR Cosmic; 1078364
RX PubMed=7591257;
DI NCIt; C4817; Ewing sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP-EW-Y1
AC CVCL_7983
SY KP-EW-YI
DR Cosmic; 1078363
RX PubMed=7591257;
DI NCIt; C4817; Ewing sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP-L-RY
AC CVCL_7984
DR Cosmic; 2378133
RX PubMed=12399976;
DI NCIt; C9140; Childhood B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-MO-TS
AC CVCL_7985
DR Cosmic; 787446
DR Cosmic; 975263
DR Cosmic; 1281322
RX PubMed=12399976;
DI NCIt; C9160; Childhood acute myeloid leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP-MRT-AN
AC CVCL_7049
RX PubMed=15355927;
RX PubMed=18281554;
RX PubMed=21871868;
DI NCIt; C6586; Extrarenal rhabdoid tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KP-MRT-NS
AC CVCL_7050
RX PubMed=10417765;
RX PubMed=15355927;
RX PubMed=18281554;
RX PubMed=21871868;
DI NCIt; C8715; Rhabdoid tumor of the kidney
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KP-MRT-RY
AC CVCL_7051
RX PubMed=18281554;
RX PubMed=21871868;
DI NCIt; C8715; Rhabdoid tumor of the kidney
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-MRT-YM
AC CVCL_7052
RX PubMed=15378398;
RX PubMed=18281554;
RX PubMed=21871868;
DI NCIt; C6586; Extrarenal rhabdoid tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-N-AY
AC CVCL_9508
DR CGH-DB; 9086-4
DR Cosmic; 848938
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=2004854;
RX PubMed=12702577;
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_9509 ! KP-N-AYR
SX Female
CA Cancer cell line
//
ID KP-N-AYR
AC CVCL_9509
DR CGH-DB; 83-1
DR CGH-DB; 9084-4
DR Cosmic; 848939
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=2004854;
RX PubMed=12702577;
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_9508 ! KP-N-AY
SX Female
CA Cancer cell line
//
ID KP-N-NH
AC CVCL_Y134
DR CGH-DB; 66-1
DR CGH-DB; 9089-4
RX PubMed=12702577;
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP-N-NS
AC CVCL_4771
DR CLO; CLO_0051416
DR BioSample; SAMN03472214
DR CCRID; 3111C0001CCC000283
DR CCRID; 3131C0001000700030
DR Cosmic; 920256
DR KCB; KCB 2011113YJ
DR RCB; RCB0687
RX PubMed=8297818;
CC Derived from metastatic site: Brain.
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 10,12
ST D16S539: 14
ST D5S818: 10,12
ST D7S820: 11,12
ST TH01: 7,9
ST TPOX: 9
ST vWA: 14,17
DI NCIt; C4827; Adrenal gland neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-N-NY
AC CVCL_Y135
DR CGH-DB; 67-1
DR CGH-DB; 9088-4
RX PubMed=12702577;
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP-N-RT-BM-1
AC CVCL_1339
SY RT-BM-1; RT-BM 1; KP-N-RT-BM; RT-BM; KP-N-RT
DR BioSample; SAMN03470963
DR CCLE; KPNRTBM1_AUTONOMIC_GANGLIA
DR CGH-DB; 69-1
DR CGH-DB; 9079-4
DR ChEMBL-Cells; CHEMBL3308339
DR ChEMBL-Targets; CHEMBL2366107
DR Cosmic; 848926
DR Cosmic; 924189
DR Cosmic-CLP; 924189
DR GDSC; 924189
DR GEO; GSM887239
DR GEO; GSM888313
DR GEO; GSM1670005
DR IFO; IFO50432
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=3731124;
RX PubMed=11129446;
RX PubMed=12702577;
RX PubMed=22460905;
RX PubMed=23268333;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Bone marrow.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 9,12
ST D16S539: 10,12
ST D18S51: 15,17
ST D19S433: 13
ST D21S11: 30,31.2
ST D2S1338: 20
ST D3S1358: 15,17
ST D5S818: 10,13
ST D7S820: 10,11
ST D8S1179: 12,13
ST FGA: 20,21
ST Penta D: 9,12
ST Penta E: 12,16
ST TH01: 6,7
ST TPOX: 8
ST vWA: 17,20
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_9511 ! KP-N-RT-LN
SX Female
CA Cancer cell line
//
ID KP-N-RT-LN
AC CVCL_9511
SY KP-N-RT(LN); RT-LN
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=3731124;
RX PubMed=23268333;
CC Derived from metastatic site: Axillary lymph node.
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1339 ! KP-N-RT-BM-1
SX Female
CA Cancer cell line
//
ID KP-N-RT-RT-BMV-C6
AC CVCL_9512
SY RT-BMV-C6; KPNRT-BMVc6; KP-N-RT-BMV
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=2547728;
RX PubMed=12702577;
RX PubMed=23268333;
CC Derived from metastatic site: Bone marrow.
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1339 ! KP-N-RT-BM-1
SX Female
CA Cancer cell line
//
ID KP-N-SI
AC CVCL_7909
SY KPNSI
DR BTO; BTO:0003547
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-N-SI (FA)
AC CVCL_9510
SY KP-N-SI(FA); KPNSI(FA); KP-N-SIFA
DR CGH-DB; 65-1
DR CGH-DB; 9080-4
DR Cosmic; 848927
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=11129446;
RX PubMed=12702577;
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7909 ! KP-N-SI
SX Male
CA Cancer cell line
//
ID KP-N-SI (LA)
AC CVCL_7910
SY KP-N-SI(LA); KP-N-SILA; KPNSI(LA)
DR CGH-DB; 64-1
DR CGH-DB; 9081-4
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=2486615;
RX PubMed=12702577;
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7909 ! KP-N-SI
SX Male
CA Cancer cell line
//
ID KP-N-SI4s
AC CVCL_7911
RX PubMed=2019470;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7909 ! KP-N-SI
SX Male
CA Cancer cell line
//
ID KP-N-SI8s
AC CVCL_7912
RX PubMed=2019470;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7909 ! KP-N-SI
SX Male
CA Cancer cell line
//
ID KP-N-SI9s
AC CVCL_1340
SY KP-N-SI9S; KP-N-S19s; KPNSI9S; SI9s
DR BioSample; SAMN03472791
DR CCLE; KPNSI9S_AUTONOMIC_GANGLIA
DR Cosmic; 907315
DR GEO; GSM887240
DR GEO; GSM888314
DR GEO; GSM1670006
DR IFO; IFO50433
RX PubMed=2019470;
RX PubMed=11129446;
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 11,14
ST D16S539: 9,13
ST D5S818: 13
ST D7S820: 8,11
ST TH01: 6
ST TPOX: 8,11
ST vWA: 17
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_7909 ! KP-N-SI
SX Male
CA Cancer cell line
//
ID KP-N-SK
AC CVCL_Y136
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP-N-TK
AC CVCL_Y137
DR CGH-DB; 81-1
DR CGH-DB; 9085-4
RX PubMed=12702577;
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-N-YN
AC CVCL_1341
DR BTO; BTO:0003546
DR BioSample; SAMN03470961
DR CCLE; KPNYN_AUTONOMIC_GANGLIA
DR CGH-DB; 80-1
DR CGH-DB; 9082-4
DR ChEMBL-Cells; CHEMBL3308265
DR ChEMBL-Targets; CHEMBL2366280
DR Cosmic; 907314
DR Cosmic-CLP; 907314
DR GDSC; 907314
DR GEO; GSM887241
DR GEO; GSM888315
DR GEO; GSM1670007
DR IFO; IFO50431
RX DOI=10.1007/0-306-46872-7_2;
RX PubMed=12702577;
RX PubMed=22460905;
RX PubMed=23268333;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 8,11
ST D16S539: 12
ST D18S51: 14
ST D19S433: 13
ST D21S11: 28,29
ST D2S1338: 17,24
ST D3S1358: 15,17
ST D5S818: 10,11
ST D7S820: 11,13
ST D8S1179: 12,13
ST FGA: 22,23
ST Penta D: 12,13
ST Penta E: 16,18
ST TH01: 7,9
ST TPOX: 8,11
ST vWA: 14,17
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-N-YN1s
AC CVCL_7913
SY YN1s
RX PubMed=2019470;
RX PubMed=11129446;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1341 ! KP-N-YN
SX Male
CA Cancer cell line
//
ID KP-N-YN2n
AC CVCL_7914
RX PubMed=2019470;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1341 ! KP-N-YN
SX Male
CA Cancer cell line
//
ID KP-N-YN3s
AC CVCL_7915
RX PubMed=2019470;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1341 ! KP-N-YN
SX Male
CA Cancer cell line
//
ID KP-N-YS
AC CVCL_1342
DR CGH-DB; 82-1
DR CGH-DB; 9083-4
DR ChEMBL-Cells; CHEMBL3308266
DR ChEMBL-Targets; CHEMBL2366065
DR Cosmic; 946363
DR Cosmic-CLP; 946363
DR GDSC; 946363
DR GEO; GSM1670008
RX PubMed=10363161;
RX PubMed=11129446;
RX PubMed=12702577;
RX PubMed=23268333;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,12
ST D16S539: 10
ST D5S818: 9,13
ST D7S820: 10,12
ST TH01: 7
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP-N-YS1n
AC CVCL_Y132
SY YS1n
RX PubMed=10363161;
RX PubMed=11129446;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1342 ! KP-N-YS
SX Male
CA Cancer cell line
//
ID KP-N-YS2s
AC CVCL_Y133
SY YS2s
RX PubMed=10363161;
RX PubMed=11129446;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1342 ! KP-N-YS
SX Male
CA Cancer cell line
//
ID KP-N-YuNo
AC CVCL_Y138
RX PubMed=23268333;
DI NCIt; C3270; Neuroblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP-P1
AC CVCL_D283
DR BioSample; SAMN03151733
RX PubMed=1246601;
RX PubMed=6451928;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=1246601, PubMed=6451928, PubMed=20143388). Originally thought to originate from a prostate carcinoma.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID KP-PN-TTBm2
AC CVCL_5147
DR GEO; GSM393040
DR IGRhCellID; KPPNTTBm2%20GEO
DI NCIt; C4817; Ewing sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KP283T
AC CVCL_EG33
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
CC Derived from metastatic site: Liver.
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 11
ST D16S539: 12
ST D21S11: 29
ST D5S818: 11,12
ST D7S820: 10,11
ST TH01: 6,9.3
ST TPOX: 8,11
ST vWA: 18
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KP363T
AC CVCL_EG34
RX PubMed=26894854;
CC Microsatellite instability: Stable (MSS) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 12
ST D21S11: 28,29
ST D5S818: 12
ST D7S820: 8,10
ST TH01: 6,9.3
ST TPOX: 8
ST vWA: 14,15
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KP7038T
AC CVCL_EG35
RX PubMed=26894854;
CC Microsatellite instability: Instable (MSI-high) (PubMed=26894854).
ST Source(s): PubMed=26894854
ST Amelogenin: X,Y
ST CSF1PO: 9,11
ST D13S317: 10,14
ST D16S539: 10,12
ST D21S11: 28,34
ST D5S818: 11
ST D7S820: 12,14
ST TH01: 7,8
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C4349; Colon adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KPAM1
AC CVCL_A107
DR Cosmic; 1206518
RX PubMed=18830255;
DI NCIt; C2993; Down syndrome
DI NCIt; C43223; Myeloid leukemia associated with Down syndrome
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KPB-L2
AC CVCL_W861
RX CelloPub=CLPUB00375;
RX PubMed=8704258;
RX PubMed=9454894;
RX PubMed=12967475;
CC Characteristics: EBV-negative.
CC Omics: Transcriptome analysis.
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KPB-M15
AC CVCL_5308
DR BioSample; SAMN03151821
RX PubMed=3461189;
RX PubMed=12592342;
RX PubMed=20143388;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KPB-M15
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a KYO-1 derivative (PubMed=12592342, PubMed=20143388).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_2095 ! KYO-1
SX Male
CA Cancer cell line
//
ID KPB-M8
AC CVCL_5309
RX PubMed=3461189;
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KPC-32
AC CVCL_M532
RX CelloPub=CLPUB00068;
RX PubMed=8080996;
RX PubMed=10936422;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KPD
AC CVCL_B412
SY KPDXM
DR Cosmic; 1529900
DR GEO; GSM879216
RX PubMed=2457439;
RX PubMed=19787792;
RX PubMed=21519327;
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KPE
AC CVCL_E731
DR dbMHC; 48929
DR IHW; IHW9242
DR IMGT/HLA; 10929
WW http://bioinformatics.hsanmartino.it/ecbr/cl242.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KPK1
AC CVCL_F947
SY KPK 1; KPK-1
DR TKG; TKG 0697
RX PubMed=7176042;
ST Source(s): TKG
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 8
ST D16S539: 9
ST D5S818: 10,11,12,13
ST D7S820: 9
ST TH01: 8
ST TPOX: 8
ST vWA: 18,19,20
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KPK13
AC CVCL_F948
SY KPK 13
DR TKG; TKG 0698
RX PubMed=7176042;
ST Source(s): TKG
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 9,16
ST D5S818: 12
ST D7S820: 11
ST TH01: 6
ST TPOX: 8
ST vWA: 14,18
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KPL-1
AC CVCL_2094
SY KPL1
DR CLO; CLO_0007118
DR EFO; EFO_0002221
DR BioSample; SAMN03151840
DR BioSample; SAMN03473349
DR CCLE; KPL1_BREAST
DR Cosmic; 2165023
DR DSMZ; ACC-317
DR GEO; GSM217583
DR GEO; GSM344368
DR GEO; GSM344418
DR GEO; GSM459707
DR GEO; GSM459720
DR GEO; GSM459721
DR GEO; GSM783974
DR GEO; GSM887238
DR GEO; GSM888312
DR GEO; GSM1374603
DR IGRhCellID; KPL1
DR NCBI_Iran; C643
RX PubMed=7710953;
RX PubMed=15677628;
RX PubMed=15767549;
RX PubMed=20143388;
RX PubMed=22460905;
RX PubMed=25485619;
WW http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=KPL-1
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a MCF-7 derivative (PubMed=20143388).
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: JFCR45 cancer cell line panel.
CC Doubling time: ~50 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (PubMed=15677628).
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 10,11
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 8,9
ST TH01: 6
ST TPOX: 9,12
ST vWA: 14,15
DI NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0031 ! MCF-7
SX Female
CA Cancer cell line
//
ID KPL-3C
AC CVCL_E122
RX PubMed=8688322;
RX PubMed=15767549;
CC Part of: JFCR45 cancer cell line panel.
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KPL-4
AC CVCL_5310
SY KPL4
DR EFO; EFO_0006624
DR BioSample; SAMN03471036
DR BioSample; SAMN03473250
DR GEO; GSM590107
DR GEO; GSM1374604
RX PubMed=10070858;
RX PubMed=15767549;
RX PubMed=21247443;
RX PubMed=23671654;
RX PubMed=25485619;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KPL-4
CC Part of: JFCR45 cancer cell line panel.
CC Microsatellite instability: Stable (MSS) (PubMed=23671654).
CC Omics: Deep RNAseq analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D16S539: 12
ST D18S51: 15
ST D21S11: 29,32.2
ST D3S1358: 16,17
ST D5S818: 11,13
ST D7S820: 9,10
ST D8S1179: 11,16
ST FGA: 19
ST Penta D: 10,14
ST Penta E: 11,12
ST TH01: 9
ST TPOX: 8
ST vWA: 14,19
DI NCIt; C4001; Inflammatory breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KPMM1
AC CVCL_9541
RX CelloPub=CLPUB00381;
RX PubMed=8797890;
RX PubMed=10936422;
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KPMM2
AC CVCL_5311
RX PubMed=7723407;
RX PubMed=8797890;
RX PubMed=10936422;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KPMM2
CC Characteristics: IL6 dependent.
CC Doubling time: ~48 hours (with IL6), ~72 hours (without IL6) (PubMed=7723407).
CC Derived from metastatic site: Ascites.
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KPNT-1
AC CVCL_0G02
DR CGH-DB; 9031-4
RX PubMed=9738977;
RX PubMed=10570904;
CC Transformant: NCBI_TaxID; 11908; Human T-lymphotropic virus 1 (HTLV-1).
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KQ0001
AC CVCL_8Y00
DR ECACC; 97120601
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KR-12
AC CVCL_3732
SY KR12
DR CLO; CLO_0007119
DR ATCC; CRL-8658
DR BioSample; SAMN03471206
RX Patent=US4693975;
RX PubMed=6092464;
ST Source(s): ATCC
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 11,12
ST D16S539: 9,11
ST D5S818: 10,11,13
ST D7S820: 9,10
ST TH01: 8,9,9.3
ST TPOX: 8
ST vWA: 16,18,19
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0014 ! RPMI-8226
HI CVCL_H617 ! GM1500-6TG-OUB
CA Hybrid cell line
//
ID KRA
AC CVCL_E732
DR IHW; IHW0607
WW http://bioinformatics.hsanmartino.it/ecbr/cl371.html
CC Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KRC-005
AC CVCL_E733
DR dbMHC; 48930
DR IHW; IHW9360
DR IMGT/HLA; 10930
WW http://bioinformatics.hsanmartino.it/ecbr/cl360.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KRC-032
AC CVCL_E734
DR dbMHC; 48931
DR IHW; IHW9361
DR IMGT/HLA; 10931
WW http://bioinformatics.hsanmartino.it/ecbr/cl361.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KRC-033
AC CVCL_F542
SY KRC033
DR IMGT/HLA; 10932
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KRC-103
AC CVCL_E735
SY KRC103; krc103
DR dbMHC; 48932
DR IHW; IHW9358
DR IMGT/HLA; 10933
WW http://bioinformatics.hsanmartino.it/ecbr/cl358.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KRC-110
AC CVCL_E736
SY KRC 110; KRC110
DR dbMHC; 48933
DR ECACC; 94071446
DR IHW; IHW9359
DR IMGT/HLA; 10934
WW http://bioinformatics.hsanmartino.it/ecbr/cl359.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KRC-7 [Human RCC]
AC CVCL_HL92
RX PubMed=10232606;
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KRC-7 [Rat hepatoma]
AC CVCL_0377
SY KRC7
DR MCCL; MCC:0000272
RX PubMed=7008195;
CC Breed/subspecies: AxC.
DI NCIt; C60416; Rat hepatocellular carcinoma
OX NCBI_TaxID=10116; ! Rattus norvegicus
HI CVCL_0285 ! H4-II-E-C3
SX Male
CA Cancer cell line
//
ID KRC/Y
AC CVCL_A448
SY KRC-Y; KRC Y; KRCY
DR Cosmic; 877457
DR Cosmic; 1152535
RX PubMed=3338971;
RX PubMed=10723130;
CC Doubling time: 73 hours, at 15th passage (PubMed=3338971).
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KRE
AC CVCL_R911
SY Kelp and Red spotted grouper Embryo
RX DOI=10.1577/1548-8667(1993)005<0127:COTCCL>2.3.CO;2;
RX DOI=10.3147/jsfp.28.27;
CC Group: Fish cell line.
CC Breed/subspecies: Hybrid of Epinephelus moara and Epinephelus akaara.
OX NCBI_TaxID=300413; ! Epinephelus moara
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KRE-2
AC CVCL_6F82
SY Kelp and Red spotted grouper Embryo-2
RX DOI=10.3147/jsfp.28.27;
CC Group: Fish cell line.
CC Breed/subspecies: Hybrid of Epinephelus moara and Epinephelus akaara.
OX NCBI_TaxID=300413; ! Epinephelus moara
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KRE-3
AC CVCL_6F83
SY Kelp and Red spotted grouper Embryo-3
RX DOI=10.3147/jsfp.29.29;
CC Group: Fish cell line.
CC Breed/subspecies: Hybrid of Epinephelus moara and Epinephelus akaara.
OX NCBI_TaxID=300413; ! Epinephelus moara
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KRIB
AC CVCL_AU05
RX CelloPub=CLPUB00319;
RX PubMed=8402677;
CC Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras.
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0439 ! MNNG/HOS Cl #5
SX Female
CA Cancer cell line
//
ID KRJ-I
AC CVCL_8886
SY KRJ-1
DR CLO; CLO_0007120
DR ECACC; 95041223
RX PubMed=17242179;
RX PubMed=19295186;
RX PubMed=21544390;
RX PubMed=22538498;
CC Discontinued: ECACC; 95041223; probable.
DI NCIt; C6422; Midgut carcinoid tumor
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_L295 ! KRJ-II
SX Male
CA Cancer cell line
//
ID KRJ-II
AC CVCL_L295
RX PubMed=21544390;
CC Derived from metastatic site: Liver.
DI NCIt; C6422; Midgut carcinoid tumor
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_8886 ! KRJ-I
SX Male
CA Cancer cell line
//
ID KRO3/4
AC CVCL_E737
SY KRO3; KRO
DR IHW; IHW0505
DR IMGT/HLA; 10936
WW http://bioinformatics.hsanmartino.it/ecbr/cl370.html
CC Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Sex undetermined
CA Transformed cell line
//
ID KRV1
AC CVCL_DR14
SY KRV-1
DR GEO; GSM1489215
DR GEO; GSM1489245
DR GEO; GSM1489455
CC From: Center for iPS Cell Research and Application; Kyoto University; Kyoto; Japan.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_DR13 ! KEP1
SX Female
CA Induced pluripotent stem cell
//
ID KS Y-1
AC CVCL_F660
SY KS Y1; KSY-1
DR ATCC; CRL-11448
DR BioSample; SAMN03151948
RX Patent=US5569602;
RX PubMed=7629884;
RX PubMed=22987579;
WW http://www.atcc.org/support/faqs/93f92/KSY1%20ATCC%20CRL11448-1061.aspx
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a T24 derivative (PubMed=22987579). Was thought to originate from a Kaposi sarcoma.
CC Discontinued: ATCC; CRL-11448; true.
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0554 ! T24
SX Female
CA Cancer cell line
//
ID KS-1 [Human glioblastoma]
AC CVCL_1343
DR BioSample; SAMN03472792
DR CCLE; KS1_CENTRAL_NERVOUS_SYSTEM
DR CGH-DB; 148-1
DR ChEMBL-Cells; CHEMBL3308170
DR ChEMBL-Targets; CHEMBL2366228
DR Cosmic; 687577
DR Cosmic; 907313
DR Cosmic; 2367535
DR Cosmic-CLP; 907313
DR GDSC; 907313
DR GEO; GSM887242
DR GEO; GSM888316
DR GEO; GSM1670009
DR IFO; IFO50436
RX PubMed=16232199;
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 11,13
ST D16S539: 11,12
ST D5S818: 8,12
ST D7S820: 11
ST TH01: 6,9
ST TPOX: 8,11
ST vWA: 14,18
DI NCIt; C3058; Glioblastoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KS-1 [Human Krukenberg tumour]
AC CVCL_D284
SY KS1
DR GEO; GSM459734
RX PubMed=2331685;
RX PubMed=2846312;
DI NCIt; C3153; Krukenberg tumor
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KS-1 [Human primary effusion lymphoma]
AC CVCL_4J72
DR ATCC; CRL-12247
RX Patent=US6306581;
RX PubMed=9639499;
CC Discontinued: ATCC; CRL-12247; probable.
DI NCIt; C6915; Primary effusion lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KS-Bu3
AC CVCL_W862
RX PubMed=8704258;
RX PubMed=9454894;
RX PubMed=12967475;
CC Characteristics: EBV-negative.
CC Omics: Transcriptome analysis.
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KS-IMM
AC CVCL_9805
SY KS-Imm; KS IMM; KSIMM
DR BTO; BTO:0002070
DR EFO; EFO_0002826
DR Cosmic; 2162544
DI NCIt; C3992; AIDS-related Kaposi sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KSCBi001-A
AC CVCL_IT62
SY hUSiPS2
DR BioSamples; SAMEA104012032
DR hPSCreg; KSCBi001-A
CC From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Induced pluripotent stem cell
//
ID KSCBi002-A
AC CVCL_IT63
SY hFSiPS1
DR BioSamples; SAMEA104012352
DR hPSCreg; KSCBi002-A
CC From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_IT64 ! KSCBi002-B
SX Male
CA Induced pluripotent stem cell
//
ID KSCBi002-B
AC CVCL_IT64
SY hFmiPS1
DR BioSamples; SAMEA104012354
DR hPSCreg; KSCBi002-B
CC From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_IT63 ! KSCBi002-A
SX Male
CA Induced pluripotent stem cell
//
ID KSCBi002-B-1
AC CVCL_IT65
SY hFmiPS2
DR BioSamples; SAMEA104012355
DR hPSCreg; KSCBi002-B-1
CC From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Korea.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_IT64 ! KSCBi002-B
SX Male
CA Induced pluripotent stem cell
//
ID KSG
AC CVCL_Z505
RX PubMed=24399253;
CC Group: Fish cell line.
CC Doubling time: 40 hours (PubMed=24399253).
OX NCBI_TaxID=41446; ! Sebastiscus marmoratus
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KShS
AC CVCL_4917
DR CLO; CLO_0007121
DR CLDB; cl3037
OX NCBI_TaxID=9823; ! Sus scrofa
CA Undefined cell line type
//
ID KSNY
AC CVCL_IW66
RX PubMed=317053;
CC Doubling time: 46 hours (PubMed=317053).
CC Anecdotal: Cell name corresponds to the first letters of the names of the first three and of the last authors.
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KsOG
AC CVCL_6557
RX PubMed=7489827;
RX PubMed=15541573;
CC Breed/subspecies: Fischer.
OX NCBI_TaxID=10116; ! Rattus norvegicus
SX Female
CA Transformed cell line
//
ID KST
AC CVCL_6A74
RX PubMed=24000610;
WW http://www.rccc.cytspb.rssi.ru/ecellbank/animal/akst.htm
OX NCBI_TaxID=9913; ! Bos taurus
SX Sex undetermined
CA Finite cell line
//
ID Kst-6
AC CVCL_6B18
RX PubMed=1550597;
RX PubMed=7914196;
CC Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC Transfected with: UniProtKB; P62577; E.coli cat.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0372 ! KB
SX Female
CA Cancer cell line
//
ID Kst-V100
AC CVCL_6B19
RX PubMed=7914196;
CC Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC Transfected with: UniProtKB; P62577; E.coli cat.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_6B18 ! Kst-6
SX Female
CA Cancer cell line
//
ID KSU
AC CVCL_T743
SY KSu
RX PubMed=1449054;
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KSU.C3
AC CVCL_T744
RX PubMed=8100098;
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_T743 ! KSU
SX Male
CA Cancer cell line
//
ID KT
AC CVCL_M379
RX PubMed=3147274;
DI NCIt; C4872; Breast carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KT-1 [Human leukemia]
AC CVCL_D200
SY KT1
RX PubMed=9427720;
CC Doubling time: 18-24 hours (PubMed=9427720).
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KT-1 [Mouse tongue]
AC CVCL_HX30
RX Patent=US20060040255;
RX PubMed=12513125;
CC Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8347.
CC Doubling time: 4 days (PubMed=12513125).
CC Breed/subspecies: C57BL/6J.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Spontaneously immortalized cell line
//
ID KT-2
AC CVCL_7055
DR BTO; BTO:0004153
DR Cosmic; 1047093
RX PubMed=17332333;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KT-3
AC CVCL_6293
RX PubMed=3052631;
RX PubMed=3120822;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KT-3
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/k/cell-lines-detail-84.html
DI NCIt; C7205; Lymphoepithelioid variant peripheral T-cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KT-4
AC CVCL_7056
DR BTO; BTO:0004154
DR Cosmic; 1047094
RX PubMed=17332333;
DI NCIt; C4450; Large cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KT-5
AC CVCL_5549
DR IFO; IFO50161
CC Breed/subspecies: C3H.
DI NCIt; C21932; Mouse astrocytic tumours
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID KT-COLO-8
AC CVCL_W485
RX PubMed=7873498;
DI NCIt; C7966; Colon mucinous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KT01
AC CVCL_X644
SY KT1
DR CLO; CLO_0050365
DR RCB; RCB2367
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT02
AC CVCL_X645
SY KT2
DR CLO; CLO_0050366
DR RCB; RCB2368
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT03
AC CVCL_X646
SY KT3
DR CLO; CLO_0050367
DR RCB; RCB2369
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule and body wall muscle.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT04
AC CVCL_X647
SY KT4
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT05
AC CVCL_X648
SY KT5
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT06
AC CVCL_X649
SY KT6
DR CLO; CLO_0050368
DR RCB; RCB2372
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule and adult muscle.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT07
AC CVCL_X650
SY KT7
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT08
AC CVCL_X651
SY KT8
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT09
AC CVCL_X652
SY KT9
DR CLO; CLO_0050369
DR RCB; RCB2375
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on body muscle.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT10
AC CVCL_X653
DR CLO; CLO_0050370
DR RCB; RCB2376
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on body muscle.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT11 [Human B-cell]
AC CVCL_E738
DR IHW; IHW0610
WW http://bioinformatics.hsanmartino.it/ecbr/cl372.html
CC Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KT11 [Mouse hybridoma]
AC CVCL_X654
DR CLO; CLO_0050371
DR RCB; RCB2377
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on body muscle.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT12 [Human B-cell]
AC CVCL_E739
SY LKT12
DR dbMHC; 48934
DR ECACC; 88012503
DR IHW; IHW9073
DR IMGT/HLA; 11000
WW http://bioinformatics.hsanmartino.it/ecbr/cl73.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KT12 [Mouse hybridoma]
AC CVCL_X655
DR CLO; CLO_0050372
DR RCB; RCB2378
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on body muscle.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT13
AC CVCL_X656
DR CLO; CLO_0050373
DR RCB; RCB2379
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on hypodermis/seam cells.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT14 [Human B-cell]
AC CVCL_E740
SY LKT14; KAS
DR dbMHC; 48935
DR ECACC; 88052103
DR IHW; IHW9103
DR IMGT/HLA; 11001
WW http://bioinformatics.hsanmartino.it/ecbr/cl103.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KT14 [Mouse hybridoma]
AC CVCL_X657
DR CLO; CLO_0050374
DR RCB; RCB2380
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx basement membrane.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT16
AC CVCL_X658
DR CLO; CLO_0050375
DR RCB; RCB2381
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT17 [Human B-cell]
AC CVCL_E741
SY LKT17
DR dbMHC; 48936
DR ECACC; 88052024
DR IHW; IHW9024
DR IMGT/HLA; 11002
RX PubMed=8307784;
WW http://bioinformatics.hsanmartino.it/ecbr/cl24.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KT17 [Mouse hybridoma]
AC CVCL_X659
DR CLO; CLO_0050364
DR RCB; RCB2382
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT18
AC CVCL_X660
DR CLO; CLO_0050376
DR RCB; RCB2383
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT19
AC CVCL_X661
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT2
AC CVCL_E742
SY LKT2
DR dbMHC; 48937
DR ECACC; 94022538
DR IHW; IHW9288
DR IMGT/HLA; 11003
WW http://bioinformatics.hsanmartino.it/ecbr/cl288.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Discontinued: ECACC; 94022538; probable.
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KT20
AC CVCL_X662
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT21
AC CVCL_X663
DR CLO; CLO_0050390
DR RCB; RCB2386
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on intestine.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT21-MG1
AC CVCL_M429
SY KT21MG1
RX PubMed=2804914;
DI NCIt; C3230; Meningioma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KT22
AC CVCL_X664
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT23
AC CVCL_X665
DR CLO; CLO_0050398
DR RCB; RCB2388
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on nuclear membrane.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT26
AC CVCL_X666
DR CLO; CLO_0050377
DR RCB; RCB2389
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on centrosome.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT27
AC CVCL_X667
DR CLO; CLO_0050378
DR RCB; RCB2390
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on dorsal hypodermis.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT28
AC CVCL_X668
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on unidentified structure.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT29
AC CVCL_X669
DR CLO; CLO_0050379
DR RCB; RCB2392
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on eggshell.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT3
AC CVCL_E743
SY LKT3; LKT-3; KT-3
DR dbMHC; 48953
DR ECACC; 94070705
DR IHW; IHW9107
DR IMGT/HLA; 11004
RX PubMed=16702430;
WW http://bioinformatics.hsanmartino.it/ecbr/cl107.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KT30
AC CVCL_X670
DR CLO; CLO_0050381
DR RCB; RCB2393
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on eggshell.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT31
AC CVCL_X671
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on sensory cilia and excretory pore.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT32
AC CVCL_X672
DR CLO; CLO_0050382
DR RCB; RCB2395
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule and pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT35
AC CVCL_X673
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule and centrosome.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT36
AC CVCL_X674
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT37
AC CVCL_X675
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT38
AC CVCL_X676
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule and pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT54
AC CVCL_X677
DR CLO; CLO_0050383
DR RCB; RCB2400
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on P granule and centrosome.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KT56
AC CVCL_X678
RX PubMed=18498356;
CC Monoclonal antibody target: C.elegans antigen on pharynx.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID KTA-1
AC CVCL_9572
SY KTA1; KTA-I
DR CGH-DB; 49-1
RX Patent=US8029793;
RX PubMed=8121182;
RX PubMed=16924234;
DI NCIt; C46008; Thyroid gland squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTA-2
AC CVCL_9573
SY KTA2; KTA-II
DR CGH-DB; 50-1
DR Lonza; 23
RX Patent=US8029793;
RX PubMed=8121182;
RX PubMed=9177455;
RX PubMed=16924234;
CC Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7525.
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KTA-3
AC CVCL_9574
SY KTA3
DR CGH-DB; 51-1
RX Patent=US8029793;
RX PubMed=16924234;
CC Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7526.
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTA-4
AC CVCL_9575
SY KTA4
DR CGH-DB; 52-1
RX Patent=US8029793;
RX PubMed=16924234;
CC Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7528.
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTA7
AC CVCL_A105
SY KTA-7
DR Cosmic; 946051
RX PubMed=1705538;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTC-1
AC CVCL_6300
SY KTC1
DR BTO; BTO:0005144
DR Cosmic; 683717
DR Cosmic; 1239967
DR Cosmic; 2054106
RX PubMed=10946899;
RX PubMed=18713817;
RX PubMed=23833040;
ST Source(s): PubMed=18713817
ST Amelogenin: X,Y
ST D13S317: 11
ST D18S51: 12,13
ST D21S11: 29
ST D3S1358: 14,15
ST D5S818: 11,12
ST D7S820: 11
ST D8S1179: 11,14
ST FGA: 23,26
ST vWA: 14,17
DI NCIt; C4035; Thyroid gland papillary carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTC-2
AC CVCL_6476
DR Cosmic; 1239964
DR Cosmic; 2054080
RX PubMed=12729473;
RX PubMed=18713817;
RX PubMed=23833040;
ST Source(s): PubMed=18713817
ST Amelogenin: X
ST D13S317: 8,12
ST D18S51: 16
ST D21S11: 30
ST D3S1358: 15
ST D5S818: 12
ST D7S820: 11
ST D8S1179: 12
ST FGA: 23
ST vWA: 17,18
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KTC-3
AC CVCL_W911
SY KTC3
RX CelloPub=CLPUB00144;
DI NCIt; C3878; Thyroid gland undifferentiated (anaplastic) carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-104
AC CVCL_B273
RX PubMed=11762795;
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-111
AC CVCL_B272
SY KTCTL 111
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-120
AC CVCL_5883
SY KTCTL120; RCC-LR
DR CLS; 300236/p806_RCC-LR
ST Source(s): CLS
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12,14
ST D16S539: 12
ST D18S51: 13,14
ST D21S11: 29,30
ST D3S1358: 16,17
ST D5S818: 13
ST D7S820: 11,12
ST D8S1179: 14,15
ST FGA: 20,22
ST Penta D: 9,14
ST Penta E: 12
ST TH01: 7,8
ST TPOX: 8,10
ST vWA: 16,17
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KTCTL-128
AC CVCL_B274
RX PubMed=11720477;
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-129
AC CVCL_5885
SY KTCTL129; RCC-MH; RCCMH
DR CLS; 300237/p685_RCC-MH
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): CLS
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11
ST D16S539: 12
ST D18S51: 16
ST D21S11: 29,30
ST D3S1358: 17
ST D5S818: 9,10
ST D7S820: 8,12
ST D8S1179: 9,15
ST FGA: 22
ST Penta D: 12,13
ST Penta E: 5,12
ST TH01: 7
ST TPOX: 8
ST vWA: 15,18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KTCTL-13
AC CVCL_5870
SY KTCTL13; KTCTL 13; RCC-ER; RCCER
DR CLS; 300238/p696_RCC-ER
DR Cosmic; 972923
DR Cosmic; 1352060
DR Cosmic; 1751971
DR Cosmic-CLP; 1524417
DR GDSC; 1524417
DR GEO; GSM1670361
RX PubMed=7915601;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Misspelling: 'KTCL13' in Cosmic 972923 and PubMed=7915601.
ST Source(s): CLS; Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 11,13
ST D16S539: 9,12
ST D18S51: 14,17
ST D21S11: 30,31.2
ST D3S1358: 18
ST D5S818: 11
ST D7S820: 10,12
ST D8S1179: 12,15
ST FGA: 21,26
ST Penta D: 10,12
ST Penta E: 11,12
ST TH01: 6
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-135
AC CVCL_5869
SY KTCTL135; RCC-EK
DR CLS; 300239/NA
CC Discontinued: CLS; 300239; true.
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-140
AC CVCL_5879
SY KTCTL140; RCC-JF; RCCJF
DR CLS; 300274/p673_RCC-JF
DR Cosmic; 972926
DR Cosmic; 1352063
DR Cosmic; 1751974
DR Cosmic-CLP; 1524415
DR GDSC; 1524415
RX PubMed=7915601;
RX PubMed=11762795;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Misspelling: 'KTCL140' in Cosmic 972926 and PubMed=7915601.
ST Source(s): CLS; Cosmic-CLP
ST Amelogenin: X
ST CSF1PO: 10,13
ST D13S317: 11,12
ST D16S539: 11
ST D18S51: 13,15
ST D21S11: 28,30.2
ST D3S1358: 17
ST D5S818: 11
ST D7S820: 7,8
ST D8S1179: 12,14
ST FGA: 18,25
ST Penta D: 10,13
ST Penta E: 7,13
ST TH01: 7,9
ST TPOX: 8
ST vWA: 18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KTCTL-185
AC CVCL_5875
SY KTCTL185; RCC-GS; RCCGS
DR CLS; 300241/p683_RCC-GS
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): CLS
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,14
ST D16S539: 9,12
ST D18S51: 14
ST D21S11: 31
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 8,10
ST D8S1179: 8,11
ST FGA: 24
ST Penta D: 11
ST Penta E: 8,10
ST TH01: 9
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-187
AC CVCL_B275
RX PubMed=11762795;
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-195
AC CVCL_5880
SY KTCTL195; RCC-JW; RCCJW
DR CLS; 300244/p680_RCC-JW
DR Cosmic; 1352064
DR Cosmic; 1751975
DR Cosmic-CLP; 1524416
DR GDSC; 1524416
DR GEO; GSM1670363
RX PubMed=11762795;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): CLS; Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 10,11
ST D13S317: 8,12
ST D16S539: 10,11
ST D18S51: 16
ST D21S11: 28,30
ST D3S1358: 16
ST D5S818: 11,12
ST D7S820: 8,11
ST D8S1179: 13
ST FGA: 22
ST Penta D: 12,13
ST Penta E: 7
ST TH01: 6,8
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-1M
AC CVCL_5884
SY KTCTL1M; RCC-MF; RCCMF
DR CLS; 300245/p799_RCC-MF
DR Cosmic; 1352065
DR Cosmic; 1751976
DR Cosmic-CLP; 1524419
DR GDSC; 1524419
DR GEO; GSM1670364
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): CLS; Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 11,14
ST D16S539: 13
ST D18S51: 13,15
ST D21S11: 29,30
ST D3S1358: 17
ST D5S818: 11,12
ST D7S820: 9,10
ST D8S1179: 10,14
ST FGA: 20
ST Penta D: 12,16
ST Penta E: 7,12
ST TH01: 6
ST TPOX: 8,11
ST vWA: 18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-2
AC CVCL_5871
SY KTCTL2; KTCTL 2; RCC-EW
DR CLS; 300246/NA
DR Cosmic; 972922
RX PubMed=7915601;
RX PubMed=10190320;
RX PubMed=11720477;
RX PubMed=15977034;
CC Problematic cell line: Contaminated. KTCTL-2 and KTCTL-30 have been shown to be identical (CLS; on the basis of STR profile).
CC Misspelling: 'KTCL2' in Cosmic 972922 and PubMed=7915601.
CC Discontinued: CLS; 300246; true.
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_5878 ! KTCTL-30
SX Female
CA Cancer cell line
//
ID KTCTL-21
AC CVCL_5868
SY KTCTL21; RCC-AB
DR CLS; 300247/NA
DR Cosmic; 1352059
DR Cosmic; 1751970
DR Cosmic-CLP; 1524418
DR GDSC; 1524418
DR GEO; GSM1670360
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Discontinued: CLS; 300247; true.
ST Source(s): Cosmic-CLP
ST Amelogenin: X,Y
ST CSF1PO: 10,13
ST D13S317: 12,13
ST D16S539: 11
ST D5S818: 11,12
ST D7S820: 9,11
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 15,19
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-26
AC CVCL_5872
SY KTCTL26; RCC-FG1; RCCFG1
DR CLS; 300248/p2065_RCC-FG1_(KTCTL-26)
RX PubMed=10190320;
RX PubMed=15977034;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): CLS
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11,12
ST D16S539: 11,13
ST D18S51: 14,17
ST D21S11: 29,30
ST D3S1358: 16
ST D5S818: 10,11,12
ST D7S820: 10,11,12
ST D8S1179: 12,13,15
ST FGA: 19,23
ST Penta D: 9,13
ST Penta E: 12,17,18
ST TH01: 9
ST TPOX: 8,11
ST vWA: 18,19
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_5873 ! KTCTL-26A
SX Male
CA Cancer cell line
//
ID KTCTL-26A
AC CVCL_5873
SY KTCTL26A; RCC-FG2
DR CLS; 300249/p2063_RCC-FG2_(KTCTL-26A)
DR Cosmic; 972924
DR Cosmic; 1352061
DR Cosmic; 1751972
DR Cosmic-CLP; 1524414
DR GDSC; 1524414
DR GEO; GSM1670362
RX PubMed=7828150;
RX PubMed=7915601;
RX PubMed=27397505;
CC Microsatellite instability: Instable (MSI-low) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Misspelling: 'KTCL26A' in Cosmic 972924 and PubMed=7915601.
ST Source(s): CLS; Cosmic-CLP
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11,12
ST D16S539: 11,13
ST D18S51: 15,17
ST D21S11: 29,30
ST D3S1358: 16
ST D5S818: 10,12
ST D7S820: 11,12
ST D8S1179: 12,15
ST FGA: 19,23
ST Penta D: 9,13
ST Penta E: 12,18
ST TH01: 9
ST TPOX: 8,11
ST vWA: 18,19
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_5872 ! KTCTL-26
SX Male
CA Cancer cell line
//
ID KTCTL-28
AC CVCL_B276
RX PubMed=11720477;
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-30
AC CVCL_5878
SY KTCTL30; KTCTL 30; RCC-HS
DR CLS; 300250/NA
DR Cosmic; 1352062
RX PubMed=11762795;
CC Problematic cell line: Contaminated. KTCTL-2 and KTCTL-30 have been shown to be identical (CLS; on the basis of STR profile).
CC Discontinued: CLS; 300250; true.
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_5871 ! KTCTL-2
SX Female
CA Cancer cell line
//
ID KTCTL-33
AC CVCL_B277
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-48
AC CVCL_5877
SY KTCTL48; RCC-HB; RCCHB
DR CLS; 300253/p687_RCC-HB
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): CLS
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12,13
ST D16S539: 12
ST D18S51: 14,16
ST D21S11: 28,30
ST D3S1358: 18
ST D5S818: 10
ST D7S820: 8,12
ST D8S1179: 13
ST FGA: 18,24
ST Penta D: 11,13
ST Penta E: 16
ST TH01: 9.3
ST TPOX: 11,12
ST vWA: 14,17
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-53
AC CVCL_5882
SY KTCTL53; KTCTL 53; RCC-KP
DR CLS; 300254/p2062_RCC-KP
DR Cosmic; 972925
RX PubMed=7915601;
CC Misspelling: 'KTCL53' in Cosmic 972925 and PubMed=7915601.
ST Source(s): CLS
ST Amelogenin: X,Y
ST CSF1PO: 9,10
ST D13S317: 11,12
ST D16S539: 9,12
ST D18S51: 13,14
ST D21S11: 30
ST D3S1358: 16
ST D5S818: 12,13
ST D7S820: 12
ST D8S1179: 10,14
ST FGA: 20,21
ST Penta D: 9,12
ST Penta E: 7,14
ST TH01: 7,9.3
ST TPOX: 8
ST vWA: 17,18
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-54
AC CVCL_5886
SY KTCTL54; RCC-OF1
DR CLS; 300255/p688_RCC-OF1
ST Source(s): CLS
ST Amelogenin: X
ST CSF1PO: 12,14
ST D13S317: 12,13
ST D16S539: 12
ST D18S51: 16
ST D21S11: 28,29
ST D3S1358: 15
ST D5S818: 10,13
ST D7S820: 10,11
ST D8S1179: 13,15
ST FGA: 19,21
ST Penta D: 9,13
ST Penta E: 13
ST TH01: 7,9.3
ST TPOX: 8
ST vWA: 17
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTCTL-84
AC CVCL_B278
RX PubMed=11720477;
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KTCTL-87
AC CVCL_5888
SY KTCTL87; RCC-WK; RCCWK
DR CLS; 300243/p682_RCC-WK
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): CLS
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 12
ST D16S539: 10,12
ST D18S51: 17
ST D21S11: 28,31.2
ST D3S1358: 16
ST D5S818: 11
ST D7S820: 9,12
ST D8S1179: 11,12
ST FGA: 21,23
ST Penta D: 12,15
ST Penta E: 5,16
ST TH01: 8,9
ST TPOX: 9,12
ST vWA: 14,16
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KTHOS
AC CVCL_T737
RX PubMed=15693848;
DI NCIt; C9145; Osteosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KTOSA5
AC CVCL_GY93
RX PubMed=24416158;
RX PubMed=25190452;
CC Breed/subspecies: Rottweiler.
DI NCIt; C120045; Canine osteosarcoma
OX NCBI_TaxID=9615; ! Canis lupus familiaris
SX Female
CA Cancer cell line
//
ID KTP
AC CVCL_4918
DR CLO; CLO_0007122
DR CLDB; cl3069
OX NCBI_TaxID=9823; ! Sus scrofa
SX Male
CA Undefined cell line type
//
ID KTR-R
AC CVCL_0R17
DR CCLV; CCLV-RIE 0060
OX NCBI_TaxID=9913; ! Bos taurus
CA Finite cell line
//
ID KTSq-1
AC CVCL_A106
DR Cosmic; 946070
DI NCIt; C3493; Squamous cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KU-1
AC CVCL_4712
SY KU1; Keio University-1
DR BTO; BTO:0003545
RX PubMed=3154018;
RX PubMed=7185004;
RX PubMed=10496353;
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KU-19-19
AC CVCL_1344
SY KU 19-19, KU19-19; KU1919; Keio University-19-19
DR CLO; CLO_0007123
DR BioSample; SAMN03473576
DR CCLE; KU1919_URINARY_TRACT
DR ChEMBL-Cells; CHEMBL3308111
DR ChEMBL-Targets; CHEMBL1075483
DR Cosmic; 907312
DR Cosmic; 1046693
DR Cosmic; 1285122
DR Cosmic; 1286001
DR Cosmic; 2050448
DR Cosmic; 2057453
DR Cosmic; 2444234
DR Cosmic-CLP; 907312
DR DSMZ; ACC-395
DR GDSC; 907312
DR GEO; GSM887243
DR GEO; GSM888317
DR GEO; GSM1374605
DR GEO; GSM1670010
RX PubMed=7542171;
RX PubMed=9464244;
RX PubMed=10022529;
RX PubMed=10496353;
RX PubMed=22460905;
RX PubMed=24367658;
RX PubMed=27397505;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KU-19-19
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~48 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 11
ST D16S539: 10,12
ST D5S818: 11,12
ST D7S820: 10,12
ST TH01: 7,8
ST TPOX: 8,11
ST vWA: 14,15
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KU-19-20
AC CVCL_5213
SY KU 19-20; KU19-20; Keio University-19-20
DR GEO; GSM374461
RX PubMed=10496353;
RX PubMed=10994781;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KU-19-20
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KU-2
AC CVCL_D267
SY KU2; Keio University-2
DR ChEMBL-Cells; CHEMBL3307795
DR ChEMBL-Targets; CHEMBL612265
RX PubMed=661038;
RX PubMed=1263309;
RX PubMed=3012186;
RX PubMed=3022569;
RX PubMed=7185005;
RX PubMed=10496353;
CC Derived from metastatic site: Lung.
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KU-20-01
AC CVCL_5212
SY KU 20-01; KU20-01; Keio University-20-01
RX PubMed=15247770;
DI NCIt; C4033; Clear cell renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KU-7
AC CVCL_4714
SY KU7; Keio University-7
DR BTO; BTO:0003544
DR BioSample; SAMN03151734
DR Cosmic; 1082646
DR Cosmic; 1302356
RX PubMed=3154018;
RX PubMed=7185004;
RX PubMed=19375735;
RX PubMed=23500642;
WW http://retractionwatch.com/2013/03/11/more-hela-problems-for-decades-a-widely-used-bladder-cancer-line-hasnt-been-what-scientists-thought/
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=23500642). Was thought to originate from a urinary bladder papillary carcinoma.
CC Part of: BLA-40 bladder carcinoma cell line panel.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID KU-7-luc2-GFP
AC CVCL_M894
CC Problematic cell line: Contaminated. Parent cell line (KU-7) has been shown to be a HeLa derivative.
CC Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression).
CC Transfected with: UniProtKB; P42212; GFP.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC Discontinued: PerkinElmer; Catalog number 128091.
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_4714 ! KU-7
SX Female
CA Cancer cell line
//
ID KU-8
AC CVCL_E330
SY Keio University-8
RX PubMed=2585941;
DI NCIt; C7729; Squamous cell carcinoma of the penis
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ku-Ep
AC CVCL_X903
RX PubMed=10761702;
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KU-HaAO1
AC CVCL_AV31
SY HaAO1
RX DOI=10.11416/jibs.77.1_25;
CC Group: Insect cell line.
OX NCBI_TaxID=29058; ! Helicoverpa armigera
SX Female
CA Spontaneously immortalized cell line
//
ID KU-HaEmb1
AC CVCL_AV32
SY HaEmb1
RX DOI=10.11416/jibs.77.1_25;
CC Group: Insect cell line.
OX NCBI_TaxID=29058; ! Helicoverpa armigera
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KU-HaEmb2
AC CVCL_AV33
SY HaEmb2
RX DOI=10.11416/jibs.77.1_25;
CC Group: Insect cell line.
OX NCBI_TaxID=29058; ! Helicoverpa armigera
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KU-HaPO1
AC CVCL_AV34
SY HaPO1
RX DOI=10.11416/jibs.77.1_25;
CC Group: Insect cell line.
OX NCBI_TaxID=29058; ! Helicoverpa armigera
SX Female
CA Spontaneously immortalized cell line
//
ID KU-HaPO2
AC CVCL_AV35
SY HaPO2
RX DOI=10.11416/jibs.77.1_25;
CC Group: Insect cell line.
OX NCBI_TaxID=29058; ! Helicoverpa armigera
SX Female
CA Spontaneously immortalized cell line
//
ID KU-MELTC-1
AC CVCL_GS50
RX PubMed=15160996;
CC From: Ikeda H.; Keio University School of Medicine; Tokyo; Japan.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KU-SENL-1
AC CVCL_IW45
SY SENL1
RX DOI=10.18178/joaat.3.4.231-238;
CC Group: Insect cell line.
CC Doubling time: 45 hours (DOI=10.18178/joaat.3.4.231-238).
OX NCBI_TaxID=7107; ! Spodoptera exigua
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KU-SN
AC CVCL_8730
DR CLO; CLO_0050141
DR BioSample; SAMN03472129
DR RCB; RCB1317
RX PubMed=1379122;
CC Derived from metastatic site: Pleural effusion.
ST Source(s): RCB
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 8,13
ST D16S539: 9
ST D5S818: 9,11
ST D7S820: 11
ST TH01: 9
ST TPOX: 8
ST vWA: 14,16
DI NCIt; C8776; Peripheral primitive neuroectodermal tumor of bone
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KU-SS-1
AC CVCL_E118
RX PubMed=10961176;
DI NCIt; C3400; Synovial sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KU-YS
AC CVCL_E131
DR BioSample; SAMN03151820
DR RCB; RCB1318
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a KU-SN derivative (PubMed=20143388).
CC Discontinued: RCB; RCB1318; true.
DI NCIt; C8776; Peripheral primitive neuroectodermal tumor of bone
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_8730 ! KU-SN
SX Female
CA Cancer cell line
//
ID KU_FMF_iPSC_1
AC CVCL_9U21
RX PubMed=26987928;
DI NCIt; C84707; Familial Mediterranean fever
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Induced pluripotent stem cell
//
ID KU2-TP15
AC CVCL_W867
RX PubMed=11291085;
CC Transfected with: HGNC; 3148; TYMP.
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_D267 ! KU-2
CA Cancer cell line
//
ID Ku812
AC CVCL_0379
SY KU812; KU-812; KU.812; KU 812
DR BTO; BTO:0000732
DR CLO; CLO_0007124
DR CLO; CLO_0007125
DR CLO; CLO_0050989
DR EFO; EFO_0002222
DR MCCL; MCC:0000274
DR CLDB; cl3070
DR ATCC; CRL-2099
DR BCRC; 60502
DR BCRJ; 0261
DR BioSample; SAMN01821693
DR BioSample; SAMN01821733
DR BioSample; SAMN03472893
DR CCLE; KU812_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 9211-4
DR ChEMBL-Cells; CHEMBL3308504
DR ChEMBL-Targets; CHEMBL613997
DR Cosmic; 787498
DR Cosmic; 907311
DR Cosmic; 919119
DR Cosmic; 922163
DR Cosmic; 924052
DR Cosmic; 949096
DR Cosmic; 991560
DR Cosmic; 999778
DR Cosmic; 1012080
DR Cosmic; 1026568
DR Cosmic; 1067444
DR Cosmic; 1078716
DR Cosmic; 1519164
DR Cosmic; 2009518
DR Cosmic-CLP; 907311
DR DSMZ; ACC-378
DR ECACC; 90071807
DR GDSC; 907311
DR GEO; GSM887244
DR GEO; GSM888318
DR GEO; GSM1374606
DR GEO; GSM1670011
DR IFO; IFO50363
DR IGRhCellID; KU812
DR JCRB; JCRB0104
DR Lonza; 1207
DR RCB; RCB0495
RX PubMed=2540861;
RX PubMed=3332852;
RX PubMed=3858609;
RX PubMed=9290701;
RX PubMed=9644295;
RX PubMed=15843827;
RX PubMed=16408098;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~80-100 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=11416159; PubMed=25877200; RCB
ST Amelogenin: X,Y
ST CSF1PO: 12,13
ST D13S317: 8
ST D16S539: 9
ST D18S51: 13
ST D21S11: 30,31.2
ST D3S1358: 15
ST D5S818: 10
ST D7S820: 12
ST D8S1179: 11,15
ST FGA: 22,24
ST Penta D: 12
ST Penta E: 5,19
ST TH01: 9
ST TPOX: 12
ST vWA: 15
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Ku812E
AC CVCL_0615
SY KU812E; KU-812E; KU 812E
DR CLO; CLO_0007126
DR CLO; CLO_0051000
DR CLDB; cl3071
DR ATCC; CRL-2100
DR BioSample; SAMN01821694
DR ECACC; 90071803
DR JCRB; JCRB0104.1
DR RCB; RCB0496
RX PubMed=2540861;
ST Source(s): ATCC; JCRB; RCB
ST Amelogenin: X,Y
ST CSF1PO: 12,13
ST D13S317: 8
ST D16S539: 9
ST D5S818: 10
ST D7S820: 12
ST TH01: 9
ST TPOX: 12
ST vWA: 15
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0379 ! Ku812
SX Male
CA Cancer cell line
//
ID Ku812F
AC CVCL_0616
SY KU812F; KU-812-F; KU-812F; KU 812F; KU812-F
DR BTO; BTO:0003142
DR CLO; CLO_0007127
DR CLO; CLO_0050974
DR CLO; CLO_0051002
DR CLDB; cl3072
DR ATCC; CRL-2101
DR BioSample; SAMN01821695
DR ECACC; 90071804
DR JCRB; JCRB0104.2
DR RCB; RCB0497
DR RCB; RCB3053
DR TKG; TKG 0304
RX PubMed=3304457;
RX PubMed=2540861;
ST Source(s): ATCC; ECACC; JCRB; PubMed=11416159; RCB; TKG
ST Amelogenin: X,Y
ST CSF1PO: 12,13
ST D13S317: 8
ST D16S539: 9
ST D18S51: 13
ST D21S11: 30,31.2
ST D5S818: 10
ST D7S820: 12
ST D8S1179: 11,15
ST FGA: 22,24
ST TH01: 9
ST TPOX: 12
ST vWA: 15
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0379 ! Ku812
SX Male
CA Cancer cell line
//
ID Kudi
AC CVCL_V743
SY P2-Kudi
RX PubMed=4321974;
RX PubMed=6018567;
CC Characteristics: EBV-negative.
DI NCIt; C2912; Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KUM.LK-2
AC CVCL_W526
SY KUM-LK-2
RX DOI=10.2491/jjsth1970.19.283;
RX PubMed=2486663;
RX PubMed=3221828;
DI NCIt; C3512; Lung adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KUM10
AC CVCL_5148
SY KUM1; KUM-1
DR CLO; CLO_0051045
DR JCRB; JCRB1176
DR JCRB; NIHS0493
DR RCB; RCB2295
RX PubMed=1373147;
RX PubMed=15996824;
CC Discontinued: JCRB; NIHS0493; true.
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUM3
AC CVCL_5149
SY KUM 3; KUM-3
DR CLO; CLO_0051034
DR JCRB; JCRB1134
DR RCB; RCB2147
RX PubMed=1373147;
RX PubMed=15996824;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUM4
AC CVCL_5150
SY KUM 4; KUM-4
DR CLO; CLO_0051031
DR JCRB; JCRB1135
DR RCB; RCB2112
RX PubMed=1373147;
RX PubMed=15996824;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUM5
AC CVCL_5151
SY KUM 5; KUM-5
DR CLO; CLO_0051035
DR JCRB; JCRB1178
DR RCB; RCB2322
RX PubMed=1373147;
RX PubMed=15996824;
RX PubMed=21155951;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUM6
AC CVCL_5152
SY KUM 6; KUM-6
DR CLO; CLO_0051032
DR JCRB; JCRB1202
DR RCB; RCB2113
RX PubMed=1373147;
RX PubMed=15996824;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUM7
AC CVCL_5153
SY KUM 7; KUM-7
DR CLO; CLO_0051037
DR JCRB; JCRB1204
DR RCB; RCB2114
RX PubMed=1373147;
RX PubMed=15996824;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUM9
AC CVCL_5154
SY KUM 9; KUM-9
DR CLO; CLO_0051033
DR JCRB; JCRB1139
DR RCB; RCB2115
RX PubMed=1373147;
RX PubMed=15996824;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUMA-1
AC CVCL_W512
SY Kuma-1
RX PubMed=7591301;
RX PubMed=23992541;
DI NCIt; C6064; Maxillary sinus squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KUMA-2
AC CVCL_W513
RX PubMed=7591301;
DI NCIt; C6064; Maxillary sinus squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KUN-DH-14
AC CVCL_Z530
SY Dh 14; DH14; Dh14
DR CLO; CLO_0002770
DR CLO; CLO_0002772
DR CLDB; cl1053
DR CLDB; cl1055
DR ECACC; 90070551
RX PubMed=7450782;
WW http://www.rccc.cytspb.rssi.ru/ecellbank/spinless/sdh14.htm
CC Group: Insect cell line.
OX NCBI_TaxID=7224; ! Drosophila hydei
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KUN-DH-15
AC CVCL_Z531
SY DH15
DR CLO; CLO_0002773
DR CLDB; cl1056
DR ECACC; 90070549
RX PubMed=7450782;
CC Group: Insect cell line.
OX NCBI_TaxID=7224; ! Drosophila hydei
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID KUN-DH-33
AC CVCL_Z532
SY DH-33; Dh 33; DH33; Dh33
DR CLO; CLO_0002771
DR CLO; CLO_0002774
DR CLDB; cl1054
DR CLDB; cl1057
DR DGRC; 23
DR ECACC; 90070559
RX PubMed=7450782;
WW http://www.rccc.cytspb.rssi.ru/ecellbank/spinless/sdh33.htm
CC Group: Insect cell line.
OX NCBI_TaxID=7224; ! Drosophila hydei
SX Male
CA Spontaneously immortalized cell line
//
ID KUN-DH-47
AC CVCL_Z533
RX PubMed=7450782;
CC Group: Insect cell line.
OX NCBI_TaxID=7224; ! Drosophila hydei
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID Kuna 14
AC CVCL_DQ73
SY KUNA 14
DR IMGT/HLA; 10945
RX PubMed=9331947;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID Kuna 20
AC CVCL_DQ74
SY KUNA 20
DR IMGT/HLA; 10946
RX PubMed=9331947;
CC Part of: International Histocompatibility Workshop cell lines.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KUP5
AC CVCL_6C88
DR RCB; RCB4627
RX PubMed=25379377;
CC Doubling time: ~19 hours (PubMed=25379377).
CC Transfected with: HGNC; 7553; MYC.
CC Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
SX Male
CA Transformed cell line
//
ID Kuramochi
AC CVCL_1345
SY KURAMOCHI
DR EFO; EFO_0006625
DR BioSample; SAMN03471055
DR CCLE; KURAMOCHI_OVARY
DR CGH-DB; 9357-4
DR ChEMBL-Cells; CHEMBL3308307
DR ChEMBL-Targets; CHEMBL2366119
DR Cosmic; 809116
DR Cosmic; 909975
DR Cosmic; 931364
DR Cosmic-CLP; 909975
DR GDSC; 909975
DR GEO; GSM186430
DR GEO; GSM186431
DR GEO; GSM659381
DR GEO; GSM888319
DR GEO; GSM1670012
DR JCRB; JCRB0098
RX PubMed=6268719;
RX PubMed=9290701;
RX PubMed=11330945;
RX PubMed=12417041;
RX PubMed=22460905;
RX PubMed=23839242;
RX PubMed=24023729;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
RX PubMed=27561551;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 82 hours (PubMed=25984343); 24-27 hours (JCRB).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep proteome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Derived from metastatic site: Ascites.
ST Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 9,12
ST D16S539: 10
ST D18S51: 13
ST D21S11: 30,32.2
ST D3S1358: 18
ST D5S818: 12
ST D7S820: 10,11
ST D8S1179: 10,11
ST FGA: 21,23
ST Penta D: 10,13
ST Penta E: 15
ST TH01: 9
ST TPOX: 8,12
ST vWA: 16,19
DI NCIt; C105555; High grade ovarian serous adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KUROIWA
AC CVCL_E744
DR dbMHC; 48938
DR ECACC; 94082230
DR IHW; IHW9131
DR IMGT/HLA; 11674
RX PubMed=8307784;
WW http://bioinformatics.hsanmartino.it/ecbr/cl131.html
CC Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KUSA
AC CVCL_L287
SY KUM2; KUM 2; KUM-2
RX PubMed=1373147;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Adult stem cell
//
ID KUSA-A1
AC CVCL_4848
SY KUSA/A1
DR JCRB; JCRB1119
DR JCRB; NIHS0427
DR RCB; RCB2081
DR Wikidata; Q27671685
RX PubMed=1373147;
RX PubMed=15996824;
RX PubMed=21155951;
CC Discontinued: JCRB; NIHS0427; true.
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_L287 ! KUSA
SX Female
CA Adult stem cell
//
ID KUSA-D
AC CVCL_L288
SY KUSA/D
RX PubMed=1373147;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_L287 ! KUSA
SX Female
CA Adult stem cell
//
ID KUSA-H1
AC CVCL_5222
SY KUSA/H1
DR CLO; CLO_0051029
DR JCRB; JCRB1129
DR RCB; RCB1990
RX PubMed=1373147;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_L287 ! KUSA
SX Female
CA Adult stem cell
//
ID KUSA-MTAg
AC CVCL_L286
RX PubMed=1373147;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_L287 ! KUSA
SX Female
CA Transformed cell line
//
ID KUSA-O
AC CVCL_5223
SY KUSA/O; KUSA-0
DR CLO; CLO_0051030
DR JCRB; JCRB1132
DR RCB; RCB1991
RX PubMed=1373147;
CC Breed/subspecies: C3H/He.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_L287 ! KUSA
SX Female
CA Adult stem cell
//
ID KUT-1
AC CVCL_G036
RX CelloPub=CLPUB00380;
RX PubMed=3026522;
CC Transformant: NCBI_TaxID; 11908; Human T-lymphotropic virus 1 (HTLV-1).
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KUT-2
AC CVCL_G037
RX CelloPub=CLPUB00380;
RX PubMed=3026522;
CC Transformant: NCBI_TaxID; 11908; Human T-lymphotropic virus 1 (HTLV-1).
DI NCIt; C9142; Adult T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KUT-3
AC CVCL_G038
RX PubMed=3026522;
DI NCIt; C9143; Adult B acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KV0006
AC CVCL_8X89
DR ECACC; 98071613
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KV6
AC CVCL_W940
DR Cosmic; 877455
DR Cosmic; 1152533
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KVL-1
AC CVCL_0380
SY KVL1
DR MCCL; MCC:0000275
RX PubMed=15665117;
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID KW-103
AC CVCL_W216
RX PubMed=7154478;
CC Doubling time: 16.0 hours (PubMed=7154478).
DI NCIt; C4912; Bladder carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KW0001
AC CVCL_8Y01
DR ECACC; 98040607
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KW0002
AC CVCL_8Y02
DR ECACC; 98040608
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KW0008
AC CVCL_8Y03
DR ECACC; 99030102
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KW0009
AC CVCL_8Y04
DR ECACC; 00062901
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C92562; Expressive language disorder
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KW0010
AC CVCL_8Y05
DR ECACC; 00062902
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C92562; Expressive language disorder
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KW0011
AC CVCL_8Y06
DR ECACC; 00062903
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C92562; Expressive language disorder
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Transformed cell line
//
ID KW0012
AC CVCL_8Y07
DR ECACC; 00062904
CC Part of: ECACC chromosomal abnormality collection.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KW1
AC CVCL_0B93
DR Cosmic; 2239106
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW10
AC CVCL_0B94
DR Cosmic; 2239112
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW13
AC CVCL_0B95
DR Cosmic; 2239113
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW15
AC CVCL_0B96
DR Cosmic; 2239114
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW17
AC CVCL_0B97
DR Cosmic; 2239115
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW2
AC CVCL_0B98
DR Cosmic; 2239107
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW22
AC CVCL_0B99
DR Cosmic; 2239116
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW24
AC CVCL_0C00
DR Cosmic; 2239117
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW3
AC CVCL_0C01
DR Cosmic; 2239108
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW6
AC CVCL_0C02
DR Cosmic; 2239109
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW7
AC CVCL_0C03
DR Cosmic; 2239110
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KW9
AC CVCL_0C04
DR Cosmic; 2239111
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KWA-RC
AC CVCL_X541
DR Cosmic; 849375
RX PubMed=11146448;
DI NCIt; C9385; Renal cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KWS-I
AC CVCL_9816
SY KWS-1
DR Cosmic; 848374
RX PubMed=3962675;
RX PubMed=15767549;
CC Part of: JFCR45 cancer cell line panel.
CC Doubling time: 35-38 hours (PubMed=3962675).
CC Derived from metastatic site: Ascites.
DI NCIt; C4004; Gastric adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KY [Human B-cell 09IHW]
AC CVCL_E745
DR IHW; IHW1402
WW http://bioinformatics.hsanmartino.it/ecbr/cl381.html
CC Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
CA Transformed cell line
//
ID KY [Human B-cell 12IHW]
AC CVCL_E746
DR dbMHC; 48939
DR ECACC; 94022539
DR IHW; IHW9222
DR IMGT/HLA; 10949
WW http://bioinformatics.hsanmartino.it/ecbr/cl222.html
CC Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID KY-ADR1
AC CVCL_Z939
RX PubMed=7934146;
CC Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_W294 ! KY-Ra
SX Male
CA Cancer cell line
//
ID KY-ADR2
AC CVCL_Z940
RX PubMed=7934146;
RX PubMed=12716468;
CC Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1346 ! KY821
SX Male
CA Cancer cell line
//
ID KY-MTX
AC CVCL_W293
SY KY821/MTX
RX PubMed=1560671;
RX PubMed=8387619;
CC Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1346 ! KY821
SX Male
CA Cancer cell line
//
ID KY-Ra
AC CVCL_W294
RX CelloPub=CLPUB00209;
RX PubMed=8387619;
RX PubMed=12716468;
CC Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1346 ! KY821
SX Male
CA Cancer cell line
//
ID KY-Rb
AC CVCL_5A05
RX CelloPub=CLPUB00209;
CC Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1346 ! KY821
SX Male
CA Cancer cell line
//
ID KY-VCR
AC CVCL_W295
RX PubMed=1472928;
RX PubMed=8387619;
RX PubMed=12716468;
CC Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1346 ! KY821
SX Male
CA Cancer cell line
//
ID KY821
AC CVCL_1346
SY KY-821
DR BioSample; SAMN03470792
DR ChEMBL-Cells; CHEMBL3308834
DR ChEMBL-Targets; CHEMBL2366190
DR Cosmic; 907300
DR Cosmic; 975264
DR Cosmic; 2089651
DR Cosmic; 2131567
DR Cosmic-CLP; 907300
DR GDSC; 907300
DR GEO; GSM827265
DR GEO; GSM1670013
DR JCRB; JCRB0105
RX CelloPub=CLPUB00069;
RX PubMed=1560671;
RX PubMed=8387619;
RX PubMed=9747033;
RX PubMed=23955599;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 9,12
ST D16S539: 10,12
ST D5S818: 10,13
ST D7S820: 12
ST TH01: 9
ST TPOX: 11
ST vWA: 17,18
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KY821A3
AC CVCL_2806
DR BioSample; SAMN03470793
DR JCRB; JCRB0105.1
RX PubMed=1560671;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,9,11
ST D16S539: 10,11,12
ST D5S818: 9,10,11
ST D7S820: 11,12
ST TH01: 7,9
ST TPOX: 8,11
ST vWA: 14,17,18
DI NCIt; C7463; Acute myelomonocytic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1346 ! KY821
SX Male
CA Cancer cell line
//
ID KYAE-1
AC CVCL_1825
SY KYAE
DR Cosmic; 1599341
DR Cosmic-CLP; 1503368
DR DSMZ; ACC-703
DR ECACC; 11012002
DR GDSC; 1503368
DR GEO; GSM1670014
DR JCRB; JCRB1483
RX PubMed=11520067;
RX PubMed=20075370;
RX PubMed=23795680;
RX PubMed=27397505;
CC Doubling time: ~3-4 days (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Derived from metastatic site: Pleural effusion.
ST Source(s): Cosmic-CLP; DSMZ; ECACC; JCRB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11,12
ST D16S539: 11
ST D5S818: 10,13
ST D7S820: 11,12
ST TH01: 6
ST TPOX: 8
ST vWA: 12,14 (DSMZ)
ST vWA: 14 (Cosmic-CLP; ECACC; JCRB)
DI NCIt; C4025; Esophageal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYAE-2
AC CVCL_4W63
DR JCRB; JCRB1595
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 13
ST D16S539: 11,13
ST D5S818: 11
ST D7S820: 8,11
ST TH01: 9
ST TPOX: 10,11
ST vWA: 16
DI NCIt; C4025; Esophageal adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYM-1
AC CVCL_3007
SY Kym-1
DR BioSample; SAMN03471640
DR CCLE; KYM1_SOFT_TISSUE
DR Cosmic; 801759
DR Cosmic; 1995475
DR Cosmic; 2144781
DR Cosmic-CLP; 1240166
DR GDSC; 1240166
DR GEO; GSM827283
DR GEO; GSM887245
DR GEO; GSM888320
DR GEO; GSM1670015
DR JCRB; JCRB0627
RX PubMed=1960402;
RX PubMed=3830265;
RX PubMed=9290701;
RX PubMed=22460905;
RX PubMed=24418192;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 9,10
ST D5S818: 11,14
ST D7S820: 11
ST TH01: 7,9
ST TPOX: 8,11
ST vWA: 17
DI NCIt; C3749; Alveolar rhabdomyosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYM-1D4
AC CVCL_5616
RX PubMed=1960402;
RX PubMed=10485267;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=KYM-1D4
DI NCIt; C3749; Alveolar rhabdomyosarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3007 ! KYM-1
SX Male
CA Cancer cell line
//
ID KYN-1
AC CVCL_7925
SY KYN1
RX PubMed=2430933;
DI NCIt; C3099; Hepatocellular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYN-2
AC CVCL_0381
SY KYN2
DR MCCL; MCC:0000276
RX PubMed=2847482;
RX PubMed=8738480;
DI NCIt; C3099; Hepatocellular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYN-3
AC CVCL_7926
SY KYN3
RX CelloPub=CLPUB00070;
DI NCIt; C3099; Hepatocellular carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KYO-1
AC CVCL_2095
SY KYO1; Kyoto 1
DR BioSample; SAMN03473497
DR CCLE; KYO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 9209-4
DR Cosmic; 787499
DR Cosmic; 1026567
DR DSMZ; ACC-601
DR GEO; GSM887246
DR GEO; GSM888321
RX PubMed=3332852;
RX PubMed=3860700;
RX PubMed=22460905;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~40-50 hours (DSMZ).
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 11,14
ST D13S317: 12
ST D16S539: 10
ST D5S818: 10,13
ST D7S820: 11
ST TH01: 6,7
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-110
AC CVCL_1643
AS CVCL_9817
SY KYSE110; KYSE 110; KY-110; KY110
DR CGH-DB; 276-1
DR CGH-DB; 9225-4
DR Cosmic; 929522
DR Cosmic; 1043239
DR Cosmic; 1123336
DR Cosmic; 1581071
DR Cosmic; 2395001
DR JCRB; JCRB1064
RX PubMed=1728357;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
CC Discontinued: JCRB; JCRB1064; probable.
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1140
AC CVCL_A097
SY KYSE1140; KYSE 1140
DR Cosmic; 918543
DR JCRB; JCRB1449
RX PubMed=9033652;
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 11,12
ST D13S317: 9,11
ST D16S539: 9
ST D5S818: 10,11
ST D7S820: 13
ST TH01: 7
ST TPOX: 9,11
ST vWA: 14
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1170
AC CVCL_A098
SY KYSE1170; KYSE 1170
DR CGH-DB; 296-1
DR CGH-DB; 9245-4
DR Cosmic; 918544
DR JCRB; JCRB1457
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 8
ST D16S539: 11
ST D5S818: 11
ST D7S820: 10
ST TH01: 9
ST TPOX: 9
ST vWA: 16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1190
AC CVCL_8501
SY KYSE1190; KYSE 1190
DR CGH-DB; 297-1
DR CGH-DB; 9246-4
DR Cosmic; 918545
DR JCRB; JCRB1421
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 13
ST D13S317: 11,12
ST D16S539: 12
ST D5S818: 12
ST D7S820: 9,11
ST TH01: 6,7
ST TPOX: 8,9
ST vWA: 14,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1230
AC CVCL_8502
SY KYSE1230; KYSE 1230
DR JCRB; JCRB1444
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 11
ST D5S818: 12
ST D7S820: 8,12
ST TH01: 8
ST TPOX: 11
ST vWA: 17,19
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1240
AC CVCL_A099
SY KYSE1240; KYSE 1240
DR CGH-DB; 298-1
DR CGH-DB; 9247-4
DR Cosmic; 918546
DR JCRB; JCRB1456
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 9
ST D16S539: 12,13
ST D5S818: 12
ST D7S820: 10,11
ST TH01: 8
ST TPOX: 8,11
ST vWA: 14,18
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1250
AC CVCL_A100
SY KYSE1250; KYSE 1250
DR CGH-DB; 299-1
DR CGH-DB; 9248-4
DR Cosmic; 918547
DR JCRB; JCRB1462
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12
ST D16S539: 9,11
ST D5S818: 13
ST D7S820: 8,11
ST TH01: 8,9
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1260
AC CVCL_8503
SY KYSE1260; KYSE 1260
DR CGH-DB; 300-1
DR CGH-DB; 9249-4
DR Cosmic; 918548
DR JCRB; JCRB1434
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10,12
ST D13S317: 8
ST D16S539: 10,11
ST D5S818: 11,12
ST D7S820: 11,12
ST TH01: 9
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-140
AC CVCL_1347
SY KYSE140; Kyse-140; KYSE 140
DR CLO; CLO_0007128
DR EFO; EFO_0006626
DR BioSample; SAMN03471046
DR CCLE; KYSE140_OESOPHAGUS
DR CGH-DB; 277-1
DR CGH-DB; 9226-4
DR ChEMBL-Cells; CHEMBL3308752
DR ChEMBL-Targets; CHEMBL1075484
DR Cosmic; 753573
DR Cosmic; 801330
DR Cosmic; 918524
DR Cosmic; 1123337
DR Cosmic; 1581072
DR Cosmic; 2267698
DR Cosmic-CLP; 753573
DR DSMZ; ACC-348
DR GDSC; 753573
DR GEO; GSM827546
DR GEO; GSM887247
DR GEO; GSM888322
DR GEO; GSM1374607
DR GEO; GSM1670016
DR JCRB; JCRB1063
DR LINCS; 50024
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~24 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; JCRB1063; probable.
ST Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 13
ST D13S317: 12
ST D16S539: 10,12
ST D18S51: 14
ST D21S11: 29
ST D3S1358: 18
ST D5S818: 10
ST D7S820: 10,11 (Cosmic-CLP)
ST D7S820: 10 (DSMZ; PubMed=25877200)
ST D8S1179: 10
ST FGA: 22,23
ST Penta D: 9
ST Penta E: 16,17
ST TH01: 7,9
ST TPOX: 8
ST vWA: 14
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1440
AC CVCL_8504
SY KYSE1440; KYSE 1440
DR CGH-DB; 301-1
DR CGH-DB; 9346-4
DR Cosmic; 918549
DR JCRB; JCRB1432
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 9,13
ST D5S818: 12
ST D7S820: 9,11
ST TH01: 6
ST TPOX: 11
ST vWA: 16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-150
AC CVCL_1348
SY KYSE150; KYSE 150; KY150
DR BTO; BTO:0002427
DR CLO; CLO_0007129
DR EFO; EFO_0006627
DR BioSample; SAMN03471047
DR CCLE; KYSE150_OESOPHAGUS
DR CGH-DB; 278-1
DR CGH-DB; 9227-4
DR ChEMBL-Cells; CHEMBL3307840
DR ChEMBL-Targets; CHEMBL613998
DR Cosmic; 907317
DR Cosmic; 918525
DR Cosmic; 929523
DR Cosmic; 1123338
DR Cosmic; 1581073
DR Cosmic; 1876252
DR Cosmic; 2267699
DR Cosmic; 2395002
DR Cosmic-CLP; 907317
DR DSMZ; ACC-375
DR GDSC; 907317
DR GEO; GSM718289
DR GEO; GSM827545
DR GEO; GSM887248
DR GEO; GSM888323
DR GEO; GSM1670017
DR JCRB; JCRB1095
DR LINCS; 50025
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 23 hours (PubMed=25984343); <25 hours, less when serum amount is increased (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; JCRB1095; probable.
ST Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 8,11
ST D16S539: 9,11
ST D18S51: 14
ST D21S11: 30,31
ST D3S1358: 15,16
ST D5S818: 12,13
ST D7S820: 10,11
ST D8S1179: 10,15
ST FGA: 21,24
ST Penta D: 10
ST Penta E: 12,18
ST TH01: 7,9
ST TPOX: 8
ST vWA: 16,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYSE-170
AC CVCL_1358
SY KYSE170; KYSE 170
DR BioSample; SAMN03472369
DR BioSample; SAMN03472501
DR CGH-DB; 279-1
DR CGH-DB; 9228-4
DR Cosmic; 801331
DR Cosmic; 918526
DR Cosmic; 1581074
DR Cosmic; 1876245
DR JCRB; JCRB1082
DR JCRB; NIHS0346
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
CC Discontinued: JCRB; NIHS0346; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12,13
ST D13S317: 9
ST D16S539: 9,10
ST D5S818: 11,12
ST D7S820: 11,12
ST TH01: 7,9
ST TPOX: 11
ST vWA: 16,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYSE-180
AC CVCL_1349
SY KYSE180; KYSE 180; KY180
DR CLO; CLO_0007130
DR EFO; EFO_0006628
DR BioSample; SAMN03471048
DR BioSample; SAMN03472502
DR BioSample; SAMN03473326
DR CCLE; KYSE180_OESOPHAGUS
DR CGH-DB; 280-1
DR CGH-DB; 9229-4
DR ChEMBL-Cells; CHEMBL3308389
DR ChEMBL-Targets; CHEMBL1075485
DR Cosmic; 801332
DR Cosmic; 907318
DR Cosmic; 918527
DR Cosmic; 1123339
DR Cosmic; 1581075
DR Cosmic; 1876246
DR Cosmic; 2267700
DR Cosmic; 2395003
DR Cosmic-CLP; 907318
DR DSMZ; ACC-379
DR GDSC; 907318
DR GEO; GSM827544
DR GEO; GSM887249
DR GEO; GSM888324
DR GEO; GSM1374608
DR GEO; GSM1670018
DR JCRB; JCRB1083
DR JCRB; NIHS0347
DR LINCS; 50026
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~40-50 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0347; true.
ST Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 9,12
ST D16S539: 9,10 (Cosmic-CLP; DSMZ; JCRB)
ST D16S539: 9 (PubMed=25877200)
ST D18S51: 20
ST D21S11: 30
ST D3S1358: 15
ST D5S818: 8,11
ST D7S820: 12 (Cosmic-CLP; DSMZ)
ST D7S820: 9,12 (JCRB; PubMed=25877200)
ST D8S1179: 10,12
ST FGA: 19,21
ST Penta D: 9
ST Penta E: 5,12
ST TH01: 7
ST TPOX: 11
ST vWA: 16,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-1860
AC CVCL_A101
SY KYSE1860; KYSE 1860
DR Cosmic; 918550
DR JCRB; JCRB1460
RX PubMed=9033652;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 9
ST D16S539: 11
ST D5S818: 10,12
ST D7S820: 10
ST TH01: 9
ST TPOX: 8,9
ST vWA: 18,19
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-190
AC CVCL_8301
AS CVCL_9818
SY KYSE190; KYSE 190; KY-190
DR CGH-DB; 281-1
DR CGH-DB; 9230-4
DR Cosmic; 918528
DR Cosmic; 929524
DR Cosmic; 1043240
DR JCRB; JCRB1084
DR JCRB; JCRB1426
DR JCRB; NIHS0348
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
CC Discontinued: JCRB; JCRB1084; probable.
CC Discontinued: JCRB; NIHS0348; true.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 11
ST D16S539: 9
ST D5S818: 10
ST D7S820: 10,12
ST TH01: 6
ST TPOX: 11
ST vWA: 16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYSE-200
AC CVCL_G698
SY KYSE200
DR BioSample; SAMN03472503
DR CGH-DB; 282-1
DR CGH-DB; 9231-4
DR JCRB; JCRB1085
DR JCRB; NIHS0364
RX PubMed=1728357;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
CC Discontinued: JCRB; JCRB1085; probable.
CC Discontinued: JCRB; NIHS0364; true.
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 8
ST D16S539: 9
ST D5S818: 10,13
ST D7S820: 9,11
ST TH01: 9,10
ST TPOX: 8
ST vWA: 18,19
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-201
AC CVCL_A102
SY KYSE201; KYSE 201
DR Cosmic; 918529
RX PubMed=9033652;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KYSE-220
AC CVCL_1359
AS CVCL_9819
SY KYSE220; KYSE 220; KY-220
DR BioSample; SAMN03472505
DR CGH-DB; 283-1
DR CGH-DB; 9232-4
DR Cosmic; 918530
DR Cosmic; 1043241
DR Cosmic; 1581076
DR Cosmic; 1995476
DR Cosmic-CLP; 1240167
DR GDSC; 1240167
DR GEO; GSM827502
DR GEO; GSM1670019
DR JCRB; JCRB1086
DR JCRB; NIHS0365
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Discontinued: JCRB; NIHS0365; true.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 8,9
ST D16S539: 11
ST D5S818: 11
ST D7S820: 12
ST TH01: 9
ST TPOX: 11
ST vWA: 18
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-2270
AC CVCL_J284
SY KYSE2270
DR CGH-DB; 302-1
DR CGH-DB; 9250-4
DR JCRB; JCRB1468
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 13
ST D13S317: 12
ST D16S539: 9
ST D5S818: 13
ST D7S820: 10,12
ST TH01: 9.3
ST TPOX: 8,11
ST vWA: 16,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-2300
AC CVCL_4W14
SY KYSE2300
DR JCRB; JCRB1472
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12,13
ST D16S539: 11
ST D5S818: 13
ST D7S820: 11,12
ST TH01: 9
ST TPOX: 8
ST vWA: 14
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-2400
AC CVCL_8505
SY KYSE2400
DR CGH-DB; 303-1
DR CGH-DB; 9251-4
DR JCRB; JCRB1424
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 13
ST D16S539: 9
ST D5S818: 10,12
ST D7S820: 10,12
ST TH01: 9
ST TPOX: 9,11
ST vWA: 14,16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-2650
AC CVCL_Y278
SY KYSE2650
DR CGH-DB; 304-1
DR CGH-DB; 9252-4
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KYSE-270
AC CVCL_1350
AS CVCL_9820
SY KYSE270; KYSE 270; KY-270
DR CLO; CLO_0007131
DR EFO; EFO_0006629
DR BioSample; SAMN01821696
DR BioSample; SAMN03471049
DR BioSample; SAMN03473328
DR CCLE; KYSE270_OESOPHAGUS
DR CGH-DB; 284-1
DR CGH-DB; 9233-4
DR ChEMBL-Cells; CHEMBL3308753
DR ChEMBL-Targets; CHEMBL1075486
DR Cosmic; 907319
DR Cosmic; 1043242
DR Cosmic; 1123340
DR Cosmic; 1581077
DR Cosmic; 1876247
DR Cosmic-CLP; 907319
DR DSMZ; ACC-380
DR ECACC; 94072021
DR GDSC; 907319
DR GEO; GSM827543
DR GEO; GSM887250
DR GEO; GSM888325
DR GEO; GSM1670020
DR JCRB; JCRB1087
DR JCRB; NIHS0366
RX PubMed=1728357;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~24 hours (DSMZ); 24 hours (ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Discontinued: JCRB; NIHS0366; true.
ST Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X,Y
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 14
ST D18S51: 14
ST D21S11: 31
ST D3S1358: 17
ST D5S818: 13
ST D7S820: 11
ST D8S1179: 15
ST FGA: 19
ST Penta D: 15
ST Penta E: 16
ST TH01: 9
ST TPOX: 8
ST vWA: 16,17 (Cosmic-CLP; DSMZ; JCRB)
ST vWA: 17 (PubMed=25877200)
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-2710
AC CVCL_4W15
SY KYSE2710
DR JCRB; JCRB1467
ST Source(s): JCRB
ST Amelogenin: X,Y
ST CSF1PO: 10
ST D13S317: 12,13
ST D16S539: 9,12
ST D5S818: 13
ST D7S820: 10,11
ST TH01: 9
ST TPOX: 9,11
ST vWA: 14,16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-273
AC CVCL_A104
SY KYSE273; KYSE 273
DR Cosmic; 918531
RX PubMed=9033652;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KYSE-2780
AC CVCL_J283
SY KYSE2780
DR JCRB; JCRB1452
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 9,11
ST D5S818: 9,10
ST D7S820: 10,12
ST TH01: 6
ST TPOX: 11
ST vWA: 14,19
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-280
AC CVCL_S527
RX PubMed=1728357;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYSE-2880
AC CVCL_4W16
SY KYSE2880
DR JCRB; JCRB1469
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 12
ST D16S539: 9,11
ST D5S818: 9,10
ST D7S820: 10,12
ST TH01: 6
ST TPOX: 11
ST vWA: 14,19
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-30
AC CVCL_1351
SY KYSE30
DR BTO; BTO:0004461
DR CLO; CLO_0007132
DR EFO; EFO_0002223
DR CLDB; cl3073
DR CLDB; cl3074
DR BioSample; SAMN03471050
DR BioSample; SAMN03471648
DR BioSample; SAMN03473314
DR CCLE; KYSE30_OESOPHAGUS
DR CGH-DB; 274-1
DR CGH-DB; 9223-4
DR Cosmic; 801333
DR Cosmic; 918521
DR Cosmic; 1123333
DR Cosmic; 1339921
DR Cosmic; 1581068
DR Cosmic; 1876249
DR Cosmic; 2267697
DR Cosmic; 2395004
DR Cosmic-CLP; 1298221
DR DSMZ; ACC-351
DR ECACC; 94072011
DR GDSC; 1298221
DR GEO; GSM827542
DR GEO; GSM887251
DR GEO; GSM888326
DR GEO; GSM1374609
DR GEO; GSM1374610
DR GEO; GSM1374611
DR ICLC; HTL97022
DR IGRhCellID; KYSE30
DR JCRB; JCRB0188
DR NCBI_Iran; C584
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=16364037;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: KuDOS 95 cell line panel.
CC Doubling time: 22 hours (PubMed=25984343); ~30 hours (DSMZ); 20.8 hours (ECACC).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Misspelling: 'KYSE-300' in Cosmic 801333.
ST Source(s): DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 9
ST D16S539: 10,12
ST D18S51: 14
ST D21S11: 28
ST D3S1358: 15,16
ST D5S818: 11
ST D7S820: 11,12 (DSMZ)
ST D7S820: 11,11.3 (JCRB; PubMed=25877200)
ST D8S1179: 12,15
ST FGA: 24
ST Penta D: 12
ST Penta E: 13
ST TH01: 9
ST TPOX: 9 (DSMZ; PubMed=25877200)
ST TPOX: 8,9 (JCRB)
ST vWA: 16,18,19
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-3210
AC CVCL_J285
SY KYSE3210
DR JCRB; JCRB1463
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 9
ST D16S539: 9
ST D5S818: 11
ST D7S820: 8,12
ST TH01: 9
ST TPOX: 8
ST vWA: 14,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-3410
AC CVCL_8506
SY KYSE3410
DR JCRB; JCRB1425
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12,13
ST D13S317: 8
ST D16S539: 10
ST D5S818: 9,14
ST D7S820: 8,11
ST TH01: 9
ST TPOX: 8
ST vWA: 14,16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-350
AC CVCL_8507
SY KYSE350; KYSE 350
DR CGH-DB; 285-1
DR CGH-DB; 9234-4
DR Cosmic; 918532
DR Cosmic; 929525
DR JCRB; JCRB1428
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11
ST D16S539: 9
ST D5S818: 10
ST D7S820: 9
ST TH01: 9
ST TPOX: 8,9
ST vWA: 16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-360
AC CVCL_G699
RX PubMed=1728357;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-3650
AC CVCL_M252
SY KYSE3650
DR JCRB; JCRB1495
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 9
ST D5S818: 11
ST D7S820: 9,12
ST TH01: 9
ST TPOX: 9,11
ST vWA: 14,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYSE-3940
AC CVCL_4W17
SY KYSE3940
DR JCRB; JCRB1481
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 11,12
ST D5S818: 11
ST D7S820: 12
ST TH01: 9
ST TPOX: 11
ST vWA: 17,18
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-410
AC CVCL_1352
SY KYSE410; KYSE 410
DR CLO; CLO_0007133
DR BioSample; SAMN03470945
DR CCLE; KYSE410_OESOPHAGUS
DR CGH-DB; 286-1
DR CGH-DB; 9235-4
DR ChEMBL-Cells; CHEMBL3308754
DR ChEMBL-Targets; CHEMBL1075487
DR Cosmic; 753574
DR Cosmic; 918533
DR Cosmic; 929526
DR Cosmic; 1123341
DR Cosmic; 2267701
DR Cosmic-CLP; 753574
DR DSMZ; ACC-381
DR ECACC; 94072023
DR GDSC; 753574
DR GEO; GSM827541
DR GEO; GSM887252
DR GEO; GSM888327
DR GEO; GSM1670021
DR JCRB; JCRB1419
DR PRIDE; PXD002486
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~45 hours (DSMZ); ~45 hours (ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11
ST D16S539: 10,12
ST D18S51: 13,15
ST D19S433: 13
ST D21S11: 30
ST D2S1338: 17,19
ST D3S1358: 15,16
ST D5S818: 13
ST D7S820: 12
ST D8S1179: 10
ST FGA: 20
ST Penta D: 11
ST Penta E: 8,12
ST TH01: 8
ST TPOX: 8,11
ST vWA: 16,18
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-450
AC CVCL_1353
SY KYSE450; KYSE 450
DR CLO; CLO_0007134
DR EFO; EFO_0006630
DR BioSample; SAMN03471051
DR CCLE; KYSE450_OESOPHAGUS
DR CGH-DB; 287-1
DR CGH-DB; 9236-4
DR ChEMBL-Cells; CHEMBL3308755
DR ChEMBL-Targets; CHEMBL1075488
DR Cosmic; 801334
DR Cosmic; 907320
DR Cosmic; 918534
DR Cosmic; 983846
DR Cosmic; 1123342
DR Cosmic; 1339910
DR Cosmic; 2267702
DR Cosmic; 2395005
DR Cosmic-CLP; 907320
DR DSMZ; ACC-387
DR GDSC; 907320
DR GEO; GSM827540
DR GEO; GSM887253
DR GEO; GSM888328
DR GEO; GSM1374612
DR GEO; GSM1670022
DR JCRB; JCRB1430
DR LINCS; 50027
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 23 hours (PubMed=25984343); ~30 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11
ST D16S539: 9
ST D18S51: 13
ST D21S11: 30
ST D3S1358: 18
ST D5S818: 10,13
ST D7S820: 11,12
ST D8S1179: 10
ST FGA: 24
ST Penta D: 9,10
ST Penta E: 11,16
ST TH01: 8,9
ST TPOX: 8
ST vWA: 14
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-50
AC CVCL_1360
AS CVCL_9821
SY KYSE50; KYSE 50; KY-50
DR BioSample; SAMN03471649
DR Cosmic; 918522
DR Cosmic; 929520
DR Cosmic; 1043238
DR Cosmic; 1123334
DR Cosmic; 1581069
DR Cosmic; 1876250
DR Cosmic; 1995477
DR Cosmic; 2395006
DR Cosmic-CLP; 1298222
DR GDSC; 1298222
DR GEO; GSM827503
DR GEO; GSM1670023
DR JCRB; JCRB0189
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=27397505;
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
ST Source(s): Cosmic-CLP; JCRB
ST Amelogenin: X
ST CSF1PO: 12 (Cosmic-CLP)
ST CSF1PO: 11,12 (JCRB)
ST D13S317: 11
ST D16S539: 10,12
ST D5S818: 11
ST D7S820: 10
ST TH01: 8
ST TPOX: 11 (Cosmic-CLP)
ST TPOX: 10,11 (JCRB)
ST vWA: 17,19
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-510
AC CVCL_1354
SY KYSE510; KYSE 510; Kyse-510
DR CLO; CLO_0007135
DR EFO; EFO_0006631
DR BioSample; SAMN03471052
DR BioSample; SAMN03473323
DR CCLE; KYSE510_OESOPHAGUS
DR CGH-DB; 288-1
DR CGH-DB; 9237-4
DR ChEMBL-Cells; CHEMBL3308081
DR ChEMBL-Targets; CHEMBL613868
DR Cosmic; 907321
DR Cosmic; 918535
DR Cosmic; 929527
DR Cosmic; 1123343
DR Cosmic; 2267703
DR Cosmic; 2395007
DR Cosmic-CLP; 907321
DR DSMZ; ACC-374
DR GDSC; 907321
DR GEO; GSM827539
DR GEO; GSM887254
DR GEO; GSM888329
DR GEO; GSM1670024
DR JCRB; JCRB1436
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: 30 hours (PubMed=25984343); ~30 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 12
ST D16S539: 9
ST D18S51: 15
ST D21S11: 31
ST D3S1358: 17
ST D5S818: 11
ST D7S820: 11,12
ST D8S1179: 10
ST FGA: 22
ST Penta D: 12
ST Penta E: 16
ST TH01: 9
ST TPOX: 8
ST vWA: 14
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYSE-520
AC CVCL_1355
SY KYSE520; KYSE 520
DR CLO; CLO_0007136
DR EFO; EFO_0006632
DR BioSample; SAMN03471053
DR CCLE; KYSE520_OESOPHAGUS
DR CGH-DB; 289-1
DR CGH-DB; 9238-4
DR ChEMBL-Cells; CHEMBL3307804
DR ChEMBL-Targets; CHEMBL612701
DR Cosmic; 753575
DR Cosmic; 918536
DR Cosmic; 929528
DR Cosmic; 1123344
DR Cosmic; 2009521
DR Cosmic-CLP; 753575
DR DSMZ; ACC-371
DR GDSC; 753575
DR GEO; GSM827538
DR GEO; GSM887255
DR GEO; GSM888330
DR GEO; GSM1670025
DR JCRB; JCRB1439
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~30 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 11
ST D16S539: 10
ST D18S51: 14
ST D21S11: 29
ST D3S1358: 16
ST D5S818: 9
ST D7S820: 11
ST D8S1179: 14,16
ST FGA: 22
ST Penta D: 12
ST Penta E: 15
ST TH01: 9
ST TPOX: 8
ST vWA: 15,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KYSE-590
AC CVCL_8508
SY KYSE590; KYSE 590
DR CGH-DB; 290-1
DR CGH-DB; 9239-4
DR Cosmic; 918537
DR JCRB; JCRB1443
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 8
ST D16S539: 9,12
ST D5S818: 11
ST D7S820: 8,11
ST TH01: 6,7
ST TPOX: 11
ST vWA: 15,16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-70
AC CVCL_1356
SY KYSE70; KYSE 70; KY70
DR CLO; CLO_0007137
DR EFO; EFO_0006633
DR BioSample; SAMN03471054
DR BioSample; SAMN03471650
DR CCLE; KYSE70_OESOPHAGUS
DR CGH-DB; 275-1
DR CGH-DB; 9224-4
DR ChEMBL-Cells; CHEMBL3308390
DR ChEMBL-Targets; CHEMBL614012
DR Cosmic; 753576
DR Cosmic; 918523
DR Cosmic; 929521
DR Cosmic; 1123335
DR Cosmic; 1581070
DR Cosmic; 1876251
DR Cosmic; 2395008
DR Cosmic-CLP; 753576
DR DSMZ; ACC-363
DR ECACC; 94072012
DR GDSC; 753576
DR GEO; GSM827537
DR GEO; GSM887256
DR GEO; GSM888331
DR GEO; GSM1374613
DR GEO; GSM1670026
DR JCRB; JCRB0190
RX PubMed=1728357;
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
RX PubMed=22460905;
RX PubMed=25485619;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~35 hours (DSMZ and ECACC).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 12
ST D13S317: 11,12
ST D16S539: 13
ST D18S51: 13
ST D21S11: 30
ST D3S1358: 15
ST D5S818: 12
ST D7S820: 8,11
ST D8S1179: 12
ST FGA: 21
ST Penta D: 9
ST Penta E: 11
ST TH01: 7 (Cosmic-CLP; DSMZ; ECACC; PubMed=25877200)
ST TH01: 7,11 (JCRB)
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-770
AC CVCL_8509
SY KYSE770; KYSE 770
DR CGH-DB; 291-1
DR CGH-DB; 9240-4
DR Cosmic; 918538
DR JCRB; JCRB1445
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 9,11
ST D13S317: 12
ST D16S539: 11
ST D5S818: 10,11
ST D7S820: 8,11
ST TH01: 6
ST TPOX: 8,11
ST vWA: 17,18
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-790
AC CVCL_8510
SY KYSE790; KYSE 790
DR CGH-DB; 292-1
DR CGH-DB; 9241-4
DR Cosmic; 918539
DR JCRB; JCRB1418
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 13
ST D16S539: 9,10
ST D5S818: 11
ST D7S820: 10,11
ST TH01: 9
ST TPOX: 8
ST vWA: 16,18
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-850
AC CVCL_8511
SY KYSE850; KYSE 850; Kyse 850
DR CGH-DB; 293-1
DR CGH-DB; 9242-4
DR Cosmic; 918540
DR JCRB; JCRB1422
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11
ST D13S317: 12
ST D16S539: 9
ST D5S818: 12
ST D7S820: 12
ST TH01: 9,9.3
ST TPOX: 8
ST vWA: 16
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID KYSE-890
AC CVCL_A103
SY KYSE890; KYSE 890
DR CGH-DB; 294-1
DR CGH-DB; 9243-4
DR Cosmic; 918541
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID KYSE-960
AC CVCL_8512
SY KYSE960; KYSE 960
DR CGH-DB; 295-1
DR CGH-DB; 9244-4
DR Cosmic; 918542
DR JCRB; JCRB1417
RX PubMed=9033652;
RX PubMed=11092977;
RX PubMed=15172977;
RX PubMed=16045545;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,13
ST D13S317: 11
ST D16S539: 10,11,12
ST D5S818: 10,13
ST D7S820: 10,12
ST TH01: 6
ST TPOX: 11
ST vWA: 16,17
DI NCIt; C4024; Esophageal squamous cell carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID Kyu-BL
AC CVCL_W938
SY KYU-BL; KYU
RX PubMed=2824665;
RX PubMed=2943927;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID KZ-R
AC CVCL_0I73
DR CCLV; CCLV-RIE 0093
OX NCBI_TaxID=9913; ! Bos taurus
CA Finite cell line
//
ID L 101
AC CVCL_J756
SY L101; M-20
DR CLO; CLO_0007149
DR ATCC; HB-8447
RX Patent=US4806628;
RX Patent=US4808704;
CC Discontinued: ATCC; HB-8447; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID L 230
AC CVCL_J017
SY L230; L2-30; M-23
DR CLO; CLO_0007177
DR ATCC; HB-8448
RX Patent=US4806628;
RX Patent=US4808704;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID L 235
AC CVCL_J018
SY L235; M-19
DR CLO; CLO_0007179
DR ATCC; HB-8446
RX Patent=US4806628;
RX Patent=US4808704;
CC Discontinued: ATCC; HB-8446; probable.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID L 660
AC CVCL_IV20
SY L660
RX PubMed=3027441;
RX PubMed=3035497;
RX PubMed=6957401;
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI NCIt; C27694; Epstein-Barr virus-related Burkitt lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID L alpha
AC CVCL_U992
DR JCRB; JCRB0125
DR JCRB; NIHS0189
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Discontinued: JCRB; NIHS0189; true.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L Cells (TK+, HBS Ag+)
AC CVCL_8887
SY Mouse L Cells (TK+, HBS Ag+); MOUSE L CELLS (TK+, HBS Ag+); MOUSE L CELLS (TK+,HBsAg+)
DR CLO; CLO_0007837
DR CLDB; cl3542
DR ECACC; 90110101
DR NCBI_Iran; C147
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID L Wnt-3A
AC CVCL_0635
SY L-Wnt-3A; L-Wnt3A; LWnt3A; LWnt-3A
DR CLO; CLO_0007145
DR ATCC; CRL-2647
DR BCRC; 60506
RX PubMed=12717451;
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: MGI; MGI:98956; Wnt3a.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L Wnt-5A
AC CVCL_0636
SY L-Wnt-5a; L-Wnt5A; LWnt5A
DR CLO; CLO_0007146
DR ATCC; CRL-2814
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: MGI; MGI:98958; Wnt5a.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-02
AC CVCL_6926
SY L02; LO2; HL-7702
DR BTO; BTO:0003543
DR BTO; BTO:0005965
DR CCRID; 3131C0001000200006
DR CCRID; 3142C0001000000077
DR GEO; GSM936770
DR TOKU-E; 3606
RX PubMed=23498809;
RX PubMed=23505090;
RX PubMed=26143199;
WW http://www.roche-applied-science.com/wcsstore/RASCatalogAssetStore/Articles/CustomerProtocol_X-tremeGENE%20HP_L02.pdf
CC Omics: Proteome analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Spontaneously immortalized cell line
//
ID L-1 [Bovine mammary gland]
AC CVCL_HG39
RX PubMed=12418925;
CC Breed/subspecies: Holstein Friesian.
OX NCBI_TaxID=9913; ! Bos taurus
OI CVCL_HG38 ! H-7
SX Female
CA Spontaneously immortalized cell line
//
ID L-1 [Human ovarian carcinoma]
AC CVCL_S918
RX PubMed=2480932;
CC Doubling time: 11.8 hours (PubMed=2480932).
DI NCIt; C7979; Ovarian endometrioid adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID L-1062
AC CVCL_M348
RX PubMed=16631476;
DI NCIt; C4817; Ewing sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID L-1091
AC CVCL_W858
RX PubMed=3034807;
RX PubMed=8704258;
RX PubMed=9454894;
DI NCIt; C3457; B-cell non-Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID L-1236
AC CVCL_2096
AS CVCL_5155
SY L1236; L 1236
DR BioSample; SAMN03473524
DR CCLE; L1236_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR Cosmic; 988702
DR Cosmic; 1013908
DR Cosmic; 1289701
DR Cosmic; 1432037
DR Cosmic; 2276328
DR Cosmic; 2464306
DR Cosmic-CLP; 1330935
DR DSMZ; ACC-530
DR GDSC; 1330935
DR GEO; GSM381297
DR GEO; GSM499722
DR GEO; GSM499730
DR GEO; GSM552449
DR GEO; GSM887257
DR GEO; GSM888332
DR GEO; GSM1670027
DR IGRhCellID; L1236
DR Lonza; 25
RX PubMed=8605360;
RX PubMed=12865944;
RX PubMed=22460905;
RX PubMed=25355872;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~48 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X,Y
ST CSF1PO: 10,14
ST D13S317: 13
ST D16S539: 9,13
ST D5S818: 11,13
ST D7S820: 9,10
ST TH01: 6
ST TPOX: 8,12
ST vWA: 17,18
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID L-132
AC CVCL_1908
SY L132; L 132
DR CLO; CLO_0007140
DR CLO; CLO_0007158
DR CLO; CLO_0007159
DR CLDB; cl3076
DR CLDB; cl3077
DR CLDB; cl3078
DR ATCC; CCL-5
DR BCRJ; 0139
DR BioSample; SAMN03151735
DR ChEMBL-Cells; CHEMBL3307504
DR ChEMBL-Targets; CHEMBL613999
DR ECACC; 89111004
DR IZSLER; BS CL 55
DR KCLB; 10005
RX CelloPub=CLPUB00071;
RX PubMed=566722;
RX PubMed=1246601;
RX PubMed=20143388;
RX PubMed=23925245;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=566722, PubMed=1246601, PubMed=20143388). Originally thought to be a lung embryonic cell line.
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC Omics: Genome sequenced (low read coverage).
ST Source(s): ATCC; ECACC; KCLB
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,13.3 (ATCC; KCLB)
ST D13S317: 12,14 (ECACC)
ST D16S539: 9,10
ST D3S1358: 15,18
ST D5S818: 11,12
ST D7S820: 8,12
ST FGA: 18,21
ST TH01: 7
ST TPOX: 8,12
ST vWA: 16,18
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
ID L-14
AC CVCL_J013
SY L-14-SCRF 55.1
DR CLO; CLO_0007162
DR ATCC; HB-8554
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID L.14
AC CVCL_5U28
SY L-14; L14; Line 14
RX DOI=10.1016/B978-0-12-249920-3.50038-7;
RX PubMed=2523424;
RX PubMed=3100639;
CC Characteristics: IL2 dependent.
CC Breed/subspecies: C57BL/6.
OX NCBI_TaxID=10090; ! Mus musculus
CA Factor-dependent cell line
//
ID L-2/M delta 2-3
AC CVCL_Z260
DR CLO; CLO_0007171
DR ATCC; CRL-10191
CC Group: Insect cell line.
CC Transfected with: FlyBase; FBgn0013311; P\T.
CC Breed/subspecies: Oregon-R.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
HI CVCL_Z232 ! Schneider 2
SX Female
CA Spontaneously immortalized cell line
//
ID L-363
AC CVCL_1357
SY L363
DR BTO; BTO:0003308
DR CLO; CLO_0007186
DR EFO; EFO_0006450
DR CLDB; cl3080
DR BioSample; SAMN03472932
DR CCLE; L363_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR CGH-DB; 9157-4
DR ChEMBL-Cells; CHEMBL3308205
DR ChEMBL-Targets; CHEMBL2366267
DR Cosmic; 720779
DR Cosmic; 924239
DR Cosmic; 1889517
DR Cosmic; 2081396
DR Cosmic; 2367279
DR Cosmic-CLP; 924239
DR DSMZ; ACC-49
DR GDSC; 924239
DR GEO; GSM887259
DR GEO; GSM888334
DR GEO; GSM1374615
DR GEO; GSM1670028
RX PubMed=207377;
RX PubMed=2537114;
RX PubMed=10087940;
RX PubMed=10583232;
RX PubMed=10936422;
RX PubMed=15215163;
RX PubMed=16956823;
RX PubMed=21173094;
RX PubMed=22460905;
RX PubMed=23074853;
RX PubMed=25485619;
RX PubMed=25984343;
RX PubMed=27397505;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: 25 hours (PubMed=25984343); ~25 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Omics: Deep exome analysis.
CC Omics: Deep RNAseq analysis.
CC Omics: DNA methylation analysis.
CC Omics: Protein expression by reverse-phase protein arrays.
CC Omics: shRNA library screening.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
ST Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST Amelogenin: X
ST CSF1PO: 10
ST D13S317: 12
ST D16S539: 10,12
ST D18S51: 14
ST D21S11: 30,32.2
ST D3S1358: 15,18
ST D5S818: 11,12
ST D7S820: 9,11
ST D8S1179: 12,13
ST FGA: 19,22
ST Penta D: 9,13
ST Penta E: 13,16
ST TH01: 6,9.3
ST TPOX: 8,12
ST vWA: 16,19
DI NCIt; C3242; Plasma cell myeloma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID L-41
AC CVCL_7170
DR BioSample; SAMN03151736
DR ECACC; 96121716
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
CC Problematic cell line: Contaminated. Parent cell line (J-96) has been shown to be a HeLa derivative (PubMed=20143388).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_3990 ! J-96
SX Female
CA Cancer cell line
//
ID L-428
AC CVCL_1361
SY L 428; L428
DR BTO; BTO:0000406
DR CLO; CLO_0007189
DR EFO; EFO_0002225
DR CLDB; cl3081
DR BioSample; SAMN03473371
DR CCLE; L428_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308873
DR ChEMBL-Targets; CHEMBL2366233
DR Cosmic; 850218
DR Cosmic; 907322
DR Cosmic; 988703
DR Cosmic; 1013907
DR Cosmic; 1086358
DR Cosmic; 1278830
DR Cosmic; 1289698
DR Cosmic; 1432036
DR Cosmic; 1714161
DR Cosmic; 2276326
DR Cosmic; 2361389
DR Cosmic; 2464304
DR Cosmic-CLP; 907322
DR DSMZ; ACC-197
DR GDSC; 907322
DR GEO; GSM499721
DR GEO; GSM499729
DR GEO; GSM552447
DR GEO; GSM637988
DR GEO; GSM887260
DR GEO; GSM888335
DR GEO; GSM1670029
DR IGRhCellID; L428
DR Lonza; 924
DR PRIDE; PXD000589
RX PubMed=2690233;
RX PubMed=2898211;
RX PubMed=6303739;
RX PubMed=6305805;
RX PubMed=7216541;
RX PubMed=7276066;
RX PubMed=8547074;
RX PubMed=9685479;
RX PubMed=11021758;
RX PubMed=22460905;
RX PubMed=25355872;
RX PubMed=25894527;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~35 hours (DSMZ).
CC Microsatellite instability: Instable (MSI-low) (Sanger).
CC Omics: Cell surface proteome.
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X
ST CSF1PO: 10,13
ST D13S317: 14
ST D16S539: 11,12
ST D5S818: 11,12
ST D7S820: 11
ST TH01: 7,9.3
ST TPOX: 8,9
ST vWA: 15
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID L-428 KS
AC CVCL_X206
SY L 428 KS; L428 KS; L428KS
RX PubMed=2690233;
RX PubMed=6303739;
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1361 ! L-428
SX Female
CA Cancer cell line
//
ID L-428 KSA
AC CVCL_X207
SY L 428 KSA; L428 KSA
RX PubMed=2690233;
RX PubMed=6303739;
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1361 ! L-428
SX Female
CA Cancer cell line
//
ID L-439
AC CVCL_M699
SY L 439; L439
RX PubMed=6305805;
RX PubMed=7216541;
RX PubMed=7276066;
CC Miscellaneous: Cell line has been lost (PubMed=6305805).
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID L-5178-Y
AC CVCL_2097
SY L5178Y; LY
DR BTO; BTO:0000795
DR CLO; CLO_0007195
DR CLO; CLO_0050168
DR CLDB; cl3133
DR ChEMBL-Cells; CHEMBL3307690
DR ChEMBL-Targets; CHEMBL614720
DR DSMZ; ACC-320
DR ECACC; 87111908
DR JCRB; JCRB0709
DR Lonza; 1262
DR RCB; RCB0135
CC Doubling time: ~20 hours (DSMZ).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID L-5178-Y-R
AC CVCL_4234
SY L5178Y-R; L5178YR; L5178-R; LY-R
DR CLO; CLO_0007193
DR CLO; CLO_0007197
DR CLDB; cl3135
DR ATCC; CRL-1722
DR CLS; 400258/p556_L5178-R
DR ECACC; 90062802
DR KCLB; 21722
RX PubMed=3876312;
RX PubMed=6883332;
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2097 ! L-5178-Y
SX Female
CA Cancer cell line
//
ID L-5178-Y-S
AC CVCL_4235
SY L5178Y-S; L5178YS; L5178-S; LY-S
DR CLO; CLO_0007194
DR CLO; CLO_0007198
DR CLDB; cl3137
DR ATCC; CRL-1723
DR ECACC; 93050408
DR KCLB; 21723
DR RCB; RCB2636
RX PubMed=3876312;
RX PubMed=6883332;
CC Discontinued: RCB; RCB2636; true.
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4234 ! L-5178-Y-R
SX Female
CA Cancer cell line
//
ID L-5222
AC CVCL_5787
SY L 5222; L5222
DR CLS; 500259/NA
RX PubMed=4616492;
CC Discontinued: CLS; 500259; true.
CC Breed/subspecies: BDIX.
DI NCIt; C60428; Rat leukemia
OX NCBI_TaxID=10116; ! Rattus norvegicus
CA Cancer cell line
//
ID L-538
AC CVCL_M700
SY L 538; L538
RX PubMed=2690233;
RX PubMed=6305805;
RX PubMed=6303739;
RX PubMed=7276066;
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_1362 ! L-540
SX Female
CA Cancer cell line
//
ID L-540
AC CVCL_1362
SY L 540; L540
DR BTO; BTO:0005176
DR CLO; CLO_0007201
DR CLDB; cl455
DR BioSample; SAMN03473399
DR CCLE; L540_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR ChEMBL-Cells; CHEMBL3308531
DR ChEMBL-Targets; CHEMBL2366153
DR Cosmic; 907323
DR Cosmic; 988705
DR Cosmic; 1013911
DR Cosmic; 1086359
DR Cosmic; 1432039
DR Cosmic; 2276327
DR Cosmic; 2464307
DR Cosmic-CLP; 907323
DR DSMZ; ACC-72
DR GDSC; 907323
DR GEO; GSM335392
DR GEO; GSM499725
DR GEO; GSM499726
DR GEO; GSM552448
DR GEO; GSM887261
DR GEO; GSM888336
DR GEO; GSM1670030
DR Lonza; 72
DR PRIDE; PXD000589
RX PubMed=2690233;
RX PubMed=6303739;
RX PubMed=6305805;
RX PubMed=7276066;
RX PubMed=11021758;
RX PubMed=12581897;
RX PubMed=22460905;
RX PubMed=25355872;
RX PubMed=25894527;
RX PubMed=27397505;
CC Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC Doubling time: ~70 hours (DSMZ).
CC Microsatellite instability: Stable (MSS) (Sanger).
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC Omics: Cell surface proteome.
CC Omics: Deep exome analysis.
CC Omics: DNA methylation analysis.
CC Omics: SNP array analysis.
CC Omics: Transcriptome analysis.
CC Omics: Virome analysis using RNAseq.
ST Source(s): Cosmic-CLP; DSMZ
ST Amelogenin: X
ST CSF1PO: 11,13
ST D13S317: 9
ST D16S539: 11,13
ST D5S818: 11,13
ST D7S820: 11,12
ST TH01: 7,9
ST TPOX: 9,10
ST vWA: 17,18
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_M700 ! L-538
SX Female
CA Cancer cell line
//
ID L-591
AC CVCL_1867
SY L 591; L591
DR BioSample; SAMN03473498
DR Cosmic; 1289697
DR Cosmic; 1432038
DR Cosmic; 2464305
DR DSMZ; ACC-602
RX PubMed=2690233;
RX PubMed=6303739;
RX PubMed=6305805;
RX PubMed=28196595;
WW http://tcpaportal.org/mclp/
CC Part of: MD Anderson Cell Lines Project.
CC Doubling time: ~72 hours (DSMZ).
CC Omics: Protein expression by reverse-phase protein arrays.
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 7,13
ST D16S539: 9,12
ST D5S818: 11,12
ST D7S820: 9,13
ST TH01: 7,9.3
ST TPOX: 8,11
ST vWA: 16,21
DI NCIt; C9357; Hodgkin lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID L-68
AC CVCL_8888
DR CLO; CLO_0007209
DR ECACC; 97050223
RX PubMed=3824526;
CC Discontinued: ECACC; 97050223; probable.
OX NCBI_TaxID=9606; ! Homo sapiens
CA Finite cell line
//
ID L-82
AC CVCL_2098
SY L82
DR BioSample; SAMN03473494
DR DSMZ; ACC-597
DR GEO; GSM1217154
RX PubMed=11908723;
RX PubMed=15356658;
CC Doubling time: ~40 hours (DSMZ).
ST Source(s): DSMZ
ST Amelogenin: X
ST CSF1PO: 10,12
ST D13S317: 8,12
ST D16S539: 10,11
ST D5S818: 12
ST D7S820: 10,11
ST TH01: 9.3
ST TPOX: 8,11
ST vWA: 16,17
DI NCIt; C3720; Anaplastic large cell lymphoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Cancer cell line
//
ID L-872
AC CVCL_M347
RX PubMed=16631476;
DI NCIt; C4817; Ewing sarcoma
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID L-8A
AC CVCL_CW08
DR ATCC; CRL-6363
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6363; true.
DI NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID L-929 D
AC CVCL_IW04
RX PubMed=823777;
CC Doubling time: 20.8 hours (PubMed=823777).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID L-929 E
AC CVCL_IW05
RX PubMed=823777;
CC Doubling time: 22.9 hours (PubMed=823777).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID L-929 F
AC CVCL_IW06
RX PubMed=823777;
CC Doubling time: 24.9 hours (PubMed=823777).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID L-929 HH
AC CVCL_IW07
RX PubMed=823777;
CC Doubling time: 23.4 hours (PubMed=823777).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID L-alpha-1a L-cells
AC CVCL_9111
DR CLO; CLO_0007235
DR ATCC; CRL-11138
RX Patent=US6075038;
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: HGNC; 280; ADRA1D.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-alpha-1b L-cells
AC CVCL_9110
SY L-a-1b
DR CLO; CLO_0007436
DR ATCC; CRL-11139
RX Patent=US6075038;
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: HGNC; 278; ADRA1B.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-alpha-1c L-cells
AC CVCL_DD01
DR ATCC; CRL-11140
RX Patent=US6075038;
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: HGNC; 277; ADRA1A.
CC Discontinued: ATCC; CRL-11140; probable.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-alpha-2A L-cells
AC CVCL_9112
DR CLO; CLO_0007236
DR ATCC; CRL-11180
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: HGNC; 281; ADRA2A.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-alpha-2C L-cells
AC CVCL_9113
DR CLO; CLO_0007237
DR ATCC; CRL-11181
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: HGNC; 283; ADRA2C.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-B7
AC CVCL_V089
DR CLO; CLO_0007264
DR CLDB; cl3083
DR IHW; IHW8023
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-DQw1-Dw12
AC CVCL_V090
DR CLO; CLO_0007288
DR CLDB; cl3085
DR IHW; IHW8201
RX PubMed=1429033;
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-DQw4-Dw15
AC CVCL_V091
DR CLO; CLO_0007289
DR CLDB; cl3086
DR IHW; IHW8206
RX PubMed=1429033;
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-DR2-Dw12
AC CVCL_V092
DR CLO; CLO_0007293
DR CLDB; cl3087
DR IHW; IHW8110
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-DR4-Dw15
AC CVCL_V093
DR CLO; CLO_0007294
DR CLDB; cl3088
DR IHW; IHW8120
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-DRw53-Dw15
AC CVCL_V094
DR CLO; CLO_0007299
DR CLDB; cl3091
DR IHW; IHW8137
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-HSO2
AC CVCL_V095
DR CLO; CLO_0007313
DR CLDB; cl3093
DR IHW; IHW8043
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-KAW
AC CVCL_A639
DR Cosmic; 721709
DR Cosmic; 1375585
RX PubMed=7543637;
RX PubMed=10071127;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Cancer cell line
//
ID L-M
AC CVCL_4535
SY LM from NCTC clone 929; LM-929; LM929
DR CLO; CLO_0007336
DR CLO; CLO_0007351
DR CLDB; cl3094
DR CLDB; cl3095
DR ATCC; CCL-1.2
DR BCRC; 60405
DR ECACC; 87032401
DR IZSLER; BS CL 59
DR KCLB; 10001.2
RX PubMed=14033129;
RX PubMed=14033130;
RX PubMed=14056989;
RX PubMed=14472756;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=L-M
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID L-M(BU-25)
AC CVCL_DE17
SY L-M (BU-25); LM BU25
RX PubMed=14033130;
RX PubMed=14056989;
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4535 ! L-M
SX Male
CA Spontaneously immortalized cell line
//
ID L-M(TK-)
AC CVCL_4536
AS CVCL_0634
SY L-M[TK-]; LM TK negative; L-M (TK-); L M (TK-); LM(TK-); LM(tk-); LM-TK-; LMTK-; L cells (TK-); L(TK-); L(tk-)
DR CLO; CLO_0007138
DR CLO; CLO_0007337
DR CLO; CLO_0007352
DR CLO; CLO_0007353
DR CLDB; cl3075
DR CLDB; cl3096
DR CLDB; cl3097
DR CLDB; cl3098
DR ATCC; CCL-1.3
DR ATCC; CRL-2648
DR BCRC; 60072
DR BCRJ; 0148
DR CCRID; 3111C0002000000044
DR CCRID; 3142C0001000000002
DR ECACC; 90083001
DR IZSLER; BS CL 60
DR TOKU-E; 2213
DR TOKU-E; 3995
RX PubMed=14056989;
RX PubMed=14109133;
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/l/cell-lines-detail-49.html
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Discontinued: BCRJ; 0148; probable.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_DE17 ! L-M(BU-25)
SX Male
CA Spontaneously immortalized cell line
//
ID L-M(TK-)1D
AC CVCL_F739
SY L M (TK-) 1D; LM (TK-) 1D; LM(TK-)1D; L-M(TK-) clone 1D; LM(TK(-)) Cl 1D; TK-LM clone 1D; L cl 1D; Cl 1D; Cl1D; Clone 1D; GM12516
DR CLO; CLO_0009359
DR CLO; CLO_0017849
DR CLDB; cl4518
DR Coriell; GM12516
DR JCRB; JCRB0722
RX PubMed=14109133;
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Transformed cell line
//
ID L-M(TK-,APRT-)
AC CVCL_0P16
DR CLO; CLO_0007354
DR CLDB; cl3099
WW http://www.rccc.cytspb.rssi.ru/ecellbank/animal/al-m.htm
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Selected for resistance to: ChEBI; CHEBI:77751; 8-azaadenine.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-MAT
AC CVCL_A640
DR Cosmic; 721717
DR Cosmic; 1375580
RX PubMed=10071127;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID L-NGC-5HT2 L-cells
AC CVCL_6498
SY L-NGC-5HT2
DR CLO; CLO_0007368
DR ATCC; CRL-10287
CC Transfected with: HGNC; 5293; HTR2A.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-NGC-alpha2B L-cells
AC CVCL_9114
DR CLO; CLO_0007369
DR ATCC; CRL-10275
CC Transfected with: HGNC; 282; ADRA2B.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L-SAK
AC CVCL_A641
DR Cosmic; 721718
DR Cosmic; 1037691
DR Cosmic; 1375593
RX PubMed=10071127;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID L-SMY
AC CVCL_A642
DR Cosmic; 721713
DR Cosmic; 998734
DR Cosmic; 1037692
RX PubMed=10071127;
DI NCIt; C7953; Childhood T acute lymphoblastic leukemia
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID L-STS
AC CVCL_L297
DR GEO; GSM966944
RX PubMed=19528452;
CC Derived from metastatic site: Lymph node.
DI NCIt; C6422; Midgut carcinoid tumor
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_L296 ! H-STS
OI CVCL_L298 ! P-STS
SX Male
CA Cancer cell line
//
ID L-WR
AC CVCL_DA05
RX PubMed=24232249;
CC Transfected with: MGI; MGI:1920030; Rspo3.
CC Transfected with: MGI; MGI:98956; Wnt3a.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0635 ! L Wnt-3A
SX Male
CA Spontaneously immortalized cell line
//
ID L-WRN
AC CVCL_DA06
DR ATCC; CRL-3276
RX PubMed=24232249;
CC Transfected with: MGI; MGI:104327; Nog.
CC Transfected with: MGI; MGI:1920030; Rspo3.
CC Transfected with: MGI; MGI:98956; Wnt3a.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0635 ! L Wnt-3A
SX Male
CA Spontaneously immortalized cell line
//
ID L/1C2
AC CVCL_V649
DR CCRID; 3142C0001000000439
RX PubMed=2654003;
OX NCBI_TaxID=10090; ! Mus musculus
CA Hybridoma
//
ID L/neo
AC CVCL_V096
DR CLO; CLO_0007148
DR CLDB; cl3106
DR IHW; IHW8400
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L.N. 4159
AC CVCL_6414
DR CLO; CLO_0007147
DR ATCC; CRL-10998
CC Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID L.P3
AC CVCL_U990
DR CLO; CLO_0050231
DR JCRB; JCRB0648
DR RCB; RCB0101
RX PubMed=4328993;
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0462 ! NCTC clone 929
SX Male
CA Spontaneously immortalized cell line
//
ID L.P3(S)
AC CVCL_U991
DR JCRB; JCRB0605
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_U990 ! L.P3
SX Male
CA Spontaneously immortalized cell line
//
ID L.R.
AC CVCL_U239
DR ATCC; CRL-6307
CC Group: Non-human primate cell line.
CC Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC Discontinued: ATCC; CRL-6307; true.
OX NCBI_TaxID=30588; ! Leontopithecus rosalia
SX Sex undetermined
CA Finite cell line
//
ID L0081785
AC CVCL_E747
DR dbMHC; 48954
DR ECACC; 88052018
DR IHW; IHW9018
DR IMGT/HLA; 11637
RX PubMed=8307784;
WW http://bioinformatics.hsanmartino.it/ecbr/cl18.html
CC Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel.
CC Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX NCBI_TaxID=9606; ! Homo sapiens
SX Male
CA Transformed cell line
//
ID L0301
AC CVCL_1F89
RX PubMed=1484432;
DI NCIt; C2926; Non-small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID L0301/CDDP
AC CVCL_1F90
RX DOI=10.2482/haigan.32.223;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
DI NCIt; C2926; Non-small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1F89 ! L0301
CA Cancer cell line
//
ID L1-1GC1
AC CVCL_W595
RX PubMed=23472874;
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W596 ! L1-1GC2
OI CVCL_W597 ! L1-1Mut
OI CVCL_W598 ! L1-2GC
OI CVCL_W599 ! L1-2Mut
SX Female
CA Induced pluripotent stem cell
//
ID L1-1GC2
AC CVCL_W596
DR SKIP; SKIP000293
RX PubMed=23472874;
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W595 ! L1-1GC1
OI CVCL_W597 ! L1-1Mut
OI CVCL_W598 ! L1-2GC
OI CVCL_W599 ! L1-2Mut
SX Female
CA Induced pluripotent stem cell
//
ID L1-1Mut
AC CVCL_W597
DR SKIP; SKIP000290
RX PubMed=23472874;
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W595 ! L1-1GC1
OI CVCL_W596 ! L1-1GC2
OI CVCL_W598 ! L1-2GC
OI CVCL_W599 ! L1-2Mut
SX Female
CA Induced pluripotent stem cell
//
ID L1-2GC
AC CVCL_W598
RX PubMed=23472874;
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W595 ! L1-1GC1
OI CVCL_W596 ! L1-1GC2
OI CVCL_W597 ! L1-1Mut
OI CVCL_W599 ! L1-2Mut
SX Female
CA Induced pluripotent stem cell
//
ID L1-2Mut
AC CVCL_W599
DR SKIP; SKIP000292
RX PubMed=23472874;
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_W595 ! L1-1GC1
OI CVCL_W596 ! L1-1GC2
OI CVCL_W597 ! L1-1Mut
OI CVCL_W598 ! L1-2GC
SX Female
CA Induced pluripotent stem cell
//
ID L1-S8
AC CVCL_AV88
DR EFO; EFO_0007599
DR ENCODE; ENCBS259CUZ
OX NCBI_TaxID=9606; ! Homo sapiens
CA Induced pluripotent stem cell
//
ID L1-S8R
AC CVCL_AV89
DR EFO; EFO_0007600
DR ENCODE; ENCBS023FES
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_AV88 ! L1-S8
CA Induced pluripotent stem cell
//
ID L1.2
AC CVCL_9576
SY L1-2
DR ChEMBL-Cells; CHEMBL3307981
DR ChEMBL-Targets; CHEMBL612572
DR Lonza; 24
DR TOKU-E; 4087
WW http://www.masstechportal.org/IP4382.aspx
CC From: Rosenberg N.; Tufts University; Boston; USA.
CC Transformant: NCBI_TaxID; 11788; Abelson mouse leukemia virus (AbMuLV).
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID L10-90
AC CVCL_9U22
RX PubMed=7586804;
CC Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (MCA).
CC Breed/subspecies: Kunming.
DI NCIt; C24068; Mouse cervical carcinoma
OX NCBI_TaxID=10090; ! Mus musculus
OI CVCL_9U43 ! P11-90
OI CVCL_9U56 ! U14
SX Female
CA Cancer cell line
//
ID L10.A
AC CVCL_K165
RX PubMed=310843;
CC Breed/subspecies: BALB/cAnN.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
CA Cancer cell line
//
ID L10.A 2J
AC CVCL_K166
SY L10A2J; L10A/2J
RX PubMed=3495708;
RX PubMed=6170720;
CC Breed/subspecies: BALB/cAnN.
DI NCIt; C21602; Mouse lymphoma
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_K165 ! L10.A
CA Cancer cell line
//
ID L100
AC CVCL_0C34
DR Cosmic; 2239101
RX PubMed=9559344;
DI NCIt; C4917; Small cell lung carcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
CA Cancer cell line
//
ID L105.1
AC CVCL_V097
DR CLO; CLO_0007150
DR CLDB; cl3107
DR IHW; IHW8135
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V055 ! DAP.3
SX Male
CA Spontaneously immortalized cell line
//
ID L10BIOBR
AC CVCL_V171
RX PubMed=12514183;
CC Breed/subspecies: B10.BR.
OX NCBI_TaxID=10090; ! Mus musculus
CA Transformed cell line
//
ID L10BIOBR-GFP
AC CVCL_V172
DR ATCC; CRL-2770
RX PubMed=12514183;
CC Transfected with: UniProtKB; P42212; GFP.
CC Breed/subspecies: B10.BR.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V171 ! L10BIOBR
CA Transformed cell line
//
ID L10BIOBR-MAPKK
AC CVCL_V173
DR ATCC; CRL-2771
RX PubMed=12514183;
CC Transfected with: MGI; MGI:1346866; Map2k1 (constitutively activated form).
CC Breed/subspecies: B10.BR.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V171 ! L10BIOBR
CA Transformed cell line
//
ID L11/135
AC CVCL_J012
DR CLO; CLO_0007152
DR ATCC; TIB-188
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_3412 ! P3X63Ag8U.1
CA Hybridoma
//
ID L11.3
AC CVCL_V098
DR CLO; CLO_0007151
DR CLDB; cl3108
DR IHW; IHW8303
RX PubMed=3517859;
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Transfected with: HGNC; 4940; HLA-DPB1.
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4536 ! L-M(TK-)
SX Male
CA Spontaneously immortalized cell line
//
ID L12.2
AC CVCL_V099
DR CLO; CLO_0007154
DR CLDB; cl3110
DR IHW; IHW8128
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V055 ! DAP.3
SX Male
CA Spontaneously immortalized cell line
//
ID L12.28-1/1
AC CVCL_4W64
DR JCRB; JCRB1615
CC Transformant: Unknown.
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 11,12
ST D13S317: 11,14
ST D16S539: 9,11
ST D5S818: 11,12
ST D7S820: 11
ST TH01: 8
ST TPOX: 8
ST vWA: 15
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0440 ! MRC-5
SX Male
CA Transformed cell line
//
ID L12.9-2(1)
AC CVCL_U651
DR CLO; CLO_0050062
DR RCB; RCB2834
CC Transformant: Unknown.
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0440 ! MRC-5
SX Male
CA Transformed cell line
//
ID L1210
AC CVCL_0382
SY L 1210; L-1210; Leukemic 1210; Leukemia 1210
DR BTO; BTO:0000702
DR CLO; CLO_0007139
DR CLO; CLO_0007155
DR CLO; CLO_0007156
DR EFO; EFO_0005284
DR MCCL; MCC:0000277
DR CLDB; cl3111
DR CLDB; cl3112
DR CLDB; cl3113
DR CLDB; cl3114
DR CLDB; cl3115
DR CLDB; cl4936
DR CLDB; cl5219
DR ATCC; CCL-219
DR BCRC; 60049
DR BCRJ; 0138
DR CCRID; 3111C0001CCC000191
DR CCRID; 3131C0001000800022
DR ChEMBL-Cells; CHEMBL3308391
DR ChEMBL-Targets; CHEMBL386
DR CLS; 400257/p2482_L-1210
DR DSMZ; ACC-123
DR ECACC; 87092804
DR ENCODE; ENCBS116ENC
DR ICLC; ATL99002
DR IZSLER; BS TCL 152
DR JCRB; JCRB9026
DR KCB; KCB 200774YJ
DR KCLB; 10219
DR Lonza; 638
DR TKG; TKG 0154
DR Wikidata; Q6456824
RX PubMed=18630317;
WW https://en.wikipedia.org/wiki/L1210_cells
WW http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/l/cell-lines-detail-479.html
CC Part of: ENCODE project mouse cell lines.
CC Doubling time: ~50 hours (DSMZ).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Cancer cell line
//
ID L1210 HHT
AC CVCL_IM26
SY L1210-HHT
RX PubMed=7987716;
CC Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; HHT).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210 TGR3
AC CVCL_F929
DR TKG; TKG 0477
CC Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210 TGR4
AC CVCL_C511
DR CLO; CLO_0050212
DR RCB; RCB2844
DR TKG; TKG 0478
CC Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210-5FU-R-TC
AC CVCL_C513
AS CVCL_C512
SY L1210-5FU-R
DR CLO; CLO_0050781
DR RCB; RCB2845
DR TKG; TKG 0155
DR TKG; TKG 0409
CC Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210-6MP-R-TC
AC CVCL_H699
SY L1210-6MP-R
DR TKG; TKG 0156
DR TKG; TKG 0410
CC Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/0
AC CVCL_Y418
RX PubMed=3167012;
RX PubMed=3828995;
RX PubMed=10200488;
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/Ara-C
AC CVCL_R996
SY L1210/ARA-C; L1210/ara C
DR ChEMBL-Cells; CHEMBL3307421
DR ChEMBL-Targets; CHEMBL614716
CC Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/CPA
AC CVCL_4Y57
RX PubMed=6354439;
CC Selected for resistance to: ChEBI; CHEBI:4027; Cyclophosphamide (CP; Endoxan).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/DACH
AC CVCL_Y419
SY L1210(DACH); L1210 (DACH); L1210DACH
DR ChEMBL-Cells; CHEMBL3308408
DR ChEMBL-Targets; CHEMBL614041
RX PubMed=1986276;
RX PubMed=3335002;
RX PubMed=3828995;
CC Selected for resistance to: ChEBI; CHEBI:90269; Dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/DDP
AC CVCL_1B40
SY L-1210/DDP
RX PubMed=1556003;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/DDP10
AC CVCL_Y420
RX PubMed=1986276;
RX PubMed=3167012;
RX PubMed=3828995;
RX PubMed=6541096;
RX PubMed=10200488;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/DDP2
AC CVCL_Y421
RX PubMed=3167012;
RX PubMed=10200488;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/DDP5
AC CVCL_Y422
SY L1210(DDP5); L1210 (DDP5); L1210DDP5
DR ChEMBL-Cells; CHEMBL3307477
DR ChEMBL-Targets; CHEMBL613512
RX PubMed=1986276;
RX PubMed=3167012;
RX PubMed=3335002;
RX PubMed=3828995;
RX PubMed=6541096;
RX PubMed=10200488;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/PtR4
AC CVCL_4V14
SY L1210 PtR4; L1210PtR4; L1210 (PtR4); L1210(PTR4)
DR ChEMBL-Cells; CHEMBL3307416
DR ChEMBL-Targets; CHEMBL614711
RX PubMed=3335002;
CC Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/R71
AC CVCL_N029
SY L1210:R71
RX PubMed=3965926;
CC Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/R81
AC CVCL_N028
SY L1210 (R81)
DR ChEMBL-Cells; CHEMBL3307415
DR ChEMBL-Targets; CHEMBL614710
RX PubMed=3965926;
CC Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210/TGO
AC CVCL_Y423
RX PubMed=3828995;
CC Selected for resistance to: ChEBI; CHEBI:472805; Ouabain.
CC Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L1210:RD1694
AC CVCL_Y424
SY L1210 (RD1694); L1210(RD1694)
DR ChEMBL-Cells; CHEMBL3307418
DR ChEMBL-Targets; CHEMBL614713
RX PubMed=7537518;
CC Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; ZD1694).
CC Breed/subspecies: DBA/2.
DI NCIt; C21604; Mouse leukemia
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_0382 ! L1210
SX Female
CA Cancer cell line
//
ID L127D6
AC CVCL_Z824
DR DGRC; 163
CC Group: Insect cell line.
OX NCBI_TaxID=7227; ! Drosophila melanogaster
SX Sex undetermined
CA Spontaneously immortalized cell line
//
ID L132 clone G-38-7
AC CVCL_M623
SY G-38-7
RX PubMed=1246601;
RX PubMed=4134499;
CC Problematic cell line: Contaminated. Parent cell line (L-132) has been shown to be a HeLa derivative (PubMed=1246601).
CC Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_1908 ! L-132
SX Female
CA Cancer cell line
//
ID L138.8A
AC CVCL_2100
DR CLO; CLO_0007160
DR CLDB; cl3118
DR DSMZ; ACC-114
RX PubMed=2788129;
WW http://www.cells-talk.com/index.php/page/copelibrary?key=L138.8A
CC Characteristics: IL3 dependent.
CC Doubling time: ~30-40 hours (DSMZ).
CC Breed/subspecies: BALB/c.
OX NCBI_TaxID=10090; ! Mus musculus
SX Female
CA Factor-dependent cell line
//
ID L14
AC CVCL_3828
SY B1 subline L14
DR CLO; CLO_0007161
DR CLDB; cl3119
DR ECACC; 91012317
RX PubMed=2394515;
RX PubMed=7951345;
CC Transformant: NCBI_TaxID; 71581; Porcine endogenous retrovirus Tsukuba-1.
CC Breed/subspecies: Miniature boar (d/d haplotype).
OX NCBI_TaxID=9823; ! Sus scrofa
HI CVCL_F749 ! B1 [Pig]
SX Male
CA Transformed cell line
//
ID L142
AC CVCL_F737
RX PubMed=1667778;
CC Transformant: NCBI_TaxID; 71581; Porcine endogenous retrovirus Tsukuba-1.
CC Breed/subspecies: Miniature boar (d/d haplotype).
OX NCBI_TaxID=9823; ! Sus scrofa
HI CVCL_3828 ! L14
SX Male
CA Transformed cell line
//
ID L150P-GC-hiPSC
AC CVCL_IK98
RX PubMed=27789395;
CC From: Bioneer A/S; Denmark.
CC Characteristics: The heterozygous PSEN1 p.Leu150Pro mutation of the donor has been corrected by CRISPR/Cas9.
DI NCIt; C123412; Familial Alzheimer's disease, type 3
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_DQ59 ! H234 C2
SX Male
CA Induced pluripotent stem cell
//
ID L164.11
AC CVCL_V100
DR CLO; CLO_0007163
DR CLDB; cl3120
DR IHW; IHW8116
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V055 ! DAP.3
SX Male
CA Spontaneously immortalized cell line
//
ID L165.6
AC CVCL_V101
DR CLO; CLO_0007164
DR CLDB; cl3121
DR IHW; IHW8118
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V055 ! DAP.3
SX Male
CA Spontaneously immortalized cell line
//
ID L166.1
AC CVCL_V102
DR CLO; CLO_0007165
DR CLDB; cl3122
DR IHW; IHW8119
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V055 ! DAP.3
SX Male
CA Spontaneously immortalized cell line
//
ID L168.2
AC CVCL_V103
DR CLO; CLO_0007166
DR CLDB; cl3123
DR IHW; IHW8112
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V055 ! DAP.3
SX Male
CA Spontaneously immortalized cell line
//
ID L17.8
AC CVCL_V104
DR CLO; CLO_0007167
DR CLDB; cl3124
DR IHW; IHW8138
CC Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel.
CC Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC Breed/subspecies: C3H/An.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_V055 ! DAP.3
SX Male
CA Spontaneously immortalized cell line
//
ID L18
AC CVCL_J014
DR CLO; CLO_0007168
DR ATCC; HB-8628
RX Patent=US4737579;
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_2155 ! P3/NS1/1-Ag4.1
CA Hybridoma
//
ID L180/1
AC CVCL_M046
DR ECACC; 91060558
RX PubMed=2411842;
CC Monoclonal antibody target: UniProtKB; W5QG77; Sheep CD58.
OX NCBI_TaxID=10090; ! Mus musculus
HI CVCL_4032 ! P3X63Ag8.653
CA Hybridoma
//
ID L1M1
AC CVCL_FG74
RX PubMed=1727655;
CC Derived from metastatic site: Left inguinal lymph node.
DI NCIt; C3224; Melanoma
OX NCBI_TaxID=9606; ! Homo sapiens
OI CVCL_FG73 ! G1M2
SX Female
CA Cancer cell line
- 公告/新闻
